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Summary 
 
22q11.2 Deletion Syndrome is a genetic syndrome that occurs in incidence of  1:4000 
and is associated with variable phenotypic expression. It is caused by a deletion at 
chromosome 22q11.2. Individuals with 22q11.2DS have a greatly increased risk of 
developing neuropsychiatric disorders, in particular schizophrenia in adulthood, and 
ADHD and ASD in childhood.  
This thesis sought to investigate the possible molecular mechanisms that underlie the 
psychiatric variability in 22q11.2DS by studying a well-characterized cohort of 76 
children with 22q11.2DS. Four mechanisms were investigated: (a) dosage sensitivity 
of genes within 22q11.2 region, (b) a disruption of the expression of genes flanking 
the deletion i.e. positional effect and genome-wide, (c) the presence of additional 
genetic risk variants within the 22q11.2 region, and (d) the presence of additional 
CNVs outside of the 22q11.2 deleted region. 
While this work revealed significant evidence for differential expression of 39 of the 
genes spanned by the deletion, there was no significant evidence for a positional effect 
at other genes on chromosome 22. The genome-wide differential gene expression 
analysis revealed four significantly enriched biological networks (FDR <0.05) that are 
involved in: 1) translation, protein synthesis machinery, and post-translation 
modifications; 2) apoptosis; 3) regulation of the immune system; and 4) 
intramembrane organelles.  
The association analyses of genetic variants present on the non-deleted 22q11.2 
chromosome did not identify any that were significantly associated with psychiatric 
phenotypes in 22q11.2DS. 
The genome-wide screen for additional CNVs identified a non-significant trend that 
large, rare CNVs were enriched in 22q11.2DS patients with psychiatric phenotypes, 
however there was no evidence that these additional CNVs were enriched for CNVs 
that had been previously implicated in developmental delay and neuropsychiatric 
disease. 
In addition, in this thesis also investigated the role of deletions at 22q11.2 in a large 
cohort of individuals with idiopathic Parkinson’s disease. This provided significant 
evidence that deletions at 22q11.2 increase the risk of Parkinson’s disease, particularly 
the early-onset form. 
Taken together, the data presented in this PhD suggested that the mechanism by which 
haploinsufficiency at 22q11.2 increases risk to psychiatric illness is likely to be 
complex. To follow up this work, future studies should utilise larger numbers of 
samples, use neurologically relevant tissue and apply more sophisticated approaches 
to screen for changes in gene expression and additional genetic variants. 
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Chapter 1: General Introduction 
 
 
1.1. 22q11.2 Deletion Syndrome 
22q11.2 Deletion Syndrome (22q11.2DS) is a genetic disorder caused by a 
hemizygous microdeletion on the long arm (q) of chromosome 22 in an area 
designated by 11.2 (Scambler et al. 1992). It is the most common interstitial 
microdeletion disorder occuring in man and the second most common genetic 
syndrome after Down’s Syndrome (Rauch et al. 2006). Moreover, 15% of congenital 
cardiac defects are represented by 22q11.2DS (Devriendt et al. 1998; Gothelf & 
Lombroso 2001). 
The disease collectively describes multiple genetic conditions with overlapping 
features including DiGeorge Syndrome (DGS), Velocardiofacial Syndrome (VCFS), 
Shprintzen Syndrome, Conotruncal Anomaly Face Syndrome (CTAF), Cayler 
Syndrome, Sedlackova Syndrome, Cardiofacial Syndrome, Takao Syndrome, and 
CATCH-22 (Shprintzen 2005). The presence of multiple names for the same disorder 
is due to the markedly wide range of phenotype expression in the patients with the 
deletion (Shprintzen 2005). However, the term 22q11.2DS has been established 
relatively recently as a name that encompasses these congenital malformations 
(Shprintzen 2005). The disorder will therefore be referred to by 22q11.2DS throughout 
this PhD thesis. 
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1.1.1. Incidence of 22q11.2DS 
The most frequently cited incidence of 22q11.2DS is 1 in 4000 live births, this 
estimation is based largely on infants with congenital anomalies leading to genetic 
testing (Goodship et al. 1998). Since 1993, 22q11.2DS patients are diagnosed based 
on a cytogenetic approach called Florescent in situ hybridization (FISH) (Tezenas Du 
Montcel et al. 1996; Goodship et al. 1998). 
An equal distribution of the disease was found among males and females (Botto et al. 
2003); however, a higher rate was found in Hispanics (~1:3800) than other ethnic 
groups (Botto et al. 2003; Kobrynski & Sullivan 2007).  
From an etiologic perspective, 22q11.2 deletions occur as a de novo mutation in the 
vast majority of the patients (~90-95%) (McDonald-McGinn et al. 2001), while the 
deletion is inherited in the remaining of the 22q11.2DS patients (5-10%) (Scambler 
2000).  
 
1.1.2. Molecular genetic of 22q11.2DS 
1.1.2.1. Causes of 22q11.2DS 
Around 85% of 22q11.2DS patients carry a 3Mb microdeletion which is called the 
typically deleted region (TDR) (Driscoll et al. 1993; Kitsiou-Tzeli et al. 2005). The 
remaining cases (15%) carry a smaller deletion ~1.5Mb that is nested within the 3Mb 
deletion (Guna et al. 2015; Shaikh et al. 2000). There is no observable correlation 
between the deletion size and the severity of clinical symptoms (Carlson et al. 1997).  
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1.1.2.2. Complexity of 22q11.2 region 
1.1.2.2.1. Low copy repeats of chromosome 22q11.2 
The 22q11.2 region is a copy number variant (CNV) hotspot, where CNVs are four 
times more likely to occur than other regions of the genome (Shaikh et al. 2000). 
Deletions in chromosome 22q11.2 occur commonly due to the genomic architecture 
of this region, specifically the region contains eight low copy repeats (LCR22s A-H) 
which share a high level of sequence identity (Shaikh et al. 2000) (Figure 1- 1). Low 
copy repeats (LCRs) are DNA sequences that have been previously duplicated via 
evolution. They are typically 10-300Kb long and homologous by 95-97% (Colnaghi 
et al. 2011). The eight LCR22s within 22q11.2 region comprise around 11% of the 
region (Babcock et al. 2003; Bailey et al. 2002).  
The 3Mb deletion spans the region of 18,658,219-21,865,185 (hg19) on chromosome 
22 that contains four LCR22s A, B, C, and D. While the smaller deletion ~1.5Mb 
spans the region of 18,658,219-20,519,134 (hg19) on chromosome 22 spanning 
LCR22s A and B (Shaikh et al. 2000) (Figure 1- 1). 
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1.1.2.2.2. Non-allelic homologous recombination 
Meiosis is a type of cell division in which number of chromosomes is reduced by half 
to produce gamete cells, eggs and sperm cells, for sexual reproduction (Alberts et al. 
2002). During meiosis I, chromosomal crossover takes place in which genetic material 
is exchanged between two homologous chromosomes (Alberts et al. 2002). Crossover 
usually occurs when matching regions on homologous chromosomes break and then 
recombine to exchange genetic materials. This process is called allelic homologous 
recombination (Alberts et al. 2002) (Figure 1- 2). 
 
 
 
Figure 1- 1: Schematic ideogram of chromosome 22. 
The figure indicates the position of LCR22s in 22q11.2 region (Black boxes). The common 3Mb 
deletion associated with 22q11.2DS spans LCR22s A-D, while the less common 1.5Mb deletion 
associated with 22q11.2DS spans LCR22s A-B, both deletions are indicated by the bottom grey 
bars (Original figure). 
 
Figure 1- 1: Schematic ideogram of chromosome 22. Indicating the position of LCR22s in 
22q11.2 (Black boxes). The common 3Mb deletion associated with 22q11.2DS spans LCR22s 
A-D, while the less common 1.5Mb deletion associated with 22q11.2DS spans LCR22s A-B, 
both are indicated by the b ttom grey ba s (Original figure). 
 
 
Figure 1- 2: Schematic ideogram of chromosome 22. Indicating the position of LCR22s in 
22q11.2 (Black boxes). The common 3Mb deletion associated with 22q11.2DS spans LCR22s 
A-D, while the less common 1.5Mb deletion associated with 22q11.2DS spans LCR22s A-B, 
both are indicated by the bottom grey bars (Original figure). 
 
 
Figure 1: Schematic ideogram of hromosome 22. 
 
 
Figure 1- 3: Schematic ideogram of chromosome 22. Indicating the position of LCR22s in 
22q11.2 (Black boxes). The common 3Mb deletion associated with 22q11.2DS spans LCR22s 
A-D, while the less common 1.5Mb deletion associated with 22q11.2DS spans LCR22s A-B, 
both are indicated by the bottom grey bars (Original figure). 
 
 
Figure 1- 4: Schematic ideogram of chromosome 22. Indicating the position of LCR22s in 
22q11.2 (Black boxes). The common 3Mb deletion associated with 22q11.2DS spans LCR22s 
A-D, while the less common 1.5Mb deletion associated with 22q11.2DS spans LCR22s A-B, 
both are indicated by the bottom grey bars (Original figure). 
 
5 
 
 
 
 
 
 
 
 
 
 
 
 
 
The presence of low copy repeats at regions, such as 22q11.2, results in a high DNA 
sequence similarity that increases the chances of there being an unequal mispairing 
and non-allelic crossing over between homologous chromosomes (Shaikh et al. 2000). 
This abnormal mechanism is called non-allelic homologous recombination (NAHR). 
NAHR is a form of homologous recombination that occurs between two DNA regions 
with a high sequence similarity but are not alleles (Edelmann et al. 1999) (Figure 1- 3). 
This mechanism is a common source of aberrant inter-chromosomal exchanges and 
results in a high susceptibility for rearrangement (Shaikh et al. 2000). 
 
Figure 1- 2: Normal process of meiosis and crossing over. 
The crossover takes place in meiosis I to exchange genetic materials 
between 2 homologous chromosomes (Red cross). In meiosis II, the 
sister chromatids are separated, carrying the exchanged regions, to 
form an egg cell or a sperm cell (Original figure). 
Meiosis I 
Homologous chromosomes exchange 
genetic materials (chromosomal 
crossover). 
 
Meiosis II 
Splitting up sister 
chromatids to form 
haploid gametes (egg 
or sperm). 
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At chromosome 22q11.2, the most common 3Mb deletion is flanked by LCR22A and 
LCR22D. These are the largest among the eight LCR22s with approximately 240Kb 
length (Babcock et al. 2003), and are composed of a 160Kb direct repeat that spanned 
by over 99% identical sequence to each other (McDonald-McGinn et al. 2015; Shaikh 
et al. 2000). 
 
1.1.2.3. Genes within these deletions 
The 3Mb deletion of chromosome 22q11.2 spans approximately 90 genes, and the 
smaller proximal ~1.5Mb deletion spans around 55 of these genes (Guna et al. 2015). 
Over half of the 90 genes are protein-coding (n= 46, 51.1%), and most of the 46 genes 
are expressed in the brain (n= 41, 89.1 %). There are 27 pseudogenes, one read-
through transcript (classified as a non-coding RNA) within the TDR (Guna et al. 
2015). Also the region contains 9 non-coding RNA genes and 7 microRNA (miRNA) 
genes, which include MIR185, MIR1306, MIR1286, MIR3618, MIR649, MIR4761, 
and MI6816 (Figure 1- 4) (Guna et al. 2015). 
Figure 1- 3: Schematic description of non-allelic homologous recombination and resulting inter-
chromosomal deletion and duplication. 
Blue boxes represent LCRs. In NAHR, the process of crossover occurs between the identical LCR regions 
in the 2 homologous chromosomes but not between the identical allelic regions as in the normal 
recombination. Also, this abnormal NAHR unequally exchange the identical LCR regions which leads to 
a duplicated segment in one homologues chromosome and a deleted segment in the other homologues 
chromosome (Original figure). 
A C 
A B C B A B C 
A B C 
Cross over 
Segment B duplicated 
Segment B deleted 
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1.1.2.4. Testing of 22q11.2 deletions 
1.1.2.4.1. Cytogenetic testing 
The resolution of laboratory techniques to detect the deletion and define the 
breakpoints vary considerably. Since 1993, FISH has enabled diagnostic clinical 
laboratories to identify individuals with 22q11.2 deletions by using probes such as 
N25 or TUPLE/HIRA (Jalali et al. 2008) (Figure 1- 5). However, one main limitation 
in using FISH is that the probe used in FISH assays can detect the deletion, but it 
cannot distinguish the 1.5Mb deletion from the common 3Mb deletion (Ramachandran 
et al. 2015). 
 
1.1.2.4.2. Molecular testing 
FISH has been replaced in most laboratories by a range of more sophisticated 
techniques that are able to detect 22q11.2 deletions of any size such as comparative 
genome hybridization (CGH), genome-wide microarrays of single nucleotide 
polymorphisms (SNPs), multiplex ligation dependent probe amplification (MLPA), 
and quantitative PCR (qPCR) (Miller et al. 2010).  
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Figure 1- 4: Genetic landscape of the human 22q11.2 region. 
 
The typical 3Mb 22q11.2DS deletion spans ~90 genes in the NCBI Reference 
Sequence Database (RefSeq genes). Region breakpoints are mediated by four 
chromosome specific LCRs (LCRA-D are indicated by white bxes; 
approximate locations shown). *Deletion breakpoints (hg19).  Figure obtained 
from (Guna et al. 2015) with modifications. 
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Figure 1- 5: Dual-colour FISH for detection of chromosome 22q11.2 
deletion. 
Interphase cells from patients were hybridized with a chromosome 
22q11.2-specific probe, HIRA (red), and a control chromosome 22 probe, 
ARSA (green). The patient (a 4 months old infant) shows only one red 
signal with two green signals; this indicates a hemizygous deletion. Figure 
obtained from (Ramachandran et al. 2015). 
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1.2. Phenotypic diversity of 22q11.2DS 
1.2.1. History of 22q11.2DS 
Several incidents of 22q11.2DS had been reported in the medical literature during the 
1950s; however, more attention was driven to the syndrome as a clinical diagnosis 
during 1990s. 
The first description of speech abnormality in 22q11.2DS was observed in the earliest 
cases by Sedlackova in 1955. They were described as having a congenital short palate 
known as occult sub-mucous cleft palate (Sedláčková 1955). Later, more patients were 
also reported by Sedlackova in 1967 to have a similar congenital palatal abnormality 
(Sedláčková 1967). These reported children had hyper nasal speech with absence of 
overt palatal cleft and distinctive facial appearance (Sedláčková 1967). The 
occurrence of such abnormalities was thought to be attributed to failure in complete 
development of the branchial arch, which is the origin of the facial muscles and velums 
(Sedláčková 1967). Unfortunately, the findings of Sedlackova were published in a 
Czechoslovakian journal that was inaccessible for the scientific community outside 
the Czech Republic (Shprintzen 2005). 
Further description of 22q11.2DS was observed in the form of immunological 
disorders and cardiac anomalies. A series of infants were reported with congenital 
absence of the thymus that leads to immunologic problems, congenital heart disease, 
and hypoparathyroidism (DiGeorge 1965). Facial dysmorphism was found later to be 
associated with the other phenotypes (Kretschmer et al. 1968). Accordingly, the term 
of DiGeorge Syndrome was established to describe patients with absent thymus, 
immunological disorder, congenital cardiac disease, and facial abnormality 
(Kretschmer et al. 1968). 
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In 1968, Strong reported 4 cases within a single family who had cardiac defects 
associated with a characteristic facial appearance and learning difficulties (Strong 
1968). Children with cardiac anomaly with asymmetric crying faces were described 
to have Cardiofacial Syndrome as a clinical diagnosis for the co-occurrence of these 
symptoms (Cayler 1969). Cases with similar atypical facial features and heart 
problems (particularity conotruncal anomalies) were later seen by Kinouchi in Japan. 
Patients with these symptoms were referred to as having CTAF Syndrome (Kinouchi 
et al. 1976).  
In 1978, Shprintzen reported a series of patients who had an association of cleft palate 
or velopharyngeal incompetence, heart defects, learning disability, and facial 
abnormality. These symptoms were collectively called VCFS (Shprintzen et al. 1978).  
In 1980s, Shimizu in Japan noticed patients with CTAF had similar clinical features 
of DGS (Shimizu et al. 1984). A year later, Shprintzen reviewed cases diagnosed with 
CTAF and suggested they had clinical symptoms of VCFS (Shprintzen et al. 1985).  
In 1981-1982, a microscopic deletion of chromosome 22q11.2 was found in patients 
with DGS (de la Chapelle et al. 1981; Kelley et al. 1982). Ten years later, Driscoll and 
colleagues identified that only 25% of DGS cases have a microscopic deletion in 
chromosome 22q11.2 while the remaining 75% of them remained questionable 
(Driscoll et al. 1992). In 1993, the FISH technique was introduced and Driscoll and 
colleagues used this method to detect a submicroscopic 22q11.2 deletion in the 
majority of DGS cases (Driscoll et al. 1993). They also demonstrated that the majority 
of VCFS patients carry a 22q11.2 deletion, which was similar to the deletion found in 
DGS patients. This finding explained the overlapping phenotypes in both syndromes 
and supported the fact that both diagnoses are for the same syndrome (Driscoll et al. 
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1993). Since then this group of clinical disorders, that share the same deletion have 
been collectively referred to as 22q11.2 Deletion Syndrome (22q11.2DS) (Bassett et 
al. 2011; Tang et al. 2015).   
 
1.2.2. Symptoms of 22q11.2DS 
Since the original description of the disease, the list of phenotypes associated with 
22q11.2DS has been expanding and now it involves more than 180 physical and 
behavioural symptoms (Demily et al, 2015). Variability of number of associated 
features in 22q11.2DS is typically broad, ranging in severity from mild to severe (Tang 
et al. 2015). 
 
1.2.2.1. Physical symptoms 
The common physical abnormalities associated with the syndrome are often referred 
to as CATCH-22, which means Cardiac abnormality, Abnormal faces, Thymic 
aplasia, Cleft palate and Hypocalcemia/Hypothyroidism. The 22 indicates the 
chromosomal abnormality found on chromosome 22 (Wilson et al. 1993). The 
frequency of their detection in 22q11.2DS is described in Table 1- 1. 
 
 
Physical phenotype 
 
 
Frequency 
Cardiac abnormality 49-83% 
Characteristic facial appearance 80-100% 
Thymus aplasia related 
immunodeficiency 
12-77% 
Cleft palate 69-100% 
Hypocalcemia  17-60% 
Renal abnormality 36-37% 
Ophthalmological abnormality 7-70% 
 
Table 1- 1: Common 22q11.2DS psymptoms (Kobrynski & Sullivan 
2007). 
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1.2.2.1.1. Cardiovascular abnormalities 
An average of 75% of 22q11.2DS patients have symptomatic congenital heart disease 
(CHD) and minor patients have asymptomatic aortic arch malformations (Momma 
2010). CHDs are the main cause of mortality in 22q11.2DS and ~90% of deaths in the 
syndrome are caused by CHDs (Ryan et al. 1997). The most frequent characteristic 
symptomatic cardiac diseases in 22q11.2DS are conotruncal defects in which the 
cardiac outflow tract are affected. 22q11.2DS associated conotruncal defects include 
tetralogy of Fallot (TF), pulmonary atresia with ventricular septal defect (PA-VSD), 
truncus arteriosus (TA), and interrupted aortic arch (IAA) (Momma 2010). TF is the 
most prevalent cardiac disease, followed by TF with PA-VSD, VSD, interruption of 
the aortic arch (type B), and TA (Momma 2010). Age is correlated with type, severity, 
and prevalence of heart diseases in 22q11.2DS (Momma 2010). Infants presenting 
with full 22q11.2DS phenotypes tend to have more severe and recurrent CHDs, while 
those presenting in adolescence tend to have less severe CHDs (Momma 2010). 
 
1.2.2.1.2. Craniofacial abnormalities 
Facial abnormality is one of the most common manifestations in 22q11.2DS, which 
identifies individuals with 22q11.2DS from other symptoms with similar clinical 
presentation (Oskarsdóttir et al. 2008). However, the characteristic facial appearance 
is often subtle in infants with 22q11.2DS and becomes more prominent in older 
children. Therefore, it could not be used as a main sign for genetic testing (Digilio et 
al. 2003). These features are characterized by longer faces, large nasal tip with 
hypoplastic nares, small mouth with everted upper lip, cupped or overfolded lower 
jaw, small dysmorphic ears, and/or periorbital fullness with narrow up-slanted 
palpebral fissures (Shprintzen 2008) (Figure 1- 6). 
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Figure 1- 6: Some of the facial features associated 
with 22q11.2DS. 
A) A 10-month old boy with the 22q11DS with 
hooded eyelids (fullness of the eyelids), a small 
mouth, a retro/micrognathi, small round/broad ears 
and a thick helix. 
B) A 5-year-old girl with the 22q11DS with a malar 
flatness, hooded eyelids, hypertelorism, a broad nasal 
bridge and a broad/round nasal tip, narrow nares, a  
small mouth and round/broad and slightly low set 
ears. 
C) An 11-year-old girl with the 22q11DS with a 
malar flatness, hooded eyelids, short palpebral 
fissures, a broad nasal bridge, a small mouth, small, 
slightly low-set posterior rotated ears and a 
thick/overfolded helix. 
Figures obtained from (Oskarsdóttir et al. 2008). 
A 
B 
C 
15 
 
1.2.2.1.3. Thymic aplasia/hypoplasia and related immune disorders 
Absent or underdeveloped thymus (thymic aplasia or hypoplasia) occurs in more than 
80% of 22q11.2DS patients (Piliero et al. 2004). The thymus has a role in maturation 
of functional white blood cells, particularly T cells, that play a central role in cell-
mediated immunity (Sullivan 2005).  Thus, 22q11.2DS patients typically have 
impaired T cell production. Immunodeficiency occurs in 22q11.2DS patients as a 
consequence of thymic hypoplasia (Sullivan 2005).  The degree of immunodeficiency 
in 22q11.2DS patients is extremely variable. Approximately 0.5-1% of 22q11.2DS 
patients have severe immunodeficiency with absent or nearly absent T cells, 20-30% 
have a normal T cells count, the remaining patients range from a mild to moderate 
defect in their T cell count (Sullivan 2005).  In addition, 22q11.2DS is associated with 
autoimmune diseases such as autoimmune thyroiditis or juvenile rheumatoid arthritis, 
and also with haematological disorders such as thrombocytopenia purpura (DePiero et 
al. 1997; Hernández-Nieto et al. 2011). 
 
1.2.2.1.4. Cleft palate and related velopharyngeal abnormalities 
22q11.2DS is one of the most common syndromes associated with cleft palate 
(Scambler 2000). Approximately 5-8% of new-borns with cleft palate had a 22q11.2 
deletion (Kirschner 2005). Velopharyngeal abnormalities are among the common 
clinical features of 22q11.2DS. On average 80% of the patients with the syndrome 
have some degree of velopharyngeal insufficiency.  Also, the syndrome is associated 
with a wide range of palatal phenotypes including cleft palate, submucosal cleft palate, 
bifid uvula, absence or hypoplasia of the musculus uvula, or other palatal muscles 
(McDonald-McGinn et al., 1999). Children with 22q11.2DS have a higher risk of 
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developing speech disorders than other children with non-syndromic cleft palate or 
other cleft palate-associated syndromes (Golding-Kushner 2005). 
 
1.2.2.1.5. Hypocalcemia/Hypoparathyroidism 
Hypocalcaemia is a consequence of hypoparathyroidism, absent or undeveloped 
parathyroid glands, that leads to low blood calcium levels (Brauner et al. 2003). 
Neonatal hypocalcaemia is recognized in most 22q11.2DS children (Ryan et al. 1997). 
While congenital hypocalcaemia is one of the strongest predictors of 22q11.2DS in 
new-borns as it occurs in 17-60% of 22q11.2DS patients (Ryan et al. 1997), it can also 
develop later in childhood or adulthood (Kitsiou-Tzeli et al. 2005). Tetany or seizures 
can be developed in undiagnosed 22q11.2DS adults as a consequence of 
hypocalcaemia, which can also be manifested in adults with acute medical conditions 
or trauma (Perez & Sullivan 2002). 
 
1.2.2.2. Cognitive and behavioural symptoms 
Psychiatric disorders associated with 22q11.2DS are amongst the most prevalent 
manifestations of 22q11.2DS (Antshel et al. 2010; Fung et al. 2010). Like other 
components of 22q11.2DS, psychiatric, cognitive, and behavioural phenotypes are 
extremely variable between 22q11.2DS patients with the same underlying 22q11.2 
deletion. In childhood, 26% and 41% of 22q11.2DS children develop ASD and ADHD 
respectively (Niarchou et al. 2014); whereas in adulthood, ~25% of 22q11.2DS adults 
develop schizophrenia (Murphy et al. 1999). Importantly, similar to the findings of the 
cardiac phenotype, no evidence showed that the length of the 22q11.2 deletion, or the 
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co-occurrence of other physical symptoms, contribute significantly to the variability 
of the cognitive or behavioural phenotype (Bassett et al. 2008; Gerdes et al. 2001). 
 
1.2.2.2.1. Developmental trajectories of developmental, cognitive, and behavioural 
phenotypes 
The brain is the least developed organ at birth, therefore phenotypic features of 
22q11.2DS that are associated with abnormal development and function of the central 
nervous system (CNS) are expected to manifest gradually throughout the patient’s life 
(Philip & Bassett 2011). Meechan and colleagues considered 22q11.2DS as a genetic 
disorder of neurodevelopment (Meechan et al. 2011). During prenatal or neonatal 
ages, a small number of CNS abnormalities, other than neonatal seizures related to 
hypocalcemia, are clinically detectable in 22q11.2DS (Bassett et al. 2005). 
Developmental delays are commonly observable during infancy (Roizen et al. 2007; 
Gerdes et al. 2001; Swillen, Devriendt, et al. 1999) including: 
1) Motor delays associated with hypotonia (Gerdes et al. 2001; Swillen, 
Devriendt, et al. 1999). 
2) Speech and language developmental delays  (Gerdes et al. 2001; Swillen, 
Devriendt, et al. 1999). 
3) Cognitive delays and learning difficulties which are common in 22q11.2DS 
(Antshel et al. 2010; Chow et al. 2006; van Amelsvoort et al. 2004; Swillen, 
Devriendt, et al. 1999). 
These are identifiable at any stage from the age of pre-school to the age of secondary 
school and also might affect functioning during adulthood (Swillen, Vandeputte, et al. 
1999). The intellectual level of the vast majority of patients with 22q11.2DS range 
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from an IQ of 70-84 (Antshel et al. 2010; Chow et al. 2006; van Amelsvoort et al. 
2004; Swillen, Devriendt, et al. 1999). 33.3% of the patients have a mild intellectual 
disability, whereas more severe levels are uncommon in 22q11.2DS (Chow et al. 
2006; Bassett et al. 2005; Swillen et al. 2000). 
The behavioural symptoms in 22q11.2DS include high rates of communication, 
cognitive, and psychiatric disorders (Swillen, Vandeputte, et al. 1999). 22q11.2DS 
children and adults manifest poor communication skills, social withdrawal, other 
behavioural symptoms such as shyness withdrawn and internalizing behaviour, 
impulsivity, disinhibited behaviour, and attentional problems (Swillen, Vandeputte, et 
al. 1999). These behavioural problems are the consequences of other disorders which 
had been reported to occur at an increased rate in 22q11.2DS patients such as ADHD, 
ASD, and anxiety disorders (Antshel et al. 2006). 
Neuropsychiatric phenotypes also change among the course of development in 
22q11.2DS (Swillen, Devriendt, et al. 1999). In childhood, attention deficit and 
anxiety disorders have been reported to be common in 22q11.2DS (Niklasson et al. 
2009; Antshel et al. 2010), considerably higher than in the general population 
(Niklasson et al. 2009). Symptoms of ASD are also common among 22q11.2DS 
children (Niklasson et al. 2009; Vorstman et al. 2006).  
In adulthood, 60% of 22q11.2DS patients have been reported to have treatable 
psychiatric disorders with no psychotic phenotypes (Fung et al. 2010). Moreover, 
generalized anxiety disorder is also common in adult patients with a prevalence of two 
to three times higher than in the general population (Fung et al. 2010). However, the 
most important psychiatric illnesses with the greatest elevation in risk associated with 
22q11.2DS in adulthood is schizophrenia. 20-25% of adult 22q11.2DS patients 
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developed schizophrenia or related psychotic disorders such as schizoaffective 
disorder (Murphy et al. 1999; Vorstman et al. 2006; Schneider et al. 2014), which is 
~20 times increased compared to the general population (Fung et al. 2010). In addition, 
multiple studies have reported ~1% of schizophrenic patients in the general population 
have 22q11.2 deletions (Karayiorgou et al. 1995; Bassett & Chow 2008; Xu et al. 
2008; The International Schizophrenia Consortium 2008; Stefansson et al. 2008; 
Kirov et al. 2009; Rees et al. 2014). 
 The International Consortium on Brain and Behaviour in 22q11.2 Deletion Syndrome 
have conducted the largest investigation of the lifetime psychiatric diagnoses in 
22q11.2DS (Schneider et al. 2014). The study included 1,402 individuals with 
22q11.2DS with different age categories; children (aged 6–12 years), adolescents 
(aged 13–17 years), emerging adults (aged 18–25 years), young adults (aged 26–35 
years), and mature adults (36 years and older). ADHD, ASD, and anxiety disorders 
were the most common psychiatric phenotypes among 22q11.2DS children, whilst 
psychosis and mood disorders are more common in adolescence and young adulthood. 
Similar prevalence and developmental trends were observed accross the countries 
(Schneider et al. 2014) (Table 1- 2). 
 
 
Psychiatric disorders 
 
Prevalence rates in 22q11.2DS 
 
Children and Adolescents Adults  
6–12 years 13–17 
years 
18–25 
years 
26–35 
years 
36+ years 
ASD 12.77% 26.54% 16.10% - - 
ADHD 37.10% 23.86% 15.59% - - 
Anxiety 35.63% 33.92% 24.07% 24.83% 27.56% 
Mood disorders 3.29% 11.85% 18.27% 14.67% 20.47% 
Schizophrenia 
spectrum disorder 
1.97% 10.12% 23.53% 41.33% 41.73% 
 Table 1- 2: Prevalence rates for common psychiatric disorders in 22q11.2DS (Schneider et al. 
2014). 
20 
 
 
To date, relatively few studies have investigated the neurological symptoms in older 
22q11.2DS patients. However, there are some initial indications that early onset 
Parkinson’s disease (PD) is associated with 22q11.2DS (Booij et al. 2010; Zaleski et 
al. 2009). In a cohort of 68 adults with 22q11.2DS (> 35 years old), four were found 
to develop PD (Butcher et al. 2013). These patients had neither a family history of PD 
nor any identifiable known pathogenic risk mutations for PD. Post mortem analysis 
revealed that in addition to classic loss of midbrain dopaminergic neurons in the four 
cases, two of them also had α-synuclein-positive Lewy bodies. These findings possibly 
indicate that 22q11.2 deletions can be a risk factor for PD.   
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1.3. Identifying 22q11.2 candidate genes for neuropsychiatric 
phenotypes 
The variability in the clinical features seen in 22q11.2DS is not explained by 
differences in gene content spanned by the deleted region (Philip & Bassett 2011). It 
is therefore likely that one or more of the genes spanned by the deletion increase risk 
for the behavioural symptoms and psychiatric disorders associated with in 22q11.2DS 
(Bassett & Chow 2008; Insel 2010; Meechan et al. 2011). The 22q11.2 region spans  
over 40 protein genes, and a number of which is expressed in mouse and human brain 
(Maynard et al. 2003; Meechan et al. 2009) and have roles in brain development, 
neurotransmitter levels, and myelination (Jungerius et al. 2008; Prasad et al. 2008). 
Some are therefore strong candidate genes for neuropsychiatric diseases and as such 
have been tested for association with these phenotypes.  
Catechol-O-methyl transferase (COMT) encodes an enzyme that plays a role in the 
degradation of catecholamines including dopamine in the synapse. Two main well-
characterized protein isoforms are encoded by this gene which display an altered 
structure, affinity, and capacity for their substrate (Tunbridge et al. 2006). The shorter 
cytoplasmic soluble form (S-COMT) predominates and accounts ~95% of total 
enzymatic activity in most assayed tissues. The other form is a longer membrane 
bound form (MB-COMT) that is more prevalent in brain tissue and responsible for 
dopamine inactivation in the surfaces of pre and post synaptic neurons (J. Chen et al. 
2011). COMT  has a nonsynonymous functional polymorphism (rs4680) with G allele 
substituted by an A allele and results an amino acid substitution (valine>methionine) 
at codon 108 in S-COMT and 158 in MB-COMT transcripts (Lachman et al. 1996). 
The outcome of the Val(108/158)Met polymorphism is an alteration in the activity of 
both COMT isoforms, with the Val COMT form (G variant) having higher activity 
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than the Met form (A variant). The COMT Met polymorphism decreases COMT 
enzymatic activity by 40% in prefrontal cortical (PFC) tissues (Chen et al. 2004). 
Although COMT is expressed in all brain regions, it has a minor role in dopamine 
clearance in comparison to the dopamine transporter and subsequent monoamine 
oxidase metabolism for neuronal synaptic uptake (Gogos et al. 1998). However, in the 
PFC the level of dopamine transporter expression is low, thus, the effect of active 
COMT is more relevant in this brain region (Gogos et al. 1998). Accordingly, 
individuals with a 22q11.2 deletion who carry the less active Met allele are expected 
to have higher dopamine levels in the PFC brain region which has been suggested 
could lead to an increased risk for developing psychosis (Egan et al. 2001). Therefore, 
COMT has been a strong 22q11.2 candidate gene for psychiatric disorders (Bearden 
et al. 2004). 
The gene PRODH encodes for the proline oxidase or proline dehydrogenases 1, an 
enzyme that plays a role in degradation of the amino acid proline. Homozygous 
mutations in PRODH result in a rare neurological illness called by hyperprolinemia 
type 1 which is associated with a highly increased level of proline (Raux et al. 2007). 
The genes GNB1L and TBX1 are adjacent genes. Haploinsufficency of which has been 
correlated with the behavioural impairment observed in 22q11.2DS mice models 
(Paylor et al. 2006). 
The gene SEPT5 is a member of the septin family that is widely expressed in the brain. 
It is a negative regulator for an elevated release of neurotransmitter by binding to 
SNARE-protein (Suzuki et al. 2009). 
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The gene RTN4R encodes NOGO receptor 1 that regulates axonal growth and post-
injury axon regeneration. Furthermore, it has been considered as a candidate gene for 
schizophrenia (Hsu et al. 2007). 
ZDHHC8 encodes for an enzyme called palmitoyltransferase. Genetic variants in this 
gene have been reported to be associated with schizophrenia (Liu, Heath, et al. 2002; 
Xu et al. 2010).  
The protein encoded by DGCR8 gene has a critical role in the biogenesis of micro-
RNAs that play a key function in regulating gene expression. This gene has been 
implicated to contribute to phenotypic variation in psychiatric and 
neurodevelopmental disorders (Stark et al. 2008). 
The role of these genes in neuropsychiatric phenotypes associated with 22q11.DS have 
been investigated by either investigating genetic variants in 22q11.2DS patients or by 
directly assessing the genes function in murine models of 22q11.2DS (Jonas et al. 
2014). 
 
1.3.1. 22q11.2DS mice model 
Using genetic linkage analysis and detailed physical mapping, Puech and colleagues 
identified the region on mouse chromosome 16 (MMU16) that is orthologous to the 
deleted region on human chromosome 22q11.2 (HSA22q11.2). Most of the genes in 
the 3Mb 22q11.2 region, from IDD (centromeric) to IGL (telomeric), are located in a 
single region of mouse chromosome 16, however, the organization of these genes is 
distinct from that in humans (Puech et al. 1997) (Figure 1- 7). Detailed physical 
mapping showed that some genes have the same order and orientation in the two 
species (IDD, TSK, ES2, GSC, and CTP), the position of some genes have changed 
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during evolution (DGR6, LZTR-1, and ZNF74), and while the relative order of some 
genes has been conserved and their overall orientation has been inverted (HIRA, 
UFD1L, CDC45L, TMVCF, CDCREL1, GPIBβ, TBX1, T10, COMT, ARVCF, and 
RANBP1) (Lindsay et al. 1999; Puech et al. 1997). ATP6E, CLTD, GNAZ, BRC, 
GSTTII, and MIF are genes present in HSA22q11.2 but not in its homologous region 
of MMU16qA13 (Puech et al. 1997). In addition, two genes (DGCR6 and DGCR6L) 
are present in HSA22q11.2 while only a single gene (Dgcr6) is present at 
MMU16qA13 (Karayiorgou et al. 2010). Similar to the human 22q11.2 locus, the 
orthologous region on MMU16 is also spanned by LCRs making it highly susceptible 
to rearrangement (Puech et al. 1997). By targeting multiple contiguous genes, or single 
genes at the MMU16 orthologous region, a number of mice strains have been 
engineered (Figure 1- 8). 
The first mouse model of 22q11.2DS has been created by deleting a ~1.2Mb region 
(Df1) of mouse chromosome 16 and were called Df1+/- mice model. This region 
spanned 22 functional genes that have human orthologues at 22q11.2 region (Lindsay 
et al. 1999). Similarly, the Df(16)1+/- mouse model has been generated with 23 
deleted genes (Lindsay et al. 1999; Paylor & Lindsay 2006). Murine models with 
longer deletions have also been created: both the Lgdel+/- (Merscher et al. 2001) and 
Df(16)A+/− (Mukai et al. 2008; Stark et al. 2008) models harbour a 1.3 Mb 
hemizygous deletion which included 27 genes. Murine models with smaller deletions 
have also been engineered: Smdel+/- mice model, that carries a 550-kb deletion 
involved 16 genes without Tbx1 gene (Puech et al. 1997), also another mice model 
with a deleted 150Kb portion of the proximal region of the deletion (Kimber et al. 
1999). 
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Moreover, a range of mice models have been engineered by attenuating or deleting a 
specific candidate gene, which include Tbx1 (Lindsay et al. 2001), Comt, Prodh 
(Paterlini et al. 2005), Dgcr8, and Zdhhc8 (Mukai et al. 2004).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1- 7: Human 22q11.2 region and the syntenic mouse 16qA13 genomic region.  
Human chromosome 22 (HSA22) and mouse chromosome (MMU16). The gene content of the human 22q11.2 and mouse 
16qA13 is shown in centromeric-telomeric order. Genes in boxes with matching colours in both species indicating they are 
homologues. Genes in blue boxes (with different blue shadows) have the same orders and orientation but a different location 
in both species. Genes in green boxes (with different green shadows) have the same order but a reverse orientation and 
different position in both species. Genes in orange boxes are present in one species and absent in the other. Gene names 
between brackets are alternative gene names used in UCSC genome browser, The National Center for Biotechnology 
Information reference (Genome.ucsc.edu, n.d.). Original figure based on the data from UCSC genome browser for mouse 
and human and the information from (Lindsay et al. 1999; Puech et al. 1997; Paylor & Lindsay 2006). 
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Figure 1- 8: Human 22q11.2 deletions and 22q11.2DS engineered mice models. 
A. Human 22q11.2 gene content is shown in centromeric–telomeric order. Grey bars indicate the common ~3Mb deletion and the 
rarer ~1.5Mb deletions found in 22q11.2DS patients. Both deletions are mediated by aberrant homologous recombination between 
blocks of low copy repeat sequences (Red boxes) distributed through the 22q11.2 region. 
B. Syntenic mouse 16qA13 gene content is shown in centromeric–telomeric order. In the mouse, there has been some reshuffling of 
gene order, orientation, and position with respect to the syntenic human chromosomal region (shown by genes matching bar colours 
in both species). 
Primarily, the order of a large block of genes (HIRA-ZDHHC8) is inverted in the mouse genome. CLTCL gene has not been identified 
in the mouse (yellow bar). Grey bars indicate 22q11.2DS generated mice models with various sizes of deletions spanning the 
homologous 22q11.2 multi genes in mice. The gene content of the various deletions is depicted.  Mice models with a single Df1 gene 
knockdown are highlighted by light red vertical bars. Along with each mice model, references for studies investigated these 22q11.2 
mice models. Original figure based on the information from (Paylor & Lindsay 2006).  
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1.3.1.1. Studies on Df1 mice model 
1.3.1.1.1. Behavioural and cognitive phenotypes in Df1 mice models 
Mice models with homozygous deletions (Df1-/-) did not survive and had embryonic 
lethality (Lindsay et al. 1999). On the other hand, although those with heterozygous 
deletions Df1+/- were viable; however, they showed congenital heart defects similar 
to those seen in 22q11.2DS (Lindsay et al. 1999), In addition to the congenital 
abnormalities observed in these mice, they also expressed behavioural abnormalities 
(Lindsay et al. 1999) (Figure 1- 9). 
Due to difficulties in studying 22q11.2DS behavioural deficit in mice models, 
cognitive functions that can be tested in 22q11.2DS patients as well as in Df1 mice 
models were examined. These functions encompassing attention, executive function, 
working memory, and short-term verbal memory which can represent the activity of 
the prefrontal cortex and hippocampus (Sobin et al. 2006). Paylor and colleagues 
reported anomalies of sensorimotor gating in the Df1+/- mice, which was 
demonstrated by impaired pre-pulse inhibition (PPI) (Paylor et al. 2001). This 
phenotypic feature was also described in patients with schizophrenia and patients with 
22q11.2DS (Sobin et al. 2006). Moreover, these mice also expressed memory and 
learning impairments (Paylor et al. 2001). Lgdel+/- mice also showed similar impaired 
PPI in addition to abnormality in grip strength and nociception (Long et al. 2006). 
Conversely, mice that are heterozygous for a deletion of proximal 150Kb region of 
Df1 showed an increased PPI (Kimber et al. 1999).  
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1.3.1.1.2. Gene expression in Df1 mice models 
The gene expression studies on the Df1 mice models showed that MMU16qA13 genes 
begin to express in mouse embryos and undergo several dynamic expression changes 
among different embryonic development stages (Amati et al. 2007).  
The effect of haploinsufficiency on gene expression was thought to account for the 
cardiac defects in these Df1+/- mice, therefore, they had been studied to investigate 
gene expression by using microarray and Real Time Quantitative PCR (RTqPCR). 
Prescott and colleagues extracted RNA from dissected branchial arch region and heart 
of Df1+/- embryos at embryonic day (E) 10.5, during which the arch-artery phenotype 
is fully penetrant (Prescott et al. 2005). 12 of the genes mapping to the Df1 deletion 
were covered by MG-U74a microarray used in this study. 75% (n= 9) of the 12 Df1 
genes were identified as significantly down regulated in Df1+/- mice (FDR <0.05). 
Figure 1- 9: Pre-pulse inhibition phenotypes in 22q11.2DS mice models.  
Grey bars indicate generated 22q11.2DS mice models with various sizes of deletions spanning the 
homologous 22q11.2 multi genes in mice. The gene content of the various deletions is depicted.  Along 
with each mice model, PPI phenotypes, either impaired indicated by a downward arrow or increased 
indicated by an upward arrow, and references for studies investigated these 22q11.2 mice models. Original 
figure based on the information from (Paylor & Lindsay 2006). 
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33.3% of the 75% genes were validated by RTqPCR and showed reduced hemizygous 
expression. Genome-wide, the analysis showed some of the downregulated genes have 
a role in vasculogenesis and cardiogenesis including Connexin 45 and Dnajb9 
(Prescott et al. 2005). These findings confirmed that the cardiac abnormality seen in 
by Df1+/-  mice is resulted possibly by some dosage sensitive genes within the Df1 
deletion and some other genes that have a key role in the cardiac pathogenesis 
(Prescott et al. 2005). 
Although the mice with a hemizygous Df1 deletion have cardiac anomalies similar to 
those seen in 22q11.2DS patients; however, Lindsay and colleagues noticed that mice 
with a deletion in one 22q11.2 chromosome and a duplication in the other chromosome 
(Df1/Dp1) have no abnormal cardiac phenotypes (Lindsay et al. 1999). This finding 
indicated that cardiac defects seen in 22q11.2DS are possibly resulted by the 
haploinsufficiency of dosage sensitive genes in 22q11.2 region (Lindsay et al. 1999). 
To identify what particular genes in 22q11.2 region that is associated with cardiac 
defects, Lindsay and colleagues further investigated Tbx1 knockout mice. The results 
showed a defective development of the 4th pharyngeal arch artery observed in Tbx1+/- 
mice, which suggested that Tbx1 gene is responsible for heart abnormality in 
22q11.2DS (Lindsay et al. 2001). In humans, this finding was confirmed by observing 
a series of individuals with typical 22q11.2DS cardiac phenotypes; however, no 
22q11.2 deletion in these individuals. However, these individuals were found to have 
a point mutation in the TBX1 gene (Yagi et al. 2003). 
A number of studies have investigated gene expression in the central nervous system 
of Df1+/-  mice. Hippocampal sections of 10 week-old Df1+/- and wild-type mice 
were used for RNA extraction for microarray and RTqPCR analyses. The results 
showed that 57.1% of the analysed Df1 genes (n= 12/21) have a highly significant 
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reduction in gene expression with an average expression reduction equal to 33%. The 
dosage sensitive genes included Prodh and Comt (Jurata et al. 2006). 
Sivagnanasundaram and colleagues confirmed these findings by using RNA samples 
extracted from the brain of adult Df1+/- and wild-type mice (Sivagnanasundaram et 
al. 2007). 41.7% of the Df1 genes expressed in the hippocampus (n= 5/12) and were 
significantly down regulated in the Df1+/- hippocampus (p-value <0.05). Globally, 
159 other genes were identified to be differentially expressed in the hippocampus of 
these mice (p-value <0.05) (Sivagnanasundaram et al. 2007). 
In another study, the expression of nine 22q11.2 orthologues genes (Idd, Prodh, 
Zdhhc8, Ranbp1, T10, Comt, Tbx1, Ufd1l, and Hira) were investigated in the brains 
or dissected brain regions from later fetal (E10.5 embryos), postnatal, adolescent, and 
adult Df1+/-  mice. The results revealed a diminished expression of these genes in 
these models by 40-60% (Meechan et al. 2006). 
 
1.3.1.2. Studies on a single 22q11.2 gene knocked out mice 
Other models of mice, which were deficient for a single 22q11.2 gene, were 
investigated for association of specific 22q11.2 genes and behavioural phenotypes 
(Meechan et al. 2011; Paterlini et al. 2005; Gogos et al. 2009; Paylor et al. 2006; Gogos 
et al. 1998; Hsu et al. 2007; Suzuki et al. 2009). 
Most of these models had impairments in PPI and/or learning and memory (Meechan 
et al. 2011; Paterlini et al. 2005). Mice with haploinsufficient Dgcr8 and Zdhhc8 genes 
showed impaired PPI (Mukai et al. 2004; Gogos et al. 1998). Impairment in PPI in  
Dgcr8+/- and Zdhhc8+/- mice was thought to be attributed to the impaired dendritic 
growth and spine development that were also observed in these mice (Stark et al. 2008; 
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Mukai et al. 2004). Defects in PPI was also found in mice with homozygous deficiency 
of Prodh gene (Gogos et al. 2009). Defect in sensorimotor gating was observed in 
mice with knocked down Comt, Rtn4r, and Sept5 genes; however, they had normal 
PPI (Gogos et al. 1998; Hsu et al. 2007; Suzuki et al. 2009). In addition, it was 
observed that mice with either haploinsufficient Tbx1 or adjacent Gnb1l have deficit 
in sensorimotor gating (Paylor et al. 2006). 
As many of these mice models expressed defects in CNS functions, it is difficult to 
pinpoint a major gene being responsible for the behavioural phenotype in 22q11.2DS 
(Williams 2011). Additionally, genes interaction is highly suggested (Meechan et al. 
2011; Paterlini et al. 2005). Studying mice with both haploinsufficient Prodh and 
Comt genes showed a deficit in working memory (Paterlini et al. 2005). Strikingly, 
mice with either haploinsufficient Prodh or Comt have no working memory deficit 
(Paterlini et al. 2005). Paylor and colleagues investigated many other overlapping 
deletions and determined a PPI critical region that compassing four genes including 
Gnb1l, Tbx1, Gp1bβ, and Cdcrel1 (Paylor et al. 2006). A summary of phenotypes in 
these mice models are given in Table 1- 3. 
 Dgcr8 
+/- 
Zdhh8 
+/- 
Prodh 
+/- 
Comt 
+/- 
Rtn4r 
+/- 
Sept5 Tbx1 
+/- 
Gnb1l 
+/- +/- -/- 
PPI          
WM          
SG          
Reference Mukai 2004 
Gogos 1998 
Gogos 2009 Gogos 1998 Hsu 2007 Suzuki 2009 Paylor 2006 
  
 
 
Table 1- 3: Behavioural and cognitive phenotypes of single22q11.2 gene knocked down mice.  
PPI: Pre-pulse inhibition 
WM: Working memory. 
SG: Sensory gating. 
Red box indicates low performance. 
Grey box indicates normal performance. 
Green box indicates high performance. 
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1.3.2. Analysis of genotypes on the haploinsufficient chromosome in 22q11.2DS  
1.3.2.1. COMT 
Bearden and colleagues genotyped the COMT Val158Met polymorphism in 44 
children with 22q11.2DS who had been subjected to neurocognitive testing (Bearden 
et al. 2004). Children with the Met allele revealed significantly better performance on 
executive functions composite score than those with Val allele (p-value <0.001). 
However, performance on verbal fluency and arithmetic tasks showed no difference 
between groups (p-value >0.05) (Bearden et al. 2004). Despite this finding being 
supported by 2 independent studies (Kates et al. 2006; Shashi et al. 2006), analyses of 
much larger sample sizes have either found evidence for association in the opposite 
direction (Gothelf et al. 2005; Bassett et al. 2007), or have failed to find evidence for 
association with neurocognitive measures (Baker et al. 2005; Glaser, Debbane, et al. 
2006; van Amelsvoort et al. 2008). 
A number of studies have investigated polymorphisms at COMT for association with 
psychiatric illness. In general, the findings have failed to identify significant evidence 
for association with psychiatric disease. In one of the earliest studies, Murphy and 
colleagues (Murphy et al. 1999) analysed 48 adults with 22q11.2DS, of which 12 
individuals had schizophrenia, and did not identify any significant evidence for the 
COMT Val158Met polymorphism being associated with psychosis (p-value= 0.70). In 
addition, the study revealed no correlation between COMT allelic distribution and 
symptom severity measured by a schizotypy scale of all 22q11.2DS individuals (p-
value = 0.50) (Murphy et al. 1999). Similarly, using an independent samples of 73 and 
92 Caucasian 22q11.2DS adults, Bassett and colleagues (Bassett et al. 2007), and Raux 
and colleagues (Raux et al. 2007) failed to show any significant evidence for 
association with schizophrenia. 
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1.3.2.2. PRODH 
Homozygous mutations in the gene PRODH result in hyperolinemia type 1, which is 
a rare neurologic disorder associated with variable phenotypes (Raux et al. 2007). The 
coding SNP rs4819756 has been associated with variable PRODH activity, with the 
A-allele resulting in a reduction in PRODH activity by ~45% (Bender et al. 2005). 
Recently, Radoeva and colleagues, investigated genotyped rs4819756 in a cohort of 
22q11.2DS individuals with (n= 19) and without (n=67) ASD (Radoeva et al. 2014). 
The results revealed no significant association with ASD diagnosis (p-value >0.05) 
(Radoeva et al. 2014). 
 
1.3.2.3. PIK4CA 
Three  SNPs (rs2072513, rs165862 and rs165793) located at PIK4C4 were initially 
reported to be significantly associated with schizophrenia in a sample of 310 
schizophrenic patients and 880 controls (Jungerius et al. 2008). As this gene is spanned 
by the common 22q11.2 deletion, a number of studies investigated their association 
with schizophrenia in patients with 22q11.2DS. The initial study of a Canadian adult 
cohort (n= 79) revealed significant evidence for a single marker (rs165793-G allele) 
being associated with schizophrenia in 22q11.2DS (p-value= 0.006), which also 
provided support to the hypothesis that the effect size would be increased in the 
22q11.2DS cohort (OR= 9.47 (1.16-77.56)) (Vorstman, Chow, et al. 2009). However, 
despite this encouraging result, a subsequent independent study of 83 individuals with 
22q11.2DS, of which 24 individuals had experienced psychosis, was not able to 
identify any significant evidence for association with schizophrenia for either 
rs165793 (p-value= 0.28) or any SNPs within PIK4CA (p-values >0.05) (Ikeda et al. 
2010).  
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1.3.2.4. GNB1L 
In an association study of 83 subjects with 22q11.2DS with and without psychosis, 
SNPs mapped to GNB1L (rs2269726 and rs5746832) were genotyped. The results 
revealed a significant allelic association of rs2269726 and rs5746832 with psychosis 
which was selective for males (p-value= 0.018) (Williams et al. 2008). By using allele 
specific expression analysis, rs2269726 was also correlated with significant 
differential allelic expression at GNB1L (p-value= 6.3x10-7); rs2269726 “T” and 
rs5746832 “G” alleles were correlated with high expression of GNB1L (Williams et 
al. 2008). These findings however require independent replication. 
 
Overall, attempts to identify small critical segments or SNPs on individual genes 
within the 22q11.2 region have not been conclusive. In addition, it is hard to predict 
whether the weak association of a SNP with a psychiatric phenotype in 22q11.2DS 
reflected the weak impact of that SNP on the protein function, or the weak contribution 
of the protein in that psychiatric phenotype (Philip & Bassett 2011).  
 
1.3.3. Evaluation of 22q11.2 genes as candidate susceptibly genes for common 
psychiatric disorders in the general population 
Several studies have attempted to test common genetic variants mapped to 22q11.2 
region for association with neuropsychiatric disorders in large case/control cohorts 
who do not carry deletions at 22q11.2. However, results of these studies showed 
inconsistent findings. 
A large number of studies have tested the COMT Val(108/158)Met polymorphism for 
association with schizophrenia. Some studies have observed a slightly elevated COMT 
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Val allele frequency in schizophrenic patients (Glatt et al. 2003; Fan et al. 2005), 
however, this finding was not observed in other studies (Williams et al. 2007; 
Nieratschker et al. 2010; C. Chen et al. 2011). In addition, no significant association 
was identified in 3 meta-analyses of published schizophrenia case/control data 
(Munafò et al. 2005; Glatt et al. 2003; Fan et al. 2005). Furthermore, larger studies of 
cohorts that were not involved in the meta analyses also showed no evidence for 
COMT association in 22q11.2DS European (Williams et al. 2005), and Asian (Fan et 
al. 2005) populations. Studies investigating the association of the COMT 
Val(108/158)Met polymorphism with prefrontal cognitive functions have also showed 
inconsistent results; with some reporting an association between the COMT Met allele 
with better cognitive functions (Egan et al. 2001; Caldú et al. 2007) and others 
reporting an association with worse cognitive performance (Caldú et al. 2007; Wang 
et al. 2013).  
Three SNPs (rs2072513, rs165862, and rs165793) at PIK4CA were initially found to 
be significantly associated with schizophrenia in a cohort of 310 Dutch schizophrenic 
patients and 880 Dutch controls (Jungerius et al. 2008). This finding has been partially 
supported by the International Schizophrenia Consortium where a single SNP 
(rs165862) was associated with schizophrenia with p-value< 0.0067 in a cohort of 
European individuals. However, this finding was not replicated in an independent 
cohort of individuals with a non-European background (Kanahara et al. 2009). 
Association analysis of genetic variants at the TBX1/GNB1L locus identified a 
significant excess of homozygous genotypes in schizophrenic patients at markers 
rs5746832 and rs2269726 (an excess of both TT (OR= 1.28) and CC (OR=1.36) 
homozygotes). This association was stronger in male schizophrenic patients (Williams 
et al. 2008). Further investigation was conducted to study if this genetic association 
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could be link to gene expression showed that the “T” allele at rs2269726 was 
associated with a 20% increase in GNB1L expression when compared to the “C” allele. 
It was suggested that the increased risk of psychosis in these patients reflected dosage 
sensitivity of GNB1L gene (Williams et al. 2008). 
Two studies have analysed genetic variants mapped to TBX1 locus in two populations 
with different ethnic backgrounds (Funke et al. 2007; Ma et al. 2007). The results 
revealed no evidence for an association of TBX1 variants with patients with psychiatric 
phenotypes compared to controls. 
Significant genetic association has also been found between functional 
polymorphisms at PRODH and schizophrenia (Kempf et al. 2008; Li et al. 2004; Liu, 
Abecasis, et al. 2002). However, these findings have not been supported by 
independent replication studies (Fan et al. 2003; Glaser, Moskvina, et al. 2006; Glaser, 
Debbane, et al. 2006; Ohtsuki et al. 2004; Williams et al. 2003).Two independent 
studies initially reported significant association between variants at ZDHHC8 and 
schizophrenia (Liu, Abecasis, et al. 2002; Mukai et al. 2004). However, these findings 
were not supported by further studies in Japanese and European populations (Glaser, 
Moskvina, et al. 2006; Otani et al. 2005; Saito et al. 2005). Xu and colleagues 
conducted a meta-analysis and identified that ZDHHC8 variants were negatively 
associated with schizophrenia (Xu et al. 2010). 
Only a single study has reported a significant association of schizophrenia and a 
functional polymorphism in UFDIL gene (De Luca et al. 2001).  
Chen and colleagues failed to provide significant evidence for association between 
four SNPs at ARVCF and schizophrenia (Chen et al. 2005); however, Mas and 
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colleagues reported a significant association of rs165815, a functional variant in exon 
15 of ARVCF, in a Caucasian sample from Catalonia (Mas et al. 2010). 
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1.4. Possible molecular mechanisms underlie the neuropsychiatric 
phenotypes variability in 22q11.2DS 
There is strong evidence that deletions at 22q11.2 confer an increased risk to develop 
psychiatric disease. This thesis will consider 3 molecular mechanisms that have been 
suggested to potentially be involved in disease pathogenesis (Williams 2011): 
1) Gene dosage sensitivity of the genes spanned by the deletion. 
2) Presence of positional effects on nearby genes that are influenced by the 
deletion. 
3) Presence of additional genetic risk variants that are independent to the primary 
22q11.2 deletions that are located either i) on the non-deleted allele, or ii) 
elsewhere in the genome. 
These molecular mechanisms will be described in details in the result chapters of this 
PhD study. 
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1.5. Thesis aims and objectives 
The main aims of this study are: 1) to investigate the molecular mechanisms that 
possibly influence the increased psychiatric phenotypes risk in 22q11.2DS, 2) to 
investigate the involvement of 22q11.2 deletions in the risk of Parkinson’s disease. 
The work in chapter three aims to obtain a cohort for 22q11.2DS children, which are 
independent; ethnically homogenous; and true 22q11.2 deletion carriers, that can be 
used for the subsequent analyses conducted in this PhD thesis.  
Chapter four aims to investigate gene expression in 22q11.2DS. The work firstly will 
assess the gene expression of haploinsufficient genes located within 22q11.2 to 
highlight dosage sensitive genes, which are potentially strong candidates for future 
investigations into the behavioural phenotype associated with 22q11.2DS. Secondly, 
expression of genes located outside 22q11.2 will be assessed to investigate positional 
effect that is possibly conferred by the deletion on adjacent genes. Thirdly, biological 
pathways that are potentially affected by the 22q11.2 deletion will be investigated by 
analysing genome-wide differential gene expression in 22q11.2DS. Lastly, changes in 
gene expression between 22q11.2 deletion carriers affected and unaffected with a 
psychiatric disorder will be investigated to identify genes that possibly play a direct 
role in the increased risk to psychiatric disease. 
The work in chapter five aims to systematically screen genetic variants in the 
remaining, non-deleted chromosome of 22q11.2 to identify those that are associated 
with the increased risk of psychiatric disorders in 22q11.2DS. 
In chapter six, we aim to investigate whether the presence of second large, rare CNVs 
in 22q11.2DS children is related to the increased risk of childhood neuropsychiatric 
phenotypes in these patients. 
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The work in chapter seven aims to investigate the association of 22q11.2 deletions 
with Parkinson’s disease, particularly the early onset form of the disease. 
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Chapter 2: Materials and Methods 
 
 
2.1. Participants 
22q11.2DS participants analysed in this PhD study were recruited by two main 
studies: the Cardiff ECHO study (Study of ExperienCes of people witH cOpy number 
variants) and the London BBAG study (Study of Brain, Behaviour And Genetics in 
22q11.2 deletion syndrome). 
The Cardiff ECHO study is an ongoing study at the MRC centre for neuropsychiatric 
genomics and genetics in Cardiff University. The principal investigators are Prof 
Marianne van den Bree and Prof Michael Owen. ECHO participants are referred from 
11 genetics clinics within the UK, as well as a number of charities. The ECHO field 
team recruited ~92 22q11.2DS children and ~71 control siblings at the time of starting 
this PhD. The 22q11.2DS children had a mean age of 10.2 years (SD= 2.1), age range: 
6–14 years. The psychopathology, cognition, and behavioural abnormalities were 
assessed in these individuals by the ECHO field team (Niarchou et al. 2014; Niarchou 
et al. 2015). Biological samples, for DNA and RNA extractions, were also collected 
during the field team visits.  
The London BBAG study is ongoing at King’s College London and is led by Dr 
Michael Craig. 22q11.2DS children and non-deleted controls were recruited mainly 
for brain imaging studies. Blood samples, for DNA and RNA extractions, were also 
collected from these individuals during their imaging sessions. Total 21 individuals 
were recruited including 3 22q11.2DS cases and 18 controls. 22q11.2DS children have 
a mean age of 13.6 years. 
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In total there were 166 samples available for DNA extraction (95 children with 
22q11.2DS and 71 non-deleted controls), and 79 samples available for RNA extraction 
(36 children with 22q11.2DS and 43 non-deleted controls) from both studies. 
 
2.1.1. Biological samples collection 
For each recruited individual, the field teams aimed to collect two biological samples, 
one for DNA extraction and the other for RNA extraction. Blood or saliva samples 
were collected for DNA extraction. Blood samples were collected either in PAXgene 
tubes or sodium EDTA tubes and accordingly different DNA extraction kits were used 
based in the collected tubes. A blood sample was collected in a PAXgene tube for 
RNA extraction. A summary of the number of samples collected in both ECHO and 
BBAG studies for DNA and RNA extractions is given in Table 2- 1. 
 
 For DNA extraction For RNA extraction 
Blood samples Saliva samples Blood samples 
22q11.2DS Controls 22q11.2DS Controls 22q11.2DS  Controls 
Cardiff 
ECHO 
study 
79 62 13 9 33 25 
London 
BBAG 
study 
3 13 0 0 3 18 
Total 82 75 13 9 36 43 
 
 
2.1.2. Psychiatric illnesses assessment 
Neuropsychiatric symptoms including ADHD and ASD, were examined in ECHO 
participants only. Psychiatric data was not available for BBAG participants. 
 
Table 2- 1: Number of samples collected by ECHO and BBAG studies for DNA and RNA 
extractions. 
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2.1.2.1. ASD diagnosis 
ASD phenotypes were assessed by the ECHO field team by using the Social 
Communication Questionnaire (SCQ) (Rutter, Bailey & Lord 2003), which was 
completed by the primary caregiver of the 22q11.2DS child.  
The SCQ questionnaire consists of 40 questions obtained from the Autism Diagnostic 
Interview-Revised algorithm (ADI-R), which is an evaluation algorithm for several 
phenotypes appearing in autism patients such as reciprocal social interaction, 
communication, restricted, repetitive, and stereotyped patterns of behaviours (Kim & 
Lord 2002). The questions included in the SCQ questionnaire assess both current 
behaviour and developmental history between the ages of 4 to 5. The questions cover 
four domains of phenotypes seen in autistic patients as follow; 
A: Qualitative Abnormalities in Reciprocal Social Interaction 
B: Qualitative Abnormalities in Communication 
C: Restricted, Repetitive, and Stereotyped Patterns of Behaviour 
D: Abnormality of Development Evident at or Before 36 Months 
ASD status of the ECHO 22q11.2DS children is mainly based on the SCQ. Total SCQ 
scores can range from 0 to 39. A cut-off of 15 suggests ASD and a cut-off of 22 is 
used to distinguish autism from other disorders on the spectrum (Berument et al. 
1999). 22q11.2DS participants have to get a score of 15 or above to meet ASD criteria.  
The average SCQ score among the recruited ECHO 22q11.2DS participants (n= 79) 
is 12.3 and the standard deviation equals to 6.8. Around 23.7% of the 22q11.2DS 
participants have an SCQ score ≥ 15 and diagnosed to have ASD; while ~61.8% are 
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healthy and have an SCQ score < 15. Summary statistics for SCQ scores in 22q11.2DS 
children affected and unaffected with ASD are given in Table 2- 2. 
 
 
2.1.2.2. ADHD diagnosis 
For ADHD diagnosis, the ECHO field team used the Child and Adolescent Psychiatric 
Assessment (CAPA) (Angold et al. 1995). It was used to obtain a DSM-IV-TR 
research diagnosis of ADHD for the 22q11.2DS participants. The CAPA is a semi-
structured interview that provides categorical diagnoses in addition to symptom counts 
of psychiatric disorders. Symptom counts were derived from responses to questions 
about worries, depression, sleep, and oppositional defiant disorder (ODD) 
behaviour/conduct problems. All interviews were undertaken by trained 
psychologists, who were supervised by a consultant child and adolescent psychiatrist. 
Also, the CAPA examines inattention, and hyperactivity and impulsivity sub-types of 
ADHD. All 22q11.2DS children who were diagnosed to have ADHD symptoms met 
DSM-IV criteria for ADHD. 
~ 38.2% of the ECHO 222q11.2DS children (n= 79) were identified to have ADHD 
phenotypes, while ~ 55.3% of them are unaffected with ADHD. 
 
Table 2- 2: Summary statistics of SCQ scores in 22q11.2DS children affected and unaffected with 
ASD. 
 22q11.2DS+ASD 22q11.2DS-ASD 
SCQ mean 21.0 8.7 
SCQ standard deviation 3.8 4.6 
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2.1.3. Cognitive assessment  
Neurocognitive assessments were conducted by trained raters in the ECHO filed team. 
The general intelligence (IQ) was estimated based on the Wechsler Abbreviated Scale 
of Intelligence (WASI) (Wechsler 1999). WASI comprised of four subtests; two 
verbal tasks, vocabulary and similarities, and two non-verbal tasks, block design and 
matrix reasoning. From these tests, verbal IQ (VIQ), performance IQ (PIQ), and full 
scale IQ (FSIQ) were derived.  
The children with 22q11.2DS children had a lower estimated total IQ (mean= 76.76; 
SD= 13) compared to their non-carrier siblings (mean= 108.56; SD= 15.6) (Niarchou 
et al 2014). Additionally, 22q11.2DS children performed worse than their normal 
siblings on all cognitive tests (Niarchou et al 2014). However, there was no IQ 
differences between 22q11.2DS children with ASD and those without ASD (Table 2- 
3). Also, no IQ difference was observed between 22q11.2DS children with and without 
ADHD (Table 2- 3). 
 
 
Therefore, as this thesis will compare the molecular changes between the 22q11.2DS 
children affected and unaffected with psychiatric phenotypes, ASD or/and ADHD, the 
observed molecular differences are more likely to be the responsible for the psychiatric 
phenotypes in these children rather than the reduced IQ. 
  
 
 
ASD ADHD 
22q11.2DS+ASD 22q11.2DS-ASD 22q11.2DS+ADHD 22q11.2DS-ADHD 
IQ mean 77.4 77.5 78.08 76.8 
Standard deviation 13.8 13.8 13.7 14.04 
Table 2- 3: Summary statistics of IQ scores in 22q11.2DS children affected and unaffected with psychiatric 
illnesses (ASD or ADHD). 
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2.2. DNA samples 
2.2.1. DNA sample extraction and storage 
Saliva samples were collected for DNA extraction by the Cardiff ECHO study used 
the Oragene DNA kit (DNA genoteck), while blood samples were collected in sodium 
EDTA tubes. All samples collected for DNA extraction by the London BBAG study 
were collected in the PAXgene DNA blood tubes. Kits for DNA extraction were 
selected based on the method of samples collection.  
 
2.2.1.1. Illustra Nucleon BACC3 DNA Kit 
All blood samples collected for DNA extraction by the Cardiff ECHO study were 
extracted by using Illustra Nucleon BACC3 Genomic DNA Extraction kit (GE 
Healthcare life sciences) according to the manufacturer’s recommendation. Briefly, 
DNA extraction was initially established by cell lysis then de-proteinisation with 
sodium perchlorate. Following treatment with chloroform and nucleon resin the DNA 
was precipitated in 100% ethanol and then washed in 70% ethanol. DNA molecules 
were then re-suspended in a TE buffer and stored at -20-25ᵒC. 
 
2.2.1.2. PAXgene DNA Kit 
Blood samples collected by the London BBAG study for DNA extraction were 
collected, stored and transported to Cardiff in PAXgene tubes. DNA molecules were 
extracted from these samples by using the combined PAXgene Blood DNA System 
kit (QIAGEN) by following the manufacturers recommended protocol. Briefly, the 
DNA isolation procedure using this kit began with degrading red and white blood cells 
by cell lysis buffer followed by washing and a re-suspension in a digestion buffer. De-
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proteinisation then was done by protease enzyme. DNA molecules were collected by 
isopropanol precipitation and washed by 70% ethanol. DNA molecules were then re-
suspended in a re-suspension buffer provided by the manufacturer and stored at -20-
25ᵒC. 
 
2.2.1.3. Oragene® DNA Kit 
All saliva samples collected in Oragene® DNA vial for DNA extraction by the Cardiff 
ECHO study were extracted by using Oragene® DNA Kit. DNA samples properly 
mixed with the Oragene® DNA solution followed by a heat-treatment step to 
maximise DNA yield and to inactivate nucleases. Then Oragene® DNA Purifier is 
added followed by incubating the sample at room temperature then centrifuging to 
precipitate impurities and inhibitors. The DNA-containing supernatant is transferred 
to a fresh tube to precipitate the DNA molecules by adding 95-100% ethanol. DNA 
sample is washed then by 70% ethanol and dried. Finally extracted DNA is rehydrated 
by TE buffer and stored at -20-25ᵒC. 
 
2.2.2. DNA sample quantification and quality control 
DNA samples were quantified and inspected for quality control using a 
Spectrophotometer (NanoDrop 8000 instrument) and Quant-iT PicoGreen® ds DNA 
assay kit.  
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2.2.2.1. Spectrophotometer DNA quantification 
Extracted DNA samples were initially quantified using a NanoDrop 8000 instrument 
(Thermo Scientific) that measured the absorbance (A) of UV light at 260nm and 
280nm wavelengths (λ). DNA concentration was calculated on the assumption that an 
A260 value of 1 was equivalent to 50µg/ml of DNA. A ratio of A260 to A280 equals to 
or larger than value of 1.8 is generally accepted as high quality DNA and absence of 
contaminating protein. If the ratio is lower than 1.8, it may indicate presence of 
contaminants such as protein, phenol or other contaminants that absorb strongly at or 
near 280nm. 
 
2.2.2.2. PicoGreen® DNA quantification 
Accurate DNA sample quantification was performed using a TECAN fluorometer 
(infinite F200 pro) and Quant-iT PicoGreen® ds DNA assay kit (Invitrogen). 
Initially, all DNA samples were diluted to ~50ng/µl based on spectrophotometer 
readings in a total volume of 20µl. Sample aliqouts were then diluted in 1X TE buffer 
in a black 96 well cliniplate to get a final DNA concentration of 0.6-1.2ng/µl. In 
parallel, a Picogreen working solution was prepared by adding 5µl of Picogreen to 
995µl of 1x TE buffer. 
100µl of the Picogreen working dilution was added to each diluted DNA sample. The 
TECAN fluorometer measured the DNA concentration of a sample using an UV 
excitation wavelength of 485nm and an emission wavelength of 535nm. A standard 
curve that had been prepared for several dilutions of standard dsDNA, was then used 
to calculate the concentration of DNA for each sample. The original samples were 
then adjusted so each was at concentration of 400-800ng in a total volume of 8µl.  
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2.3. DNA sample genotyping 
2.3.1. Genotyping 
The microarray platform used for genotyping 22q11.2DS samples was the Illumina 
Infinium Human CoreExome-24 BeadChip. This genotypes a total 551,839 SNPs, 
which include 300,000 common and highly informative SNPs that cover the entire 
genome. The array also included an additional 240,000 SNPs, which are exome 
focused markers and 27,000 custom markers that were selected because of their 
relevance to neuropsychiatric and neurological disorders. 
 
2.3.2. Pre-genotyping samples quality control 
22q11.2DS participants were selected for genotyping based on the quality of their 
DNA samples. Only DNA samples with high quality, including high DNA purity 
(A260/A280 ratio ≥1.8), and adequate DNA concentration, were selected for the 
analysis. Samples with a concentration lower than the required working concentration 
and volume for genotyping microarrays (200-400ng in 4µl) were excluded. Summary 
for DNA samples quality control is illustrated in Figure 2- 1. 
 
2.3.3. DNA samples preparation 
All DNA samples had a high quality with adequate concentration and volume, 
therefore, they were optimized to the working DNA concentration for the genotyping 
microarray (200-400ng). The manufacturer recommends using DNA samples at a 
concentration of 50-100ng/µl in total volume of 8µl, thus, total amount of DNA used 
was 400-800ng. Only 4µl (200-400ng) of each sample aliquot was processed for 
genotyping and loading on the chip. 
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2.3.4. Illumina genotyping protocol 
The Illumina infinium assay protocol is based on direct hybridization of isothermally 
amplified and fragmented DNA samples to locus-specific probes. After hybridization, 
allelic specificity is conferred by enzymatic base extension, and the products are 
fluorescently stained and detected by the Illumina iScan instrument. Then, the 
genotyping module (version 1.9.4) on GenomeStudio (v2011.1) was used for genotype 
calling and signal intensity data normalization. An overview of this protocol is given 
in Figure 2- 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2- 1: Flowchart for DNA samples quality control. 
 
 
Removed from the analysis 
Removed from the analysis 
166 DNA samples 
Processed for genotyping 
microarray analyis 
Yes 
Yes 
No 
No 
Pure DNA 
(A260/A280 
ratio ≥1.8)? 
High DNA 
concentration 
(400-800ng)? 
52 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2- 2: Illumina Infinium HumanCoreExome BeadChip genotyping protocol. 
Original figure based on the information from (Fan et al. 2006). 
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A. 200-400ng of gDNA is required for Illumina HumanCore Exome 
BeadChips. 
 
 
B. gDNA is amplified using PCR-free whole genome amplification. 
 
 
C. Amplified DNA is fragmented using an enzymatic fragmentation 
approach. 
 
D. Amplified fragmented DNA is hybridized to louci specific probes 
on the beadchip. 
 
 
 
E. Two-steps allele detection: 
 
 
1- Selectivity: Unlabelled DNA fragments hybridize to 50 mer 
probe on the array. 
 
2- Specificity: Enzymatic single base extension with labelled 
nucleotide. 
 
 
F. Hybridized arrays are scanned by iScan system which is a cutting-
edge array scanner that supports rapid, sensitive, and accurate 
imaging of Illumina BeadChips for genetic analysis results. 
 
G. GenomeStudio is employed for genotype calling, signal intensity 
data normalization and LRR and BAF establishing for each SNP. 
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2.3.4.1. Scanning genotyping chip 
Hybridized microarrays were scanned by the iScan system, which is an array-scanner 
that supports accurate imaging of Illumina BeadChips for genetic analysis results. The 
iScan system has high performance lasers, optics and detection systems that enable 
the iScan to provide a sub-micron resolution with a high signal-to-noise ratio, and high 
sensitivity scanning. 
The iScan system determined the signal intensity for each genotyped SNP by detecting 
the amount of the green signal of streptavidin and the red signal of dinitrophenol 
(DNP) attached to every bead (Figure 2- 3). Each bead chip had its own decode file 
(.dmap) provided by Illumina which contained the bead locations. This file was 
uploaded to the iScan and matched to the array by a barcode. Scanning results were 
reported in several output files including an intensity data file (.idat), that contained 
the mean signal intensity for red and green signals for each bead type, and a manifest 
file (.bpm or .opa), that listed the SNP ID and annotation for each bead type. These 
files were uploaded to GenomeStudio for data analysis. 
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Figure 2- 3: Beads signal intensity determination by iScan. 
Every single bead has a locus-specific probe and DNA sequence that 
matches probe sequence binds to the probe. Then a single base extension 
takes place to determine genotype in this marker. Based on the genotype 
either green streptavidin (For A and T genotypes) or red anti DNT (for G 
and C genotypes). Accordingly, anti-streptavidin-biotin and anti-Ab-DNP 
will form a complex. Based on the illuminated signal colour from each 
bead, green or red, which is detected by iScan, marker genotype is 
determined. Original figure based on the information from (Fan et al. 2006).  
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2.3.4.2. Genotypes calling (GenomeStudio) 
The GenomeStudio software (Illumina) visualizes and analyses the data generated by 
Illumina microarray platforms. The Genotyping Module was used to conduct genotype 
data normalization, genotype calling, genotype clustering and data intensity analysis. 
It was also used to generate SNP statistics and to provide a graphical display of 
genotypes. For each genotyped marker, each sample was displayed as a dot according 
to its signal intensity and allele frequency. Genotypes were clustered based on A and 
B alleles composition with data points colour coded for the call (red = AA, purple = 
AB, blue = BB) (Figure 2- 4). 
In addition, the Genotyping Module was used to estimate the Log R ratio (LRR) and 
B-allele frequency (BAF) for copy number analysis. Genotype data was exported for 
downstream analysis in the third party applications Plink (Purcell et al. 2007) and 
PennCNV (K. Wang et al. 2007). 
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2.3.4.3. Extracting genotype data 
Genotype data for each sample was exported after normalization and genotype calling 
in the form of PED and MAP files. The PED file was a space delimited file that 
contained six columns with information: family ID, individual ID, paternal ID, 
maternal ID, sex (1= male; 2= female; -9 or 0= unknown), and phenotype (-9 or 0= 
missing; 1= unaffected; 2= affected). The MAP file was also a space or tab delimited 
file, which contained information about genotyped markers. Each line of this file 
described a single marker and contained 4 columns: chromosome (1-22, X or Y), rs 
number or SNP identifier, genetic distance, and base-pair position (bp units). 
Figure 2- 4: A screenshot from GenomeStudio for genotypes 
clustering plot in rs367922 marker. 
The red cluster represents homozygote genotypes for allele A 
where signal intensity for A allele is high and signal intensity for 
B allele is zero; the blue cluster represents homozygote genotypes 
for allele B where signal intensity for B allele is high and signal 
intensity for A allele is zero; and the purple cluster represents 
heterozygote genotypes where signal intensities for both alleles A 
and B are detected (GenomeStudio). 
 
Figure 2- 6Figure 2- 7: A screenshot from GenomeStudio for 
genotypes clustering plot in rs367922 marker. The red cluster 
represents homozygote genotypes for allele A where signal 
intensity for A allele is high and signal intensity for B allele is zero; 
the blue cluster represents homozygote genotypes for allele B 
where signal intensity for B allele is high and signal inte sity for 
A allele is zero; and the purple cluster represents heterozygote 
genotypes where signal intensities for both alleles A and B are 
detected (GenomeStudio). 
 
Figure 2- 8: Flowchart for CNVs quality controls. 
 
Figure 3- 1Figure 2- 9Figure 2- 10: A screenshot from 
GenomeStudio for genotypes clustering plot in rs367922 marker. 
The red cluster represents homozygote genotypes for allele A 
where signal intensity for A allele is high and signal intensity for 
B allele is zero; the blue cluster represents homozygote genotypes 
for allele B where signal intensity for B allele is high and signal 
intensi y fo  A all le is zero; and the purple cluster represents
heterozygote genotypes where signal intensities for both alleles A 
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Figure 2- 11Figure 2- 12: A screenshot from GenomeStudio for 
genotypes clustering plot in rs367922 marker. The red cluster 
represents homozygote genotypes for allele A where signal 
intensity for A allele is high and signal intensity for B allele is zero; 
the blue cluster represents homozygote genotypes for allele B 
where signal intensity for B allele is high and signal intensity for 
A allele is zero; and the purple cluster represents heterozygote 
genotypes where signal intensities for both alleles A and B are 
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Moreover, files including markers genotypes, LRR, and BAF values for all genotyped 
samples were extracted for PennCNV calling. 
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2.4. Genotype imputation 
The genotypes for SNPs not on the array were imputed by the following protocol: 
1) Aligning. The genotype data for all samples was first matched with the reference 
panel of haplotypes of the 1,000 Genome phase 3 data, using GRCh37/hg19 
coordinates. Plink was used to flip all genotypes into the positive strand and 
SHAPEIT2 (v2 (r837)) was used to align the genotype data and to exclude any 
polymorphisms that could not be aligned (Delaneau et al. 2014; O’Connell et al. 2014).  
2) Pre-phasing. SHAPEIT2 was used to estimate the haplotypes in the genotype data 
by applying statistical estimation algorithms such as the hidden Markov model 
(HMM). 
3) Imputing: The FCGENE tool (1.0.7) was used to convert the genotype data into the 
format required for the program IMPUTE2. Genotype imputation was then performed 
using the pre-phase/imputation stepwise approach using IMPUTE version 2 (Howie 
et al. 2009). Imputation was based on a chunk size of 5Mb and was conducted only on 
autosomal chromosomes SNPs. Finally, FCGENE was used to convert the data 
generated by IMPUTE2 format to Plink format for association analyses. 
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2.5. CNV calling  
2.5.1. CNV calling by PennCNV 
CNV calling was performed using PennCNV  (2009Aug27version) by following a 
well-established protocol (K. Wang et al. 2007). PennCNV required signal intensity 
values from genotype data in the form of LRR and BAF, which were exported from 
GenomeStudio. In addition to these values, population frequency of B alleles (PFB), 
SNP genome coordinates, and an appropriate HMM model data were also required for 
CNV calling. The PFB file was provided by Dr Elliott Rees, who worked on a study 
with a larger sample size that was genotyped by arrays similar to those used in this 
study. From this large cohort Dr Rees estimated the population frequency of B alleles 
for each genotyped marker. The HMM model was provided by the PennCNV package. 
PennCNV implemented a GC model for wave adjustment to reduce false positive calls. 
CNV calls were subjected to an intensive quality control procedure to select reliable 
calls and this data was also used to conduct additional quality control of genotyped 
samples. Details about sample quality control analysis are explained in chapter 6 
sections 6.4.1 and 6.5.1. 
 
2.5.2. CNV quality control  
The following quality control procedures were applied to all CNV calls in order to 
maximise the chances that the subsequent analysis included only true CNVs. 
First, the called CNVs were restricted to only those spanning a minimum 10 
consecutive SNPs, and larger than 100Kb with a minimum 20,000 SNPs density, 
which means a minimum number of 20,000 SNPs within 1Kb long. As large CNVs 
can be split by CNV calling algorithms, adjacent CNV calls larger than 100Kb were 
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merged if they existed in a single individual with an interval gap less than 50% of the 
entire length of the newly merged CNV (The International Schizophrenia Consortium 
2008). The log R ratio and B allele frequency of SNPs spanning all CNVs, including 
the newly merged CNVs, were manually inspected before approval. At loci where it 
was not possible to manually exclude the existence of 2 independent CNVs, the 
adjacent CNVs were not merged (e.g. heterozygote genotype calls between adjacent 
hemizygous CNVs).  A summary of CNVs quality control is given in Figure 2- 5. 
 
 
 
 
  
Figure 2- 5: Flowchart for CNVs quality control. 
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2.6. RNA samples 
2.6.1. Blood samples for RNA extraction 
Blood samples for RNA extraction were collected in PAXgene Blood RNA Tubes 
(IVD). These tubes are intended to be used for the collection, transport, and storage of 
blood samples to stabilize intracellular RNA for subsequent isolation and purification 
of intracellular RNA from whole blood. The tubes are combined with the PAXgene 
Blood RNA kit (QIAGEN).  
58 ECHO blood samples were collected in PAXgene blood RNA tubes for RNA 
extraction. These samples included 33 samples from 22q11.2DS patients and 25 
samples from healthy controls. An additional 21 samples were obtained from the 
London BBAG project, which were similarly collected in PAXgene RNA blood tubes, 
and these were composed of 22q11.2DS patients (n= 3) and controls (n= 18). Thus, 
collectively there were 79 available samples including, 36 deletion carriers and 43 
non-deleted controls.  
 
2.6.2. RNA extraction and storage 
The procedure of PAXgene RNA extraction began with centrifuging the blood sample 
to pellet RNA molecules in PAXgene blood tube, followed by a washing and a re-
suspension steps. Re-suspended RNA molecules were then incubated in optimized 
buffers with proteinase K for protein digestion. Then cell lysate and residual cell debris 
were removed, while lysate was transferred to a PAXgene RNA spin column for 
centrifugation during which the RNA was selectively bound to the PAXgene silica 
membrane. Contaminants that passed through the membrane were discarded, whereas 
the RNA-bound membrane was washed and treated with DNase-I to remove trace 
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amounts of bound DNA. Finally, RNA was eluted in an elution buffer and then heat-
denatured. The quality of the extracted RNA samples was assessed and RNA 
molecules were quantified and finally stored at -80ᵒC. 
 
2.6.3. RNA quantification and quality control 
2.6.3.1. Bioanalyzer RNA quantification and quality assessment 
The most critical step before gene expression analysis is determining RNA integrity 
to select only RNA with high quality for expensive cRNA synthesis and gene 
expression microarray hybridization. RNA integrity was assessed by determining RIN 
value using Agilent 2100 Bioanalyzer System and associated Agilent RNA 6000 Nano 
kit (Agilent Technologies). The Bioanalyzer also was used for RNA quantification. 
This method is based on using electrophoretic separation on micro-fabricated chips, 
where RNA samples were separated and detected by laser induced fluorescence 
detection.  
 
2.6.3.2. Nanodrop for RNA quantification and RNA quality assessment 
Additionally, extracted RNA samples were also quantified and assessed by the 
Nanodrop 8000 instrument (Thermo Scientific). A ratio of A260nm to A280nm equal to 
or larger than value of 2 was accepted for a high quality RNA sample.  
 
Then based on Bioanalyzer and Nanodrop results RNA samples were subjected for 
quality control to select only pure, high integrity, and adequate concentration RNA for 
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gene expression analysis processing. Full details for RNA samples quality control are 
explained in chapter 4 sections 4.4.1 and 4.5.1.   
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2.7. Bioinformatic tools and statistical analyses 
2.7.1. Bioinformatic tools 
Various statistical and bioinformatic tools were used to handle and analyse the 
genotype and gene expression data. 
Linux (version Fedora 16) was mainly used to handle large genotype data extracted 
from GenomeStudio in the form of PED and MAP files. Linux on the Cardiff 
University server (Raven), in which the data was stored. It facilitates modifying and 
sorting data for association analyses using Plink. 
Plink (v1.07-10/Aug/2009) was used for all quality control analyses, for the 
association analyses of genotypes, and also for the CNV burden analyses. 
For results visualization, R (version 3.2.2-2015-08-14), which is a language and an 
environment for statistical computing and graphics, was used for plotting results of 
principle component analysis (PCA). R and Bioconductor packages (Limma, Lumi, 
and Combat) were used for gene expression data quality control, gene expression data 
pre-processing, and differential gene expression analysis. The results for these 
processes were also visualised using R. The R package was also used for conducting 
association and correlation analyses. 
For visualising genotypes association results, LocusZoom was used to plot Manhattan 
plots (Pruim et al. 2010). 
For visualising pathway analysis results obtained from DAIVD analysis tool, 
Cytoscape (v.3.4.0) was used to categorize functional groups into functional networks 
(Shannon et al. 2003). 
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Power calculation for association studies was conducted by using the Genetic Power 
Calculator (Purcell, Cherny & Sham 2003), while it was performed by using the pwr 
package (version 1.2-0), implemented in R and G*Power tool v3.0.10 for the CNV 
burden study (Champely 2016; Rucker et al. 2016). PS software version 3.1.2 (Dupont 
& Plummer 1990) was used for power calculation for gene expression studies. 
 
2.7.2. Statistical analyses 
Statistical analyses applied for each study are explained in the result chapters.
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Chapter 3: Characterization of the 22q11.2DS Cohort 
 
 
3.1. Summary 
The main aim of this introductory chapter is to obtain a well-characterized cohort of 
22q11.2DS patients that have high quality genotype data for the subsequent analyses 
performed in this PhD thesis. To achieve that, pipelines for sample and genotype 
quality control were followed.  
As a result of sample quality control analysis 19 samples were excluded from the 
original 95 that were ascertained. The remaining 76 individuals were confirmed to be 
independent, ethnically homogenous, and true 22q11.2 deletion carriers. These 
individuals will form the basis of the work presented in chapters 4, 5, and 6 of this 
thesis. 
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3.2. Introduction 
Recently, association analyses of SNPs and CNVs have been conducted at increasing 
frequency using case-control samples to identify genomic loci that influence human 
traits (Turner et al. 2011). Particularly in the field of neuropsychiatric disorders 
genome-wide association studies (GWAS) have analysed common genetic variants 
spanning the whole genome (Ripke et al. 2014; Simón-sánchez et al. 2009; Weiss et 
al. 2009; Cross-Disorder Group of the Psychiatric Genomics Consortium 2013), and 
global burden analyses have analysed the structural variants genome-wide (Williams 
et al. 2010; Williams et al. 2012; Kirov et al. 2009; Girirajan et al. 2010; McQuillin et 
al. 2011). 
 
The capability of association studies to identify true genetic associations depends upon 
the overall quality of the data (Turner et al. 2011). Samples included in association 
analyses that have not been properly cleaned based on the genotype data can 
potentially lead to false-negatives and false-positive associations (Turner et al. 2011). 
A typical genotype-based sample quality control (QC) procedure will investigate 
gender inconsistencies, sample relatedness, population substructure, and sample 
genotyping efficiency or call rate (Turner et al. 2011). 
 
Testing for gender inconsistencies tests for potential sample identity problems that 
typically occur as a result of possible errors in sample handling (Turner et al. 2011). 
This analysis is performed by determining sex empirically based on X chromosome 
heterozygosity rates, then matching the molecular sex with the reported one (Turner 
et al. 2011). 
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Closely related or duplicated samples are identified by identity by descent (IBD) 
analysis (Turner et al. 2011). This approach calculates the proportion of loci where a 
pair of individuals share zero, one, or two alleles that are identical by descent. Either 
monozygotic twins, or a single sample processed twice share two alleles IBD at every 
locus. While unrelated individuals share zero alleles IBD at every locus. Parent-child 
pairs share one allele IBD at every locus. Whereas siblings, on average, share zero 
alleles IBD at 25%, one allele IBD at 50%, and two alleles IBD at 25% of the genome 
(Turner et al. 2011). The higher proportion of the IBD loci, the more alleles are shared 
between two pair of individuals (Turner et al. 2011). 
 
Population stratification occurs in studies that include multiple groups of individuals 
who vary systematically in genetic ancestry or other main variables such as 
phenotypes (Cardon & Palmer 2003). Differences in allele frequency are introduced 
by systemic ancestry differences, which might interfere with the allelic associations 
and produce type 1 errors (Price et al. 2006). Thus, it is critical to check for population 
stratification within the samples involved in association studies. That can be achieved 
by applying principle component analysis (PCA), and using a global reference for 
human genetic variants database such as 1000 Genome project database (The 1000 
Genomes Project Consortium 2015) to identify the samples ancestry and detect any 
systematic differences among the samples  (Ringnér 2008). 
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3.3. Aims of this chapter 
This chapter aims to conduct quality control of the 95 individuals that have been 
ascertained in order to establish a cohort of 22q11.2DS patients that can be used for 
the subsequent analyses conducted in this PhD thesis. This was achieved by 
conducting a series of assessments of genome-wide SNP array data in order to 
establish which individuals were true 22q11.2 deletion carriers, to identify a sample 
with minimal evidence for population stratification, and to ensure that they were all 
independent and uncontaminated samples. 
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3.4. Materials and methods 
3.4.1. Samples quality control 
The DNA for all 95 recruited participants was genotyped using an Illumina Infinium 
Human CoreExome-24 BeadChip array as described in chapter 2 section 2.3.  The 
genotype data was subjected to a standard SNP-based quality control procedure by 
using Plink (v1.07-10/Aug/2009) (Purcell et al. 2007). Samples were excluded if they 
met one of the following criteria: 
1) A SNP call rate lower than 0.98. 
2) Were identical by descent (IBD) (PiHat>0.95) with another sample, indicating 
a sample duplicate, or monozygotic (MZ) twin. 
3) Were identical by descent (IBD) (PiHat>0.15) with another sample, indicating 
a potentially contaminated sample, or two closely related individuals. 
4) Had a reported gender that was different to that determined by molecular 
analysis. 
 
To confirm that all 22q11.2DS samples had the expected deletion, CNVs spanning the 
22q11.2 region were identified by using the 790 SNPs spanning chr22:18,658,219-
21,865,185 using PennCNV (2009Aug27version) as fully described in chapter 2 
section 2.5 (K. Wang et al. 2007). Only samples confirmed to carry deletions spanning 
the common 3Mb 22q11.2 region (chr22:18,658,219-21,865,185 on hg19) or less 
common 1.5Mb region (chr22:18,658,219-20,519,134 on hg19) were included.  
 
Principal component analysis was performed on all SNPs for the 22q11.2DS patients 
combined with the individuals of 1000 Genome phase 2 (The 1000 Genomes Project 
Consortium 2015), who have known ethnic backgrounds by using R statistical 
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environment (version 3.2.2-2015-08-14) (R-project.org, n.d.). Outlying samples that 
deviate from the homogenous Caucasian 22q11.2DS samples cluster, located within 
0.04< PC1 ≥0.03 and PC2 ≥0.04 region on PCA plot, possibly indicating a non-
Caucasian ancestry were excluded. Summary for sample quality control is given in 
Figure 3- 1. 
 
3.4.2. Psychiatric phenotypes in 22q11.2DS 
The subsequent well-characterized 22q11.2DS patients, who passed the sample 
quality control, then were categorized into three psychiatric diagnosis groups based on 
the presence and absence of neuropsychiatric phenotypes in these patients, which were 
assessed by the Cardiff ECHO field team as described in chapter 2 section 2.1.2. 
22q11.2 deletion carrier manifested ADHD phenotypes, either inattentive, hyperactive 
or mixed, were grouped into 22q11.2DS+ADHD. Whereas, carriers who showed 
phenotypes of ASD with high SCQ score (15-22), were grouped into 22q11.2+ASD. 
Collectively, carriers who manifested ADHD, ASD or both phenotypes were grouped 
in 22q11.2DS+PSYCH group. 
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Figure 3- 1: Flowchart for sample quality control based on genotype data. 
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3.5. Results 
3.5.1. Samples quality control 
The reported gender of all 95 samples matched the sex-chromosome determined 
gender. The results of PennCNV calling for 22q11.2 deletions identified five of the 
individuals (5.2%) who did not carry either a 3Mb (spanning LCR22s A-D) or a 1.5Mb 
deletion (spanning LCR22s A-B) at 22q11.2 (Figure 3- 2).  These 5 samples could not 
be classed as 22q11.2DS and were removed from the study. 
As can be seen in Figure 3- 3, PCA analysis indicated that 78 individuals were 
homogenous with the individuals of known European ancestry, while the remaining 
12 samples were clear outliers. The plot suggests that the outliers descend from a 
mixed ethnic background. Five outliers appear to have a mixed African background 
and located within -0.02< PC1≤ 0.02 and 0.04> PC2> 0.02 region. While a single 
outlier is suspected to have a mixed Asian ancestry and located within 0.04> PC1> 
0.02 and 0.02< PC2 ≤0.0 region. The remaining six outliers appear to have a mixed 
African, Asian, and European background with more dominant European genotypes 
as they are not fully homogenized with the European cluster. Accordingly, the 12 non-
Caucasian samples were excluded from the study.  
IBD analysis was sought to identify any related, duplicated or possibility contaminated 
samples. Two pairs were identified to have IBD proportion > 0.15 indicating 
relatedness. A single sample of each pair was removed. 
 
A summary for samples QC results is given in Table 3- 1.  
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Figure 3- 2: BAF and LRR traces for the five 22q11.2DS samples that are not carrying 22q11.2 
deletions. 
In the top, the long arm of chromosome 22 with base location (on hg19) and the cytogenetic bands. The 
red boxes are the target 3Mb 22q11.2 region (chr22:18,658,219-21,865,185 on hg19).  A control 
22q11.2 deletion carrier sample shows all SNPs within the area are homozygous in BAF trace and the 
general signal intensity drops within the 22q11.2 region in LRR trace that indicate presence of a deletion 
in the region. The LRR and BAF traces of five samples show the absence of 22q11.2 deletion in 
comparison to the 22q11.2 deletion control sample. The red arrows indicate an irrelevant rare 
chromosome 22 deletion detected in E_021_1_1 sample (LRR and BAF traces are obtained from 
GenomeStudio). 
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3.5.2. Characterization of 22q11.2DS cohort 
The 76 individuals that survived this standard SNP-based quality control procedure 
formed the basis of the work presented in chapters 4, 5, and 6 of this thesis. The 76 
  
QC filters 
  
  
*Threshold 
  
**Initial total 
  
***Removed  
  
****Final total 
Genotype call rate 0.98 95 cases 0 cases 95 cases 
22q11.2 deletion Presence of 22q11.2 
deletion 
95 cases 5 cases 90 cases 
PCA Caucasian 90 cases 12 outliers 78 cases 
IBD 0.15 78 cases 2 cases 76 cases 
Sex check Reported gender is 
molecularly confirmed 
76 cases 0 cases 76 cases 
Table 3- 1: Results of sample quality control. 
* Filtering threshold or criteria. 
** Initial total: Initial total number of samples. 
*** Removed: Number of removed samples due to failure in meeting filtering threshold or criteria. 
**** Final total: Final total number of samples.  
 
 
* Filtering threshold or criteria. 
** Initial total: Initial total number of samples. 
*** Removed: Number of removed samples due to failure in meeting filtering threshold or criteria. 
**** Final total: Final total number of samples.  
 
       22q11.2DS patients 
        Outlier 22q11.2DS patients  
        Han Chinese in Beijing, China 
        Finnish in Finland 
        Yoruba in Ibadan, Nigeria 
          
 
Figure 3- 3: PCA plot for 22q11.2DS patients and 1000 Genomes participants. 
The plot shows three big clusters for the 1000 Genome participants with different ancestries. The blue cluster 
represents individuals with the African ethnicity, the orange cluster represents individuals with the Asian 
ethnicity and the green cluster represents individuals with the European ethnicity. The clusters distributed in 
the plot based on eigenvectors resulted from PCA analysis. Homogenous 22q11.2DS patients (n= 78) are in 
the red cluster which appears to descend from European ancestry. 22q11.2DS patients that are suggested to 
have a mixed ethnical background are highlighted with black as they deviated from the main cluster of 
22q11.2DS patients. X-axis represents PC1 values and Y-axis represents PC2 values from PC analysis (PCA 
plot is plotted by R). 
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individuals with 22q11.2DS had a mean age of 11.9 years. Three of the 22q11.2DS 
patients (~4%) were found to carry the ~1.5Mb deletion spanning LCR22s A-B, 
whereas 73 22q11.2DS patients (~96%) have the ~3Mb deletion spanning LCR22s A-
D (Figure 3- 4). 
Of the 76 22q11.2DS patients, 43 individuals are males (57%) while the remained 33 
are females (43%). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3- 4: Schematic ideogram of 22q11.2 regions spanned by 1.5Mb and 3Mb 
deletions. 
LCR22s are indicated by black boxes and 22q11.2 deletions indicated by grey boxes. 
73 individuals in our cohort carry 3Mb deletion (spanning LCR22A-D) while only 3 
individuals carry the 1.5Mb deletion (spanning LCR22A-B). Therefore, total 76 
individuals, including those who carry the small nested 1.5Mb deletion, share the 
deleted region spanning the proximal 1.5Mb (LCR22A-B), while only 73 individuals, 
who carry the larger deletions, shared the deleted region spanning the distal 1.5Mb 
region (LCR22B-D) (Original figure). 
 
Figure 4- 1Figure 3- 5: Schematic ideogram of 22q11.2 regions spanned by 1.5Mb 
and 3Mb deletions. LCR22s are indicated by black boxes and 22q11.2 deletions 
indicated by grey boxes. 73 individuals in our cohort carry 3Mb deletion (spanning 
LCR22A-D) while only 3 individuals carry the 1.5Mb deletion (spanning LCR22A-B). 
Therefore, total 76 individuals, including those who carry the small nested 1.5Mb 
deletion, share the deleted region spanning the 1.5Mb (LCR22A-B), while only 73 
individuals, who carry the larger deletions, shared the deleted region spanning the 
remaining 1.5Mb region (LCR22B-D) (Original figure). 
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The 76 individuals were classified into 3 categories based on the psychiatric 
phenotypes present; 1) presence/absence of ADHD, 2) presence/absence of ASD, 3) 
presence/absence of psychiatric illnesses i.e. either ASD, ADHD or both (Table 3- 2). 
  
76 samples carrying 1.5Mb 22q11.2 deletion 
(3 samples carry the 1.5Mb deletion and 73 carry the 3Mb 
deletion) 
 
ADHD ASD Psychiatric illness 
(ADHD, ASD or both) 
Affected 29 18 37 
Unaffected 42 47 35 
Missing information 5 11 4 
Total 76 76 76 
  
73 samples carrying 3Mb 22q11.2 deletion 
 
 ADHD ASD Psychiatric illness 
(ADHD, ASD or both) 
Affected 27 18 35 
Unaffected 42 46 35 
Missing information 4 9 3 
Total 73 73 73 
 
 
It is worth noting that 10 of 76 22q11.2 deletion carriers manifest both ADHD and 
ASD. Only 19 of the 76 have ADHD symptoms only, whereas only 8 showed ASD 
symptoms only. The 37 individuals with 22q11.2DS who have a psychiatric illness 
presented with the phenotypes of ADHD only, ASD only, or both ADHD and ASD. 
The 10 individuals who presented symptoms of both ADHD and ASD were included 
in both the 22q11.2DS+ADHD and 22q11.2DS+ASD groups, as well as in the 
combined group with psychiatric disease, 22q11.2DS+PSYCH. This was aimed at 
maximizing the power in each test. However, those unaffected with psychiatric illness 
have neither symptoms of ADHD nor for ASD.  
Table 3- 2: Psychiatric phenotypes in 22q11.2DS cohort. 
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3.6. Discussion 
The main aim of this chapter is optimize our 22q11.2DS patients and the genotype 
dataset for the further analyses conducted in this PhD by following standard QC 
pipelines. Therefore, all the 95 recruited were subjected to an intensive QC procedure 
to exclude non-22q11.2 deletion carriers, non-Caucasian, related, duplicated, or 
possibly contaminated samples. The final number of 22q11.2DS samples after QC was 
76 well-characterized 22q11.2 deletion carriers.  
All the recruited 95 samples were selected based on genetic clinic diagnosis of 
22q11.2DS. However, molecular analysis revealed that 5 did not carry a deletion at 
22q11.2. Further information for these referred patients were obtained from their 
genetic clinics. 
Sample 1 (E_076_1_1), was referred from a medical genetic clinic based on the 
manifestation of DiGeorge Syndrome phenotypes diagnosed at age of 2 years without 
confirming the presence of 22q11.2 deletion. FISH analysis results were obtained 
afterward and showed normal results in addition to an array analysis that did not 
identify a 22q11.2 deletion, nor a TBX1 mutation, nor an array abnormality. 
Sample 2 (E_073_1_1), the patient was described as having multiple congenital 
anomalies suggestive of DiGeorge Syndrome but no cardiac defects. FISH analysis 
was carried out three times after recruiting the case by the ECHO team and this failed 
to detect a 22q11.2 deletion.  
Sample 3 (E_021_1_1), the laboratory results identified that this patient does not carry 
the standard 22q11.2 deletion, however, the patient instead carries a deletion that 
partly overlaps the distal deleted region in 22q11.2DS. This deletion mapped to 
chr22:21,796,000-22,916,000 on hg19 and spans LCR22s D-E. The deletion was 
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detected using Agilent's 4x44K array (version 2) and it was confirmed using the FISH 
probes LL22NC03-23C6 and LL22NC03-30E12. This finding was confirmed by the 
analysis of genotype data and CNVs calling in this chapter (Figure 3- 2). Thus, this 
sample was removed as there is no evidence that the deletion identified is relevant to 
22q11.2DS. 
Sample 4 (E_040_1_1), was found to be a mislabelled sample based on IBD analysis 
results. This patient was detected to be related to individuals from a different family 
with 50% shared genotypes. This percentage of genotype sharing between two 
individuals means they are first degree relatives. In this case, this sample is possiblely 
had been falsely labelled as no deletion was identified. 
Sample 5 (E_068_1_1), was labelled as a 22q11.2 deletion carrier, however, while no 
22q11.2 deletion was found, a deletion at 16p11.2 was identified instead. The ECHO 
field team confirmed that this samples was indeed a carrier of a 16p11.2 deletion and 
it had been mislabelled. 
In conclusion, after intensive QC procedures, the final dataset composed of 76 well-
characterized 22q11.2DS patients. The 76 22q11.2 carriers were then categorized into 
22q11.2DS+ADHD, 22q11.2DS+ASD, and 22q11.2DS+PSYCH groups for the 
subsequent analyses described in chapter 4, 5, and 6 of this PhD thesis.  
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Chapter 4: Investigating Dosage Sensitive Genes in 22q11.2 
Deletion Syndrome 
 
 
4.1. Summary 
Patients with 22q11.2DS have an increased risk of developing a diverse spectrum of 
behavioural phenotypes. As deletions at 22q11.2 are relatively homogeneous, it is 
possible that haploinsufficiency of dosage sensitive genes spanning the deleted region 
results in changes in gene expression that influence the pathogenesis of the resulting 
psychiatric phenotypes. Dosage sensitive genes that span 22q11.2 are therefore 
candidate loci for psychiatric phenotypes in 22q11.2DS patients. This chapter set out 
to identify which genes at 22q11.2 are dosage sensitive by conducting differential gene 
expression analysis of RNA obtained from the leukocytes of 22q11.2DS patients and 
non-deleted controls.  
The results of differential gene expression analysis showed ~42.5% of 22q11.2 probes, 
representing 39 genes, are significantly differentially expressed (FDR <0.05) with 
down regulation effects in 22q11.2DS patients relative to healthy controls. 
Secondly, the possibility that the deletion can influence the expression of genes located 
outside of the deletion was investigated by testing the correlation of differential gene 
expression with the probe’s distance from the deletion. The results identified only a 
minor correlation (r2 =0.0022) that was not statistically significant (p-value =0.13), 
which does not provide support for the 22q11.2 deletion causing a strong positional 
effect. 
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A pathway analysis for global differentially expressed probes revealed four 
significantly enriched biological networks (FDR <0.05) that are involved in: 1) 
translation, protein synthesis machinery, and post-translation modifications; 2) 
apoptosis; 3) regulation of the immune system; and 4) intramembrane organelles. 
These enriched biological networks could possibly suggest the involvement of dosage 
sensitive genes in some of the phenotypes associated with 22q11.2DS such as immune 
system abnormality. 
Finally, in order to establish evidence whether any dosage sensitive genes could 
potentially influence the increased risk to psychiatric diseases, differential gene 
expression analysis was conducted between 22q11.2 deletion carriers who were 
affected and unaffected with a psychiatric disorder. The differential expression 
analysis results showed no significantly differentially expressed probes were found in 
22q11.2DS patients affected by neuropsychiatric diseases relative to those unaffected 
(FDR >0.05). 
 
  
82 
 
4.2. Introduction 
As microdeletions at 22q11.2 are considered to be the key genetic defect in the 
majority of 22q11.2DS cases, the resulting phenotypes for the syndrome are expected 
to be a result of haploinsufficiency of one or more genes within the deleted region 
(Williams 2011). In theory, as the hemizygous genes within the deleted 22q11.2 region 
have a reduced DNA copy number they are predicted to have a reduced level of 
expression when compared to the genes not spanned by a deletion (Williams 2011). 
In spite of that, it is well known that the expression level of many haploinsufficient 
genes can remain similar to those of disomic cells (Inoue & Lupski 2002; Stranger et 
al. 2007). This therefore indicates that not all the genes spanned by the deletion are 
necessarily sensitive to the DNA dosage imbalance. It is possible that the expression 
of these genes is compensated by homeostatic regulation at higher stages of the 
regulatory network that results in them retaining their normal expression level 
(Williams 2011; Stranger et al. 2007). Dosage sensitive genes at 22q11.2 have been 
shown to result in a number of phenotypes associated with 22q11DS. Highlighting 
dosage sensitive genes is a key role for identifying candidate genes for the 
neuropsychiatric phenotypes associated with 22q11.2DS (Williams 2011). 
A number of studies have investigated the effect of the 22q11.2 deletion on gene 
expression in 22q11.2DS patients or in mice that have been engineered to carry a 
deletion of the syntenic region. 
 
4.2.1. Gene expression studies in 22q11.2DS mice models 
As described in chapter 1 section 1.3.1.1.2, a number of studies have investigated gene 
expression in tissues from the central nervous system of the Df1+/- mice models to 
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identify dosage sensitive genes that might be influenced by the 22q11.2 deletion and 
play a role in the behavioural phenotypes seen in these mice. Approximately 33-41.7% 
of Df1 genes were identified to be differentially expressed in 22q11.2DS mice relative 
to wild-type mice (Jurata et al. 2006; Sivagnanasundaram et al. 2007). 
 
4.2.2. Gene expression studies in 22q11.2DS patients 
To date there are only two published studies of gene expression in humans with 
22q11.2 deletions. First, Van Bervern and colleagues analysed the RNA from blood 
samples for 7 patients with 22q11.2DS and 7 non-carrier controls. Ten transcripts were 
identified to be differentially expressed, 7 of which were located within the 22q11.2 
region and all were downregulated in 22q11.2DS. These genes were found to be 
enriched in signalling pathways relevant to the phenotypes seen in 22q11.2DS such as 
immunodeficiency and schizophrenia (van Beveren et al. 2012). The small sample size 
of this study is a major limitation of this study that is likely to result in an 
underpowered analysis. A second study has investigated gene expression in RNA 
extracted from the blood of 46 22q11.2DS patients and 66 healthy controls 
(Jalbrzikowski et al. 2015). This study was published while the study of gene 
expression analysis in 22q11.2DS described in this chapter was being conducted. 
Results of differential gene expression showed 45 probes that mapped to the 22q11.2 
region were significantly downregulated in 22q11.2DS. Genome-wide analysis 
identified differentially expressed genes in 22q11.2DS patients that were involved in 
the regulation of neuronal action potentials, myelination, and axon ensheathment of 
neurons. Moreover, Jalbrzikowski and colleagues compared gene expression between 
22q11DS patients with and without psychosis, and 22q11.2DS with and without ASD. 
No significantly differentially expressed probes mapped to the 22q11.2 region 
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(Jalbrzikowski et al. 2015). The 22q11.2DS analysed in the study of Jalbrzikowski and 
colleagues (Jalbrzikowski et al. 2015) were a mixture of children and adults (33 
patients under 18 years and 13 patients between 18 and 61 years of age). The control 
cohort consisted of 24 and 42 individuals under and over 18 years of age respectively. 
This mixture of children and adults, together with their imbalance in the case/control 
cohorts are a potential limitation of this study. 
 
4.2.3. CNVs positional effects on the expression of adjacent genes 
It is possible that genomic structural variants have an impact not only on the 
expression of genes spanning them, but by removing or altering a regulatory locus, 
CNVs can directly influence the expression of nearby genes (Inoue & Lupski 2002). 
This phenomenon is called a ‘position effect’ in which genes within the same 
chromosome could be altered (in CIS position effect) or potentially on other 
chromosomes (in TRANS position effect) (Williams 2011). Stranger and colleagues 
(Stranger et al. 2007) have shown that there is significant long-distance disruption in 
gene expression for a large number of dosage sensitive genes that flank a CNV by 
more than 2Mb (Stranger et al. 2007).  
Focussing on the 7q11.23 deletion that causes Williams-Beuren Syndrome (WBS), 
Merla and colleagues (Merla et al. 2006) investigated differential gene  expression in 
RNA extracted from lymphoblastoid cell lines from 10 patients and from 40 healthy 
controls. The results showed evidence for a position effect for genes flanking the 
7q11.23 deletion. For example, HIP1, POR, and KCTD7 that are located at distances 
of 0.7, 1.2, and 6.5 Mb from the WBS region, respectively, showed a significant 
differential expression (Mann-Whitney test p-values= 0.025, 0.04 and 5.1x10-3 
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respectively). Overall differential expression appeared more pronounced for genes 
mapping closer to the breakpoint, suggesting the presence of distant long range in CIS 
regulatory elements within the deleted region (Merla et al. 2006). 
In studying gene expression in the Df1+/- mice models, Prescott and colleagues 
demonstrated significant evidence for a CIS positional effect when they identified the 
reduced expression of the Crkl gene (that flanks the Df1 deleted region) in Df1+/- 
mice compared to the wild-type mice (Prescott et al. 2005). In addition, as it plays a 
central role in miRNA production, haploinsufficiency of DGCR8 gene could 
potentially lead to CIS and TRANS positional effects (Stark et al. 2008). This is 
supported by studies that have analysed Dgcr8+/- knockout mice that have identified 
a downregulation of a specific set of mature miRNA (Stark et al. 2008), and the 
subsequent upregulation of expression for a number of genes in the brain of Dgcr8+/- 
mice (Stark et al. 2008).  
These findings suggest that CIS and TRANS positional effects could be relevant to the 
22q11.2 deletion and if so could have an influence on the underlying biology in 
22q11.2DS. Nevertheless, although mouse chromosome 16qA13 has synteny with 
human chromosome 22q11.2, there is a major divergence in gene organization and the 
sequences flanking the deletions. These therefore complicate applying the evidence of 
position effects observed in Df1 mice models to humans. Studies of gene expression 
in humans are therefore required to investigate possible position effects in relation to 
the psychiatric phenotypes associated with 22q11.2DS.  
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4.2.4. Transcriptome profiling of peripheral blood in 22q11.2DS 
Studies of transcriptome profiling aimed at investigating the neuropsychiatric 
disorders associated with 22q11.2DS should ideally conduct gene expression analysis 
in brain tissues of 22q11.2DS patients. However, the availability of post mortem 
human brain from 22q11.2DS patients is particularly limited. All studies have 
therefore conducted gene expression analysis on RNA extracted from peripheral blood 
mononuclear cells (PMCs) from 22q11.2DS patients. While this is not ideal, these 
cells have been demonstrated to express many brain-relevant genes (Sullivan et al. 
2006). In this study, Sullivan and colleagues analysed transcriptional profiling of 
33,698 genes in 79 human tissues which included whole blood and 16 samples from 
the CNS (amygdala, caudate nucleus, cerebellum, cerebellum peduncles, cingulate 
cortex, globus pallidus, hypothalamus, medulla oblongata, occipital lobe, parietal 
lobe, pituitary, pons, prefrontal cortex, subthalamic nucleus, temporal lobe, and whole 
brain). Gene expression analysis demonstrated that ~50% transcripts were expressed 
in both whole blood and CNS and half of a set of schizophrenia candidate genes were 
expressed in both whole blood and prefrontal cortex (Sullivan et al. 2006). Therefore, 
the authors indicated that gene expression in whole blood is neither perfectly 
correlated nor perfectly uncorrelated with gene expression in multiple brain tissues. 
Thus, compared to the more inaccessible CNS tissues, RNA from peripheral blood can 
offer a more accessible tissue for gene expression, however, extra caution and 
consideration are necessary to interpret the data from peripheral blood gene expression 
(Sullivan et al. 2006). 
 
Encouragingly, a study of a functional gene expression analysis has revealed that 7 
genes that have orthologues in 22q11.2 (DGCR6, RANBP1, ZDHHC8, HTF9C, 
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COMT, CLDN5, and UFD1L) have similar relative expression levels in: 1) 
hippocampus when compared in Df1+/- and wild-type mice (Sivagnanasundaram et 
al. 2007), 2) PBMC when compared in 22q11.2DS patients and controls (van Beveren 
et al. 2012). The relative expression levels of mice and humans are correlated strongly 
and significantly (r2 =0.677, one-sided p-value =0.05), which showed reduced 
expression in Df1+/- mice and 22q11.2DS patients compared to wild-type mice and 
controls respectively by 40-60% (van Beveren et al. 2012). Similarly, in a study 
investigating the expression in the brain of developing and adult Df1+/-  mice, 9 genes 
with orthologues at 22q11.2 had a similar reduction in expression levels in both brain 
and PBMC by 40-60% (Meechan et al. 2006). 
Taken together, these findings indicate that while recognising that it is not ideal, when 
analysed with caution it is possible to study the gene expression profile of brain-
relevant genes in peripheral blood.  
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4.3. Aims of this chapter 
The study in this chapter will investigate the effect that 22q11.2 deletions have on 
gene expression of RNA extracted from leukocytes. Compared to previous studies, 
this will benefit from the increased power of analysing a larger cohort of 22q11.2 
deletion children carriers and age-matching controls. The study will perform the 
following lines of investigation: 
1) An assessment of gene expression of haploinsufficient genes located within 
22q11.2. As not all genes are dosage sensitive the identification of genes that 
are differentially expressed between 22q11.2 deletion carriers and non-deleted 
controls will highlight those whose expression are influenced by the deletion. 
These dosage sensitive genes will be candidates for future investigations into 
the behavioural phenotype associated with 22q11.2DS. 
2) An assessment of the expression of genes located outside 22q11.2. It has been 
reported that the expression of genes that are not spanned by a CNV can be 
directly influenced the presence of the CNV (Stranger et al. 2007). This 
phenomenon is called a ‘position effect’ in which the expression of genes can 
be effected within the same chromosome (in CIS). This will be investigated by 
performing gene expression analysis of RNA extracted from 22q11.2 deletion 
carriers and non-deleted controls for genes located on chromosome 22 but 
outside of the 3Mb deleted region. In addition, an analysis of genome-wide 
differential gene expression changes will allow the investigation of biological 
pathways that are potentially affected by the 22q11.2 deletion. 
3) An investigation of differential gene expression between 22q11.2 deletion 
carriers with and without a psychiatric disorder. Differentially expressed genes 
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that are located at 22q11.2 will reveal those that could play a direct role in the 
increased risk to psychiatric disease. 
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4.4. Materials and methods 
4.4.1. Samples 
A total of 79 blood samples were recruited for RNA extraction from: 36 patients with 
a molecularly confirmed diagnosis of a 22q11.2 deletion, and 43 unaffected healthy 
controls. Specific full details for the recruited participants and the collected blood 
samples are given in chapter 2 sections 2.1.1 and 2.6.1. RNA were extracted from 
whole blood samples using the PAXgene Blood RNA extraction kit (QIAGEN). 
Detailed protocols of RNA extraction and RNA quantification are fully explained in 
chapter 2 sections 2.6.1, 2.6.2, and 2.6.3. 
All 79 RNA samples were put through quality control to select high quality RNA 
samples for cRNA synthesis. RNA samples meeting one of the following criteria were 
excluded: 
1) Poor RNA integrity with an RNA integrity number (RIN) below 7 (Schroeder 
et al. 2006). 
2) RNA with a ratio of A260/A280 below 2, potentially indicating contamination 
with residual phenol or other reagent associated with the extraction protocol 
(Manchester 1996). 
3) Low total RNA concentration below 400ng (i.e. the working concentration for 
cRNA synthesis based on the manufacturer’s recommendation). 
4) A duplicated sample. 
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4.4.2. cRNA synthesis 
400ng of RNA for each of the samples that passed QC was subjected to biotinylated 
cRNA synthesis using the Illumina® TotalPrepTM RNA Amplification kit (Ambion 
from Life Technologies). This involved an initial reverse transcription using an oligo 
(dT) primer including a T7 promoter and a reverse transcriptase (RT) called 
ArrayScript™ to produce first cDNA strand. In vitro transcription (IVT) of the cDNA 
with biotin-UTP produced a biotinylated, antisense RNA copy of each single mRNA 
in the sample, which is called cRNA (Figure 4- 1). 
 
 
 
 
 
4.4.3. Gene expression microarray 
Whole-genome transcriptional profiling was performed using Illumina HumanHT-12 
Expression microarrays (Illumina). The Illumina HumanHT-12 expression BeadChip 
targets 47,231 oligonucleotide probes that represent 34,602 genes.  
750ng in a total volume of 5µl of biotinylated cRNA products were hybridized to 
Illumina Human V4.0-HT-12 BeadChips following the manufacturer’s protocol. 
Loaded BeadChips were incubated for 14 hours for hybridization at 58ᵒC, then washed 
Figure 4- 1: Method of biotinylated cRNA synthesis for gene expression microarray. 
The procedure starts with reverse transcription to synthesize the first strand of cDNA by using a T7 Oligo(dT) primer to 
synthesize cDNA containing a T7 promoter sequence. Then, the second strand cDNA is synthesized by converting the 
single-stranded cDNA into a double-stranded DNA (dsDNA) template for transcription. Then, in vitro transcription takes 
place to synthesize cRNA to generate multiple copies of biotinylated cRNA from the double-stranded cDNA templates 
(green dots in the cRNA represent biotin). Finally, cRNA is ready for use with Illumina’s direct hybridization array kits. 
Obtained from (Illumina® TotalPrep™ RNA Amplification kit manual, n.d.) with modification. 
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and processed for signal detection by introducing Cy3-Streptavidin (Thermo Fisher) 
to bind to the hybridized biotinylated cRNA probes to the BeadChip. This allows for 
differential detection of signals when the BeadChips were scanned by iScan system. 
Scanned gene expression data was analysed by gene expression module (version 1.9.0) 
in GenomeStudio software (v2011.1). GenomeStudio analyses intensity signal for 
each probe and converts the signal into an intensity value.  Each probe has a signal 
value that represents the concentration of an RNA transcript in the sample.  
 
4.4.4. Gene expression data quality control and pre-processing 
4.4.4.1. Internal control probes quality control 
Illumina have incorporated internal control features into the Gene Expression 
BeadChip, which includes 886 internal control probes to monitor data quality. These 
control features are either sample-independent metrics that use oligonucleotides in the 
hybridization solution, or sample-dependent metrics that use measurements from the 
actual loaded samples. The results of these controls were visualized by obtaining the 
Control Summary analysed by GenomeStudio (Gene Expression Microarray Data 
Quality Control, n.d.). Unprocessed gene expression data was initially checked for 
quality using the internal control probes in the expression microarrays. Internal control 
probes were also used for an initial background correction after which they were 
removed before the gene expression data under went pre-processing and batch effect 
correction. 
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4.4.4.2. Samples quality control 
To detect possible sample handling errors, the gene expression data of probes within 
22q11.2 were used to determine the deletion status of each carrier, and these results 
were compared to those previously determined from their DNA in chapter 3 section 
3.5.1. Moreover, probes of two gender-specific genes RPS4Y1 and XIST, which had 
been reported to be differentially expressed between males and females (Vawter et al. 
2004), were analysed to confirm the reported gender molecularly.  
Lastly, the quality of the microarray data for each of the remaining samples was 
analysed by calculating the proportion of high quality probes. Samples quality control 
filtering is explained in Figure 4- 2. 
The remaining high quality samples then were categorized based on the manifested 
psychiatric symptoms as described in chapter 3 section 3.5.3. 
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Figure 4- 2:  Flowchart for RNA sample quality control. 
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4.4.4.3. Target probes quality control 
In order to improve the power of detecting differential gene expression, probes with 
low expression were removed (Raw signal intensity threshold= 7000). In addition, 
probes with non-specific expression were identified by using annotation probe quality 
information obtained from gene expression platform specific annotation packages. 
~12,741 probe sets were identified to have low or non-specific expression which then 
were removed from the subsequent analysis. A remaining of 34,490 target probes were 
selected for the differential gene expression analysis. 
 
4.4.4.4. Gene expression data pre-processing 
Gene expression data (34,490 probe sets) for each of the samples, that passed QC, 
were subjected for background correction by using the array negative control probes 
using Bioconductor (version 3.4) Lumi package version 2.26.4 in R statistical 
environment (Du et al. 2008). Raw intensities were normalized by the quantile 
normalization approach and transformed by the Log2 transformation approach. 
Intensity plots for optimizing normalization and transformation approaches for our 
gene expression data are given in appendix 9.1 section 9.1.2. 
 
4.4.5. Batch effect identification and correction 
Batch effects are non-biological experimental variations that are commonly observed 
across multiple batches of microarray experiments. The main advantage of combining 
microarray data sets is increasing the study power by increasing sample size. However, 
it is unsuitable to combine gene expression data sets without correcting the 
experimental batch effect (Johnson et al. 2007). 
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Therefore, batch effects were identified in the gene expression data by using the 
approach of dendrogram clustering provided by the Bioconductor (version 3.4) Limma 
package, version 3.30.8, in R (Ritchie et al. 2015). The dendrogram clustered the 
samples, that passed QC, based on the most variable probes, which were determined 
by calculating the Interquartile range (IQR) for each probe among all samples. Probe 
IQR values then were ordered to identify the 500 (an arbitrary number) most variable 
probes. These probes then were used to categorize the samples into clusters (Dunning 
et al., 2016). Number of samples in the largest two clusters were determined based on 
their gender, phenotype, original study (ECHO or BBAG), and wave (A or B waves). 
The data then analysed by Fisher’s exact test to test for significance. The identified 
batch effects were corrected by using Bioconductor (version 3.4) SVA package, 
version 3.22.0, including ComBat tool in R. ComBat applies parametric and 
nonparametric empirical Bayes approaches for correcting expression data for the 
identified batch effects (Johnson et al. 2007). Further illustrations about identifying 
batch effects are explained in appendix 9.1 section 9.1.3.1, and about the data after 
batch effects correction in appendix 9.1 section 9.1.3.2. 
 
4.4.6. Differential gene expression analyses 
4.4.6.1. Global differential gene expression analysis 
Pre-processed expression data were analysed by using Bioconductor (version 3.4) 
Limma package version 3.30.8 in R (Ritchie et al. 2015) by fitting a linear model and 
applying empirical Bayes estimation approach to compare the signal intensity values 
between the 22q11.2DS samples and control samples for differential expression. 
Differential gene expression was calculated by mean of the log2 fold change 
(coefficients) and the resulting p-value for each probe were adjusted for multiple 
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testing by using Benjamini Hochberg False discovery rate (FDR) method (Benajmini 
& Hochberg 1995). FDR significance threshold used in this analysis was equal to 0.05 
to accept 5% of significant results as false positive. 
 
4.4.6.2. 22q11.2 region differential gene expression analysis 
Differential expression analysis of probes within the 1.5Mb region (LCR22sA-B) (n 
=74) utilised all the 22q11.2DS samples (n =33); however, expression analysis for 
probes spanned by LCR22s B-D (n= 46) utilised only those that carry a 3Mb deletion 
at 22q11.2 (n =32). 
 
4.4.6.3. In CIS and in TRANS positional effect analyses 
To study in CIS position effect, adjacent probes to the 22q11.2 deletion in chromosome 
22 (n =596) were selected. Expression level of these probes were compared between 
the 33 22q11.2DS samples and the 35 control samples. In order to investigate whether 
probes located within a short distance to the deletion are more prone to be 
differentially expressed in 22q11.2DS than those which are located within a long 
distance to the deletion, a linear regression analysis was performed to test the 
correlation between significance level (FDR) of each adjacent probe, as an 
independent variable, and probe distance from the deletion, as a dependent variable. 
On the other hand, to investigate for the presence of a TRANS positional effect, 
differential gene expression analysis was performed on probes outside chromosome 
22 (n =33,707) comparing all 22q11.2DS samples to control samples. 
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4.4.6.4. Differential expression analysis in 22q11.2DS patients with psychiatric 
illnesses 
Also, similar genome-wide, in CIS, and 22q11.2 differential gene expression analyses 
were performed to compare 22q11.2DS patients affected and unaffected with 
psychiatric diseases. Only 26 of the total 33 22q11.2DS samples, which were recruited 
by the ECHO Cardiff study group, have available neuropsychiatric symptom data and 
were categorized based on their manifested psychiatric phenotypes. Then, we 
performed the following contrast analyses separately: 1) 22q11.2DS+ADHD vs 
22q11.2DS-PSYCH, 2) 22q11.2DS+ASD vs 22q11.2-PSYCH, and 3) 
22q11.2+PSYCH vs 22q11.2DS-PSYCH. 
 
4.4.7. Pathway analysis 
Global significantly differentially expressed probes (FDR <0.05) outside the 22q11.2 
region (n =785) were selected for pathway analysis. The Database 
for Annotation, Visualization and Integrated Discovery (DAVID) version 6.7 (Huang 
et al. 2009) was used to identify biological networks that are enriched with 
differentially expressed probes. DAVID is a bioinformatics enrichment tool that 
performs a functional interpretation of large lists of genes to identify biological 
processes that are most pertinent to our study. DAVID has an extent annotation content 
coverage to over 40 annotation categories including gene ontology terms, protein–
protein interactions, protein functional domains, disease associations, bio-pathways, 
sequence general features, homologies, gene functional summaries, gene tissue 
expression, literatures, and more (Huang et al. 2007).  
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A minimum number of ten differentially expressed probes was used to identify an 
enriched pathway. Significance of enriched pathways were assessed by FDR with 
significance threshold equal to FDR= 0.05.  
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4.5. Results 
4.5.1. Samples quality control 
The gene expression data from 69 out of the initial 79 samples passed the initial quality 
control procedures. The deletion status determined from the RNA of all 22q11.2DS 
samples were identical to that determined from their DNA, however, a single control 
sample showed unmatched molecular gender which was removed from the subsequent 
analysis. This resulted in a total of 68 samples of which 33 belong to 22q11.2DS 
patients and 35 belong to age-matched non-deleted controls. Bioconductor analysis 
revealed two significant batch effects in the gene expression data of these samples 
(sample wave (p-value =0.0041) and sample original study (p-value =0.0019)) that 
were subsequently corrected. The resulting gene expression data of the 68 samples 
was of sufficient quality and was used for all gene expression work presented in this 
chapter. Breakdown of excluded samples is explained in Table 4- 1. 
 
 
 
Quality controls 
filtering 
 
*Threshold **Initial total ***Removed ****Final total 
RIN score   7.0 79 3 76 
RNA concentration 
(ng) 
400 76 3 73 
A260/A280 ratio 2.0 73 0 73 
Duplicated sample - 73 4 69 
Gender Reported gender 
confirmed molecularly 
69 1 68 
22q11.2 deletion  Reported 22q11.2 
deletion status confirmed 
molecularly 
68 0 68 
Quality of gene 
expression data 
Large proportion of high 
quality probes 
68 0 68 
Table 4- 1: Results of samples quality control analyses. 
* Filtering threshold or criteria. 
** Initial total: Initial total number of samples. 
*** Removed: Number of removed samples due to failure in matching filtering threshold or criteria. 
**** Final total: Final total number of samples.  
 
 
* Filtering threshold or criteria. 
** Initial total: Initial total number of samples. 
*** Removed: Number of removed samples due to failure in matching filtering threshold or criteria. 
**** Final total: Final total number of samples.  
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 The 33 22q11.2DS patients were categorized based on the presented psychiatric 
diseases into 3 groups: 22q11.2DS+ADHD, 22q11.2DS+ASD, and 
22q11.2DS+PSYCH to determine comparison contrasts for the subsequent gene 
expression analyses (Table 4- 2). 
 
 
Categories 
 
Description 
 
Number of 
individuals 
22q11.2DS+ADHD 22q11.2 deletion carriers with ADHD phenotypes 13 
22q11.2DS+ASD 22q11.2 deletion carriers with ASD phenotypes 5 
22q11.2DS+PSYCH 
 
22q11.2 deletion carriers with ADHD and/or ASD 
phenotypes 
14 
22q11.2DS-PSYCH 22q11.2 deletion carriers with no ADHD and ASD 
phenotypes 
12 
 
 
 
4.5.2. Estimating the background rate of differential gene expression in 
22q11.2DS  
To establish an estimation for the background rate of differential expression in 
22q11.2DS, a global expression analysis was performed by comparing the 34,370 
probes that were outside of the 3Mb deleted region at 22q11.2 between the 33 patients 
with 22q11.2DS and the 35 non-deleted controls. The results showed that only 2.3% 
probes are significantly differentially expressed (FDR <0.05). This finding was used 
as a comparison to the rate of differential gene expression seen for genes spanned by 
the 3Mb deletion at 22q11.2 (Table 4- 3). 
 
 
 
 Table 4- 2: Number of 22q11.2 deletion carriers affected and unaffected by psychiatric disorders.  
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Global differential expression analysis 
Total 
number of 
probes 
Significantly differentially 
expressed probes 
(FDR <0.05) 
Significantly 
downregulated probes 
(FDR <0.05) 
Significantly upregulated 
probes 
(FDR <0.05) 
 
34,370 
Number Percentage Number Percentage Number Percentage 
785  2.3% 477  1.4% 308  0.90% 
 
4.5.3. Investigating dosage sensitive genes within 22q11.2 region 
Differential gene expression analysis of the 120 probe sets spanning the 3Mb deletion 
at 22q11.2 between 22q11.2DS patients and controls was aimed at identifying dosage 
sensitive genes at 22q11.2. The results revealed that 51 probes (42.5%) were 
significantly differentially expressed in 22q11.2DS relative to controls (FDR <0.05), 
all of which were downregulated in 22q11.2DS patients compared to controls (Table 
4- 4). The level of gene expression difference of these probes are variable with a log2 
fold change ranges from -0.053 to -1.142 (Table 4- 5). The average level of expression 
difference of these probes was -0.568 with SD equal to 0.31, indicating there is a 
substantial variability in gene expression levels within 22q11.2DS patients. 
The 51 differentially expressed probes implicate transcripts for 39 genes at 22q11.2, 
of which 29 have been reported to be brain-expressed (Guna et al. 2015) (Table 4- 5). 
 
Table 4- 3: Results of differential gene expression analysis on genome-wide probes excluding those within 
22q11.2.  
Table 4- 4: Results of differential gene expression analysis on 3Mb 22q11.2 region probes. 
22q11.2 differential expression analysis 
Total 
number 
of probes 
Significantly 
differentially expressed 
probes 
(FDR <0.05) 
Significantly 
downregulated probes 
(FDR <0.05) 
Significantly 
upregulated probes 
(FDR <0.05) 
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Number Percentage Number Percentage Number Percentage 
51 42.5% 51  42.5% 0 0.0% 
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* Lowest FDR for genes within 1.5Mb region. 
** Lowest FDR for probes within 3Mb region. 
Genes highlighted with red are expressed in the brain. 
 
Probe 
ID 
 
Target gene 
 
CHR 
 
Region 
 
Start 
(hg19) 
 
End 
(hg19) 
Log2 fold change 
22q11.2 del carries 
vs non-22q11.2 del 
carriers 
 
P-value 
 
FDR 
 
6900253 DGCR6 22 1.5Mb 18899136 18899185 -1.114 5.05x10-20 1.25x10-18 
1010364 DGCR6 22 1.5Mb 18899542 18899591 -0.987 4.98x10-13 3.35x10-12 
7200274 DGCR6 22 1.5Mb 18899545 18899591 -0.968 8.73x10-13 4.97x10-12 
5670167 DGCR2 22 1.5Mb 19023794 19109967 -0.937 4.72x10-19 8.73x10-18 
7560554 *DGCR14 22 1.5Mb 19122576 19122625 -0.912 3.16x10-20 1.17x10-18 
870020 HS.572896 22 1.5Mb 19159833 19159882 -0.157 0.0005 0.0012 
6900440 SLC25A1 22 1.5Mb 19163460 19163509 -1.142 1.74x10-20 1.17x10-18 
1090427 CLTCL1 22 1.5Mb 19175106 19175155 -0.340 8.66x10-11 4.27x10-10 
5090414 MRPL40 22 1.5Mb 19423280 19423329 -0.410 3.59x10-6 1.02x10-5 
5860156 C22orf39 22 1.5Mb 19428409 19435755 -0.538 1.01x10-9 4.67x10-9 
730100 UFD1L 22 1.5Mb 19437950 19437999 -0.313 1.16x10-7 3.90x10-7 
1260475 UFD1L 22 1.5Mb 19438089 19438138 -0.085 0.0009 0.0022 
5130382 CLDN5 22 1.5Mb 19510627 19510676 -0.909 2.75x10-7 8.48x10-7 
5890537 SEPT5 22 1.5Mb 19706119 19706168 -0.154 0.0036 0.0081 
6960022 SEPT5 22 1.5Mb 19712239 19712288 -0.775 1.42x10-5 3.75x10-5 
4230719 GNB1L 22 1.5Mb 19775933 19842462 -0.618 7.91x10-8 2.79x10-7 
5860136 LOC728139 22 1.5Mb 19780042 19780091 -0.299 0.0011 0.0026 
6110246 C22orf29 22 1.5Mb 19833660 19842371 -0.968 2.44x10-18 3.61x10-17 
2230397 TXNRD2 22 1.5Mb 19863040 19929515 -0.738 6.84x10-14 5.62x10-13 
520446 COMT 22 1.5Mb 19948774 19948812 -0.664 4.65x10-8 1.72x10-7 
6940243 COMT 22 1.5Mb 19956318 19956367 -0.762 1.34x10-17 1.65x10-16 
630446 C22orf25 22 1.5Mb 20053229 20053278 -0.824 4.39x10-8 1.71x10-7 
290053 DGCR8 22 1.5Mb 20099142 20099191 -0.366 5.92x10-7 1.75x10-6 
7150291 TRMT2A 22 1.5Mb 20099388 20104818 -0.262 4.31x10-8 1.71x10-7 
1300402 TRMT2A 22 1.5Mb 20099388 20104818 -0.339 1.71x10-7 5.50x10-7 
6220170 TRMT2A 22 1.5Mb 20099388 20104818 -0.116 0.0015 0.0034 
7000735 RANBP1 22 1.5Mb 20109797 20109846 -0.961 9.94x10-16 9.19x10-15 
4610047 RANBP1 22 1.5Mb 20114499 20114548 -0.790 6.17x10-13 3.80x10-12 
4590154 ZDHHC8 22 1.5Mb 20133867 20133916 -0.847 2.14x10-13 1.58x10-12 
5420014 DGCR6L 22 1.5Mb 20301760 20307628 -1.047 5.24x10-17 5.54x10-16 
6270630 TMEM191B 22 1.5Mb 20379312 20379361 -0.691 3.98x10-11 2.10x10-10 
3360762 TMEM191B 22 1.5Mb 20379507 20379556 -0.638 4.50x10-9 1.96x10-8 
2360414 PI4KAP1 22 1.5Mb 20383730 20398695 -0.605 1.32x10-5 3.62x10-5 
2710093 ZNF74 22 3Mb 20761879 20761928 -0.541 2.17x10-9 1.08x10-8 
7570692 SCARF2 22 3Mb 20778873 20792146 -0.053 0.0015 0.004 
5290259 KLHL22 22 3Mb 20795805 20850170 -0.839 2.46x10-14 2.66x10-13 
6770672 MED15 22 3Mb 20929457 20929506 -0.619 1.05x10-7 4.03x10-7 
5420243 MED15 22 3Mb 20941648 20941697 -0.971 3.60x10-10 2.04x10-9 
4220195 DKFZp434N035 22 3Mb 21056978 21056997 -0.256 2.37x10-6 8.06x10-6 
4120347 DKFZp434N035 22 3Mb 21057949 21057980 -0.365 3.21x10-5 9.55x10-5 
450706 PI4KA 22 3Mb 21061978 21213100 -0.401 3.49x10-6 1.15x10-5 
4920273 PIK4CA 22 3Mb 21062115 21062164 -0.626 2.05x10-12 1.36x10-11 
7100437 SNAP29 22 3Mb 21243886 21243935 -0.617 3.28x10-9 1.56x10-8 
5960767 CRKL 22 3Mb 21307655 21307704 -0.700 6.50x10-10 3.52x10-9 
4260551 AIFM3 22 3Mb 21335320 21335320 -0.252 0.0001 0.0003 
290086 LZTR1 22 3Mb 21353194 21353243 -0.738 1.69x10-12 1.18x10-11 
2450132 **THAP7 22 3Mb 21354060 21356404 -0.994 2.44x10-16 3.63x10-15 
5560021 THAP7 22 3Mb 21354060 21356404 -0.065 0.0049 0.0117 
5820672 HIC2 22 3Mb 21805532 21805581 -0.211 0.0029 0.0071 
1110278 TMEM191C 22 3Mb 21822478 21822491 -0.171 0.0057 0.0133 
4480753 LOC220686 22 3Mb 21828944 21828946 -0.335 0.0008 0.0023 
Table 4- 5: Results of differential gene expression analysis for probes within 3Mb 22q11.2 region.  
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4.5.4. Investigating positional effects of the 22q11.2 deletion 
Analysis of a CIS positional effect of 22q11.2 deletion sought to investigate whether 
the deletion has a direct effect on expression of nearby genes in chromosome 22. 
The results of linear regression analysis showed a positive correlation between the 
probes differential expression significance level (FDR) and the probes distance from 
the deletion, however, this correlation was found very small with a correlation 
coefficient (r2) of 0.0022 and was not statistically significant with p-value= 0.13. This 
indicates that there is a potential enrichment of differentially expressed probes closer 
to the deletion and it is potentially that closer probes are more likely to be differentially 
expressed than the ones in a remoter distance. However, no significant evidence for 
this potential in CIS positional effect conferred by the deletion. A Manhattan plot 
shows more significantly differentially expressed probes are present in nearby regions 
(Figure 4- 3). 
 
 
 
 
 
 
 
 
 
 
 
Figure 4- 3: Manhattan plot for differential gene expression analysis for probes adjacent to 22q11.2 
deletion. 
X-axis represents the flanking region distance from the 3Mb 22q11.2 deletion by Mb. Y-axis represents 
log10(FDR) for each probe in these regions. Each probe in the region is represented by a black dot. The red 
line represents FDR significance threshold (FDR= 0.05). The blue line represents a linear regression line 
showed a small positive correlation of 0.0022. As the probes located in longer distance from the deletion, 
they are unlikely to be differentially expressed. The plot was generated by R.   
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Analysis of a TRANS positional effect sought to investigate whether the 22q11.2 
deletion influence probes outside chromosome 22. The results identified only 2.1% 
probes outside chromosome 22 are significantly differentially expressed (FDR <0.05). 
This finding is similar to the background rate of differential expression identified at 
this chapter section 4.5.2.  
 
4.5.5. Investigating dosage sensitive genes in 22q11.2DS patients affected by 
neuropsychiatric disorders 
This analysis sought to highlight candidate genes by identifying differentially 
expressed genes in 22q11.2 deletion carriers affected by neuropsychiatric phenotypes.  
The results of differential gene expression analysis comparing either the 
22q11.2DS+ADHD group (n=13) or the 22q11.2DS+ADHD group (n=5) to the 
22q11.2DS-PSYCH group (n=12) revealed no 22q11.2 probes are significantly 
differentially expressed in 22q11.2DS patients affected by ADHD or ASD relative to 
those unaffected by any psychiatric symptoms (FDR threshold =0.05). To increase our 
sample size, the expression pattern was compared collectively between all 22q11.2 
deletion carriers affected with ADHD or/and ASD (n=14) to the 12 deletion carriers 
who showed no psychiatric phenotype. Again, the results demonstrated no probes 
within 22q11.2, within nearby regions, and genome-wide reached the significance cut-
off of multiple testing correction (FDR= 0.05). 
 
4.5.6. Identifying functional pathways enriched for differentially-expressed genes  
The 785 significantly differentially expressed probes (FDR <0.05) located outside the 
3Mb 22q11.2 deleted region in 22q11.2DS patients were selected for building 
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biological networks and investigating relationships by pathway analysis. This analysis 
could give an insight about biological functions that possibly underlie the phenotypes 
manifested in 22q11.2DS.  
Pathway analysis using DAVID revealed 25 significant functional groups (FDR 
<0.05) (Table 4- 6), that were categorised into four enriched functional networks which 
are involved in: 
1) Translation machinery, protein synthesis by ribosomes, and post-translation 
modifications (PTM) including acetylation, phosphorylation, and 
ubiquitination. 
2) Programmed cell death and apoptosis. 
3) Immune system response. 
4) Intramembrane organelles and cytosol. 
 
The largest functional network consisted of 13 functional groups, that are involved in 
translation machinery, protein synthesis by ribosomes, and PTM (Figure 4- 4). 11 of 
the 13 groups were found in the most significant functional groups (minimum FDR= 
8.88x10-6). In addition, the top functional group with the highest proportion of the 
differentially significant probes (48.5%) was associated with phosphoprotein (FDR 
=1.1x10-4) included in this functional network (Table 4- 6).  Proteins are synthesized 
by ribosomes that translate mRNA into polypeptide chains, which may then subject to 
PTMs to produce the mature protein product. PTMs are the modifications that occur 
covalently and generally via enzymes during or post protein synthesis, which are one 
of the key components in the process of cell signalling (Verdin & Ott 2014; Drazic et 
al. 2016). Therefore, we could indicate that a high number of the differentially 
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expressed probes in 22q11.2DS patients are involved in protein synthesis and PMTs 
processes. 
The second largest functional network is apoptosis and programmed cell death 
including 6 functional groups (minimum FDR= 0.0015). This apoptosis network 
included ~3-6% of the differentially expressed probes (Figure 4- 4; Table 4- 6). 
Apoptosis is a process of programmed cell death which is a vital component of various 
cellular processes including normal cell turnover, proper development and functioning 
of the immune system, hormone-dependent atrophy, embryonic development and 
chemical-induced cell death (Elmore 2007).  
A smaller functional network is involved in intramembrane organelles and cytosol. It 
composed of 4 functional groups with a proportion of differentially expressed probes 
ranged from 3-14% (minimum FDR= 8.44x10-5) (Figure 4- 4; Table 4- 6). 
The smallest functional network is involved in immune system response, particularly 
lymphocyte and leukocyte activation, that included two significant functional groups 
(FDR <0.05) enriched with ~4% differentially expressed probes in 22q11.2DS (Figure 
4- 4; Table 4- 6). 
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Annotation categories 
 
Functional group 
* Total number 
of genes 
** Number 
of DE genes 
Percentage 
of DE genes 
 
P-value 
 
FDR 
SP_PIR_KEYWORDS Ribosome                563 16 2.7 6.3x10-9 8.9x10-6 
SP_PIR_KEYWORDS Ribonucleoprotein                563 30 5.1 1.3x10-8 1.9x10-5 
GOTERM_CC_FAT GO:0005840-Ribosome                415 26 4.4 3.1x10-8 4.2x10-5 
GOTERM_BP_FAT GO:0006414-Translational 
elongation               
434 18 3.1 4.1x10-8 7.2x10-5 
GOTERM_CC_FAT GO:0005829-Cytosol                415 83 14.1 6.1x10-8 8.4x10-5 
SP_PIR_KEYWORDS Ribosomal protein               563 23 3.9 6.3x10-8 8.9x10-5 
SP_PIR_KEYWORDS Phosphoprotein                563 286 48.5 7.7x10-8 1.1x10-4 
GOTERM_MF_FAT GO:0003735-Structural 
constituent of ribosome             
405 21 3.6 3.0x10-7 4.4x10-4 
KEGG_PATHWAY hsa03010: Ribosome                194 16 2.7 1.1x10-6 0.0013 
GOTERM_BP_FAT GO:0008624-Induction of 
apoptosis by extracellular 
signals           
434 17 2.9 8.6x10-7 0.0015 
GOTERM_BP_FAT GO:0006412-Translation                434 30 5.9 8.9x10-7 0.0016 
SP_PIR_KEYWORDS Protein biosynthesis               563 21 3.6 1.5x10-6 0.0022 
GOTERM_CC_FAT GO:0033279-Ribosomal 
subunit               
415 18 3.1 1.7x10-6 0.0023 
GOTERM_CC_FAT GO:0030529-
Ribonucleoprotein complex               
415 39 6.6 2.7x10-6 0.0038 
GOTERM_CC_FAT GO:0022626-Cytosolic 
ribosome               
415 14 2.4 2.9x10-6 0.0040 
GOTERM_BP_FAT GO:0045321-Leukocyte 
activation               
434 24 4.7 3.6x10-6 0.0063 
GOTERM_BP_FAT GO:0043065-Positive 
regulation of apoptosis             
434 34 5.8 5.8x10-6 0.0101 
GOTERM_BP_FAT GO:0046649-Lymphocyte 
activation               
434 21 3.6 5.9x10-6 0.0103 
GOTERM_BP_FAT GO:0001775-Cell activation               434 26 4.4 6.0x10-6 0.0104 
GOTERM_BP_FAT GO:0043068-Positive 
regulation of programmed 
cell death           
434 34 5.8 6.7x10-6 0.0117 
GOTERM_MF_FAT GO:0005198-Structural 
molecule activity              
405 42 7.1 7.9x10-6 0.0119 
GOTERM_BP_FAT GO:0010942-Positive 
regulation of cell death            
434 34 5.8 7.5x10-6 0.0130 
GOTERM_BP_FAT GO:0006917-Induction of 
apoptosis              
434 28 4.7 8.6x10-6 0.0151 
GOTERM_BP_FAT GO:0012502-Induction of 
programmed cell death            
434 28 4.7 9.1x10-6 0.0160 
GOTERM_CC_FAT GO:0044445-Cytosolic part               415 18 3.1 1.7x10-5 0.0240 
 
 
 
 Table 4- 6: Significantly enriched functional groups by genome-wide differentially expressed probes in 22q11.2DS 
patients identified by using DAVID. 
* Total number of genes involved in this functional group. 
** Number of significantly differentially expressed genes identified in this functional group. 
Blue boxes are functional groups involved in translation, protein synthesis and PMTs. 
Red boxes highlighted functional groups implicated in cell death and apoptosis. 
Grey boxes are functional groups related to intracellular and cytosolic components. 
Yellow boxes indicated functional groups associated with immune system. 
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Figure 4- 4: Significantly enriched functional networks by genome-wide differentially expressed probes in 
22q11.2DS patients. 
Each red circle represents a functional group and as the group involved more probes the circle gets larger. The green 
lines represent there are shared probes between the two connected functional groups. The largest functional network 
is associated with protein synthesis process, followed by a network associated with apoptosis, then a smaller network 
associated with cell components, The smallest network is related to immune system. The figure is generated by DAVID 
and Cytoscape (v.3.4.0) (Shannon et al. 2003). 
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4.6. Discussion 
It has been suggested that the underlying cause of the psychiatric phenotypes 
associated with 22q11.2DS is the haploinsufficiency of genes within the 22q11.2 
region. In this chapter, gene expression was analysed and compared in 22q11.2DS 
patients and non-deleted controls to identify dosage sensitive genes that are 
differentially expressed in 22q11.2DS.  
The results of differential gene expression analysis showed that 42.5% (n= 51) of the 
probes within 3Mb 22q11.2 deleted region are significantly differentially expressed in 
22q11.2DS patients compared to healthy controls (FDR <0.05). This identified 39 
dosage sensitive genes within the 3Mb deleted region that were found to be 
downregulated in 22q11.2DS patients.  
Seven of the 39 genes were also reported to be differentially expressed in a smaller 
22q11.2DS cohort (n= 7) (van Beveren et al. 2012), while 29 of them were also 
identified as dosage sensitive genes in a larger 22q11.2DS cohort (n= 46) 
(Jalbrzikowski et al. 2015). Six additional dosage sensitive genes identified by 
Jalbrzikowski and colleagues were not identified by this study, while an additional 8 
differentially expressed genes were identified only our study (Table 4- 7). Comparing 
these findings to those of murine models of 22q11.2DS,  7 of the 39 genes were also 
found to be differentially expressed in the brain tissues of the Df1+/- mice compared 
to the wild-type mice (Sivagnanasundaram et al. 2007) (Table 4- 7). These observations 
indicate that there is a degree of consistency between the findings in all 2 gene 
expression studies conducted in 22q11.2DS (van Beveren et al. 2012; Jalbrzikowski 
et al. 2015). 
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Heterozygous knockout mouse models have been generated for a number of the genes 
that this study identified as being differentially expressed in 22q11.2, including Dgcr8, 
Zdhh8, Comt, Sept5, Tbx1, and Gnb1l (Gogos et al. 2009; Gogos et al. 1998; Hsu et 
al. 2007; Mukai et al. 2004; Paylor et al. 2006; Suzuki et al. 2009). Mouse models 
haploinsufficient for Dgcr8 and Zdhh8 manifested impaired PPI (Mukai et al. 2004; 
Gogos et al. 1998), while those with haploinsufficiency for Comt (Gogos et al. 1998), 
Sept5 (Suzuki et al. 2009), Tbx1, and Gnb1l (Paylor et al. 2006) showed defects in 
sensory gating function. Both phenotypes are cognitive functions achieved by activity 
in the prefrontal cortex and the hippocampus and are considered as endophenotypes 
of schizophrenia and psychiatric symptoms in 22q11.2DS patients (Paylor et al. 2001). 
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Dosage sensitive 
genes identified by 
our study 
Dosage sensitive genes 
identified by 
(Jalbrzikowski et al. 2015) 
Dosage sensitive genes 
identified by 
(van Beveren et al. 2012) 
Dosage sensitive genes identified 
by 
(Sivagnanasundaram et al. 2007) 
COMT COMT COMT Comt 
CRKL CRKL CRKL Ranbp1 
DGCR14 DGCR14 DGCR14 Ufd1l 
RANBP1 RANBP1 RANBP1 Cldn5 
SLC25A1 SLC25A1 SLC25A1 Dgcr6 
UFD1L UFD1L UFD1L Sept5 
MRPL40 C22orf25 MRPL40 Zdhhc8 
C22orf25 C22orf29  Arvcf 
C22orf29 C22orf39  Prodh 
C22orf39 CLDN5  Rtn4r 
CLDN5 CLTCL1  Htf9c 
CLTCL1 DGCR2  D16H22S680E 
DGCR2 DGCR6   
DGCR6 DGCR8   
DGCR8 GNB1L   
GNB1L KLHL22   
KLHL22 LOC220686   
LOC220686 LZTR1   
LZTR1 MED15   
MED15 PI4KAP1   
PI4KAP1 PIK4CA   
PIK4CA SEPT5   
SEPT5 SNAP29   
SNAP29 THAP7   
THAP7 TMEM191B   
TMEM191B TRMT2A   
TRMT2A TXNRD2   
TXNRD2 ZDHHC8   
ZDHHC8 ZNF74   
ZNF74 DKFZp434-N035   
DKFZp434-N035 ATF4   
AIFM3 GRAP2   
DGCR6L LOC150356   
HIC2 LOC400890   
HS.572896 PIK3IP1   
LOC728139 RFPL2   
PI4KA    
SCARF2    
TMEM191C    
 
Table 4- 7: Dosage sensitive genes lists identified in differential genes expression studies in 22q11.2DS patients 
and 22q11.2DS mice models. 
Grey labelled genes represent dosage sensitive genes that were identified in our study and the two studies in 22q11.2DS patients and the one 
study in 22q11.2DS mouse model. 
Blue labelled genes represent dosage sensitive genes that were only identified in our study 
Red labelled genes represent dosage sensitive genes that were identified in other studies but not in our study. 
Yellow labelled genes represent dosage sensitive murine orthologues of human 22q11.2 genes that were identified in 22q11.2DS mouse model 
but not in 22q11.2DS patients. 
Underlined genes represent murine orthologues of human 22q11.2 genes that have same expression levels  in both microarray and RTqPCR data. 
 
Grey labelled genes represent dosage sensitive genes that were identified in our study and the two studies in 22q11.2DS patients and the one 
study in 22q11.2DS mouse model. 
Blue labelled genes represent dosage sensitive genes that were only identified in our study 
Red labelled genes represent dosage sensitive genes that were identified in other studies but not in our study. 
Yellow labelled genes represent dosage sensitive murine orthologues of human 22q11.2 genes that were identified in 22q11.2DS mouse model 
but not in 22q11.2DS patients. 
Underlined genes represent murine orthologues of human 22q11.2 genes that have expression levels similar in both microarray and RTqPCR 
data. 
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With reference to the gene expression profiles in (Jalbrzikowski et al. 2015; Guna et 
al. 2015), 29 of the 39 differentially expressed genes spanning the 3Mb 22q11.2 region 
were identified to be brain-expressed genes. This highlights these genes as potential 
candidate loci for the psychiatric phenotypes in 22q11.2DS. There was, however, a 
substantial variability in the gene expression levels in the 22q11.2DS patients.  
An assessment of the gene expression of genes spanning the whole genome between 
22q11.2 deletion carriers and non-deletion carriers revealed that 2.3% of probes were 
significantly differentially expressed (FDR <0.05). Pathway analyses of this data 
revealed there to be four functional biological networks that were significantly 
enriched (FDR <0.05) with differentially expressed genes (cell death programing; T-
cells activation; protein synthesis, ribosome and translation regulation; and 
intermembrane organelles regulation). In comparison, the pathway analysis conducted 
by Jalbrzikowski and colleagues implicated a biological network associated with 
cellular development, growth, and proliferation which was not associated in this study. 
However, they also identified significant GOterms that were related to immune 
response, regulation phosphate metabolic process, and regulation of epithelial to 
mesenchymal transition (Jalbrzikowski et al. 2015), which are in line with the enriched 
biological pathways reported in this thesis. While the results of pathway analysis could 
indicate a role of the immune system abnormalities in 22q11.2DS, it is also possible 
that the results are being adversely influenced by the use of RNA from blood. As such 
these observations will require replication when sufficient post-mortem brain tissue 
from 22q11.2DS patients becomes available.  
In analysing the differential expression of genes flanking the 22q11.2 deletion, this 
study failed to provide significant evidence that the deletion at 22q11.2 causes a large 
positional effect in CIS. A non-significant positive correlation between the probes 
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being differentially expressed and their distance to the deletion was observed, 
however, this correlation is very small (r2= 0.0022) and statistically non-significant 
(p-value= 0.13). Failure in providing a CIS positional effect is most likely due to 
limited power of the study, if the effect is weak then it is possible that it could be 
identified by analysing larger numbers of samples. It is also possible that a position 
effect could be tissue specific and as such it could potentially be revealed by future 
investigations in other tissue/cell types from 22q11.2DS patients.  
 
Comparing gene expression between 22q11.2DS patients with and without psychiatric 
illnesses was aimed to highlight candidate genes that could be specifically relevant to 
psychiatric disease. However, the results failed to provide an evidence for significantly 
differentially expressed probes in 22q11.2DS patients with psychiatric illness (FDR 
>0.05). Failure to identify differentially expressed genes is perhaps attributed to very 
small number of 22q11.2DS patients with available psychiatric phenotype data used 
for the analysis (n= 26). Jalbrzikowski and colleagues successfully identified 131 
probes that were differentially expressed between 22q11.2DS patients with (n= 16) 
and without ASD (n= 24), however, none of these probes were mapped to the 22q11.2 
region (Jalbrzikowski et al. 2015). More samples are therefore required for more 
fruitful study results. 
 
Despite suggestions that studying gene expression in peripheral blood can be a useful 
representative for gene expression in the CNS if the relevant gene is expressed in both, 
its use in this study was nevertheless a major limitation. It is however neither feasible 
nor ethical to extract brain samples from living 22q11.2DS patients. This limitation 
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will be addressed when sufficiently sized samples of post-mortem brain tissue from 
22q11DS patients are available. 
 
It is also worth mentioning that some of the non-deleted controls used in this analysis 
were age-matched siblings of the 22q11.2 DS patients. As these cohorts were not fully 
independent it is possible that this might have diluted the power of the study. The study 
of Jalbrzikowski and colleagues faced the same problem, which they addressed by 
carrying out a secondary analysis in which 22q11.2DS patients were compared to a 
subset of age-matched, unrelated controls. The results of the secondary study were 
compatible to the results of overall analysis and showed a high correlation to the 
original study r2 =0.91 (p-value <2.2x10-16) (Jalbrzikowski et al. 2015). This indicates 
that it is unlikely that this issue adversely affected results presented in this thesis. 
 
PS Power and Samples Size Calculation software version 3.1.2 was used to calculate 
the power of the sample size used in our gene expression study (Dupont & Plummer 
1990). The sample size of 33 22q11.2DS patients vs 35 non-deleted controls had an 
increasing power to detect differentially expressed genes by fold differences of 2 (SD= 
0.30) with false positive rate of 0.05. Also, the sample size for comparing gene 
expression in the 22q11.2DS patients who are affected with psychiatric disease to 
those unaffected (14 affected carriers vs 12 unaffected carriers) had a high power to 
detect differentially expressed genes by fold differences of 2 (SD= 0.11) with false 
positives rate of 0.05. This indicates that our differential gene expression analyses 
were enough powered to detect dosage sensitive genes that are influenced by the 
hemizygous deletion. Therefore, it is possible to say that as we had this statistical 
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power, in addition to the consistency of our findings with the previous studies, the 
identified differentially expressed probes in our analyses are highly possible to be 
realistic in 22q11.2DS patients. 
 
In conclusion, 22q11.2 gene haploinsufficiency is one of the suggested molecular 
mechanisms behind the neuropsychiatric phonotypes heterogeneity in 22q11.2DS. 
The results of this analysis revealed that not all genes within the deleted 22q11.2 
region are dosage sensitive. Only 42.5% of 22q11.2 probes are differentially expressed 
in 22q11.2DS patients. This represents 39 genes, of which 29 are brain expressed. 
Pathway analysis of genome-wide differentially expressed genes, excluding those 
within the 22q11.2 region, identified biological pathways that could possibly be 
relevant to the phenotypes seen in 22q11.2DS. Future studies with larger numbers of 
22q11.2DS samples and controls are necessary to confirm these preliminary findings 
and to obtain more powerful study. Moreover, in order to identify genes that are related 
to psychiatric disorders future studies should analyse either post mortem brain tissue 
or neuronal cell lines derived from induced pluripotent cell lines obtained from 
22q11.2DS deletion patients. 
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Chapter 5: Investigating the Role of a Second Independent 
Genetic Variant Located Within the 22q11.2 Region in 
Psychiatric Disease 
 
 
5.1. Summary 
There are several mechanisms that have been proposed in which deletions at 22q11.2 
could potentially increase risk to psychiatric diseases (Williams 2011). In this chapter, 
one possible molecular mechanism was investigated. We hypothesized that if an 
individual was a heterozygous carrier of an additional risk variant, that is associated 
with the increased risk of psychiatric disease, located at 22q11.2 then the deletion 
could potentially unmask the deleterious effect of this allele that remains within the 
non-deleted chromosome. These variants might exist in the form of CNVs or SNPs on 
the non-deleted allele at 22q11.2 and potentially contribute to the diverse behavioural 
phenotypes. 
Association analyses of 5,027 SNPs spanning the 3Mb 22q11.2 deleted region 
revealed no evidence for significant allelic association with psychiatric phenotypes in 
22q11.2DS.  
Three regions that potentially harboured a second deletion were identified. 
Association analyses of potential deletions failed to provide any evidence for a 
significant enrichment for secondary deletions in 22q11.2DS patients with psychiatric 
disorder.  
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The main limitation of this study is the small sample size (n= 76) used in the analyses, 
which limited the power of the study. Furthermore, a more precise method is required 
to reliably detect secondary CNVs occurring on the non-deleted 22q11.2 chromosome. 
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5.2. Introduction 
The molecular mechanism that is most likely to contribute to the increased risk of 
psychiatric phenotype in 22q11.2DS patients is haploinsufficiency of the genes 
located within the deleted region. Haploinsufficient genes result from a single allele 
being removed by the hemizygous deletion and this can lead to a reduction in gene 
expression (Inoue & Lupski 2002). However, as not all individuals with 22q11.2DS 
develop a psychiatric phenotype, this alone is not likely to explain the clinical 
phenotypes. 
 
Ordinarily, a recessive mutation will manifest its functional effect when it is present 
in a homozygous state. Alternatively, recessive mutations can also be deleterious when 
they co-occur with a second independent recessive mutation that affects the same gene 
and occurs on the normally wild-type chromosome. This compound heterozygosis 
typically occurs either when one recessive allele is transmitted from each healthy 
parent or when one allele is inherited while the other has arisen as a de novo mutation 
(Hochstenbach et al. 2012) (Figure 5- 1). 
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It has been hypothesized that the incomplete penetrance of the psychiatric phenotype 
associated with 22q11.2DS could be the result of additional risk alleles that occur in 
compound heterozygous form on the non-deleted chromosome (Williams 2011). In 
this context, it is suggested that the primary 22q11.2 deletion could ‘unmask’ an 
additional risk allele that would then lead to the patient having an increased risk of 
psychiatric disease.  
 
5.2.1. Investigating the mechanism of unmasking of recessive alleles in patients 
with disorders associated with hemizygous deletions and manifesting complex 
phenotypes 
A number of examples have been reported that describe ‘unmasking’ additional risk 
alleles by hemizygous microdeletions and resulting in additional or more severe 
Figure 5- 1: Unmasking of recessive allele and mode of inherence. 
This diagram explains the possible ways for independent loss of the two alleles in deletion 
syndromes. A. The affected daughter inherited the recessive mutated allele from her 
unaffected father also she inherited the deletion from her unaffected mother which 
unmasked the paternal recessive mutation. B. The affected daughter inherited the recessive 
mutated allele from her unaffected father and a de novo deletion has arisen and unmasked 
the recessive paternal mutation (Original figure). 
Mutation carrier Deletion carrier Mutation carrier Wildtype 
A B 
Affected female 
Inherited a deletion and a mutation De novo mutation carrier and inherited mutation 
Unaffected male Unaffected female 
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phenotypes. These unmasked risk alleles could occur in variable forms such as a small 
structural variant, a single nucleotide variant, or a single nucleotide polymorphism. 
An example for unmasking an additional single nucleotide variant by a primary 
hemizygous deletion was illustrated in a patient with Smith Magenis Syndrome (SMS) 
and a severe hearing impairment. SMS is caused by hemizygous deletions of 
chromosome 17p11.2 that span the MYO15A gene. The typical phenotype of this 
syndrome is characterised by multiple congenital anomalies, intellectual impairment, 
severe developmental disorders, and hearing impairment. ~68% of SMS patients 
showed variable degree of hearing loss. Conductive hearing impairment occurs more 
commonly than sensorineural hearing loss (SNHL) in these patients, whereas mixed 
hearing loss is also a feature of this disorder (Liburd et al. 2001). Also, it has been 
shown that mutations in MYO15A genes in consanguineous families with non-
syndromic autosomal recessive profound hearing loss (DFNB3) are responsible for 
their deafness (Liburd et al. 2001). Therefore, it was hypothesized that a mutation 
located in MYO15A but present on the non-deleted chromosome 17p11.2 could explain 
the hearing loss variability in SMS patients. In attempting to test this hypothesis, eight 
SMS patients with SNHL were sequenced to screen for mutations of MYO15A. Seven 
of the eight SMS patients had mild SNHL, while one patient had moderately severe 
high frequency hearing loss. The latter single SMS patient has been identified to have 
a second missense mutation on the non-deleted MYO15A allele, whereas none of the 
remaining seven patients have a mutation in MYO15A (Liburd et al. 2001). 
The second example is of a small CNV that is unmasked when spanned by a primary 
hemizygous deletion. A single case from patients with idiopathic mental retardation 
or developmental delay with or without multiple congenital abnormalities was 
identified with an inherited ~2.2Mb deletion at chromosome 16q23.3 (chr16: 
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82,660,578-84,826,825 on hg19). This 16q23.3 deletion was transmitted from a 
healthy hemizygous carrier mother. A second, paternally derived, smaller ~16.04Kb 
16q23.3 deletion (chr16: 83,841,341-83,857,382 on hg19) was also detected in this 
patient, that specifically disrupted HSBP1 gene which is located within the deleted 
region (Hochstenbach et al. 2012). This patient had a severe mental retardation, lack 
of speech, microcephaly, cheilognathopalatoschisis, and bilateral hearing loss. In a 
Hsbp1 knockdown mice, a reduced neuroblast migration was observed which possibly 
indicated that this gene is involved in brain development in these mice (Khodosevich 
et al. 2009). This finding offers some support to the hypothesis that nullizygousity of 
the HSBP1 gene confers a form of mental retardation in this patient (Hochstenbach et 
al. 2012).  
Both examples demonstrate the mechanism of unmasking a second mutation by a 
primary large hemizygous deletion and the possibility of this mechanism to confer 
more complex and/or severe forms of the disease. 
 
5.2.2. Investigating the mechanism of unmasking of recessive alleles in 22q11.2DS 
patients with atypical symptoms 
A number of studies have investigated this mechanism in 22q11.2DS. A 22q11.2DS 
patient was identified to have phenotypic features of Bernard-Soulier Syndrome 
(BSS), a rare congenital bleeding disorder (Ludlow et al. 1996). BSS is characterized 
by a prolonged bleeding time, thrombocytopenia, and abnormally large platelets. This 
22q11.2DS patient was identified with the BSS phenotype but Southern blotting 
analysis was not able to detect any platelet GpIbβ protein. Sequencing analysis of this 
patient revealed a mutation in the GATA binding site in the promoter of the remaining 
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allele of the GPIBβ gene. Therefore, the BSS phenotypes seen in this patient could be 
explained by a deleted copy of GPIBβ allele that unmasks a mutated GATA binding 
site in the promoter of the remaining allele (Ludlow et al. 1996). 
Most recently, McDonald-McGinn and colleagues studied 17 carriers of 22q11.2 
deletions who presented rare clinical phenotypes that atypically occurred in less than 
10% of 22q11.2DS patients including laryngo-tracheal-oesophageal abnormalities, 
limb differences, polymicrogyria, myelomeningocele, cleft lip, and genitourinary 
abnormalities (McDonald-McGinn et al. 2013). This study sought to identify 
additional mutations that contribute to these atypical phenotypes. Whole exome 
sequencing analysis was performed on four patients presenting laryngo-tracheal-
oesophageal and limb abnormalities. One patient (1) was identified with 2 variants 
present within the region of 22q11.2. One variant was a frameshift insertion within 
SNAP29 gene, whereas the other was a non-synonymous variant within CLTC1 gene. 
The frameshift insertion within SNAP29, c.388_389insGA, was identified to be 
paternally inherited and interfered by a de novo deletion on the 22q11.2 chromosome 
inherited from the mother. To support the presence of mutated SNAP29 in the other 
patients with atypical phenotypes, the coding exons 5` and 3` splice sites of SNAP29 
were screened in additional 12 patients by Sanger sequencing. Two 22q11.2DS 
patients were identified to have additional SNAP29 mutations; one patient (2) had a 
5bp deletion in exon 1 (c.28_32delCCGTT), which was transmitted from the mother; 
the other patient (3) had a missense point mutation (c.265G>A). A point missense 
mutation in the coiled-coil domain (c.268C>T; p.R90C) was identified in a fourth 
patient (4) by Targeted exome sequencing and confirmed by Sanger sequencing. 
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Two patients (1 and 2) share common clinical features that are consistent with 
phenotypes of  Cerebral Dysgenesis, Nephropathy, Icthyosis, and Keratoderma 
(CEDNIK) syndrome which is an autosomal recessive condition that is caused by 
truncating mutations in SNAP29 and characterised by cerebral dysgenesis, neuropathy, 
ichthyosis, and keratoderma (Sprecher et al. 2005). The third patient (3) expressed 
atypical symptoms that overlap with the phenotypes described in the autosomal 
recessive Kousseff syndrome particularly sacral meningocele, conotruncal cardiac 
anomalies, and dysmorphic features (Kousseff 1984). The fourth patient (4) showed 
symptoms that have been described in individuals with the heterogeneous Opitz 
G/BBB syndrome including a combination of cleft lip and palate, hypertelorism, 
laryngotrachealesophageal anomalies and hypospadias (Robin et al. 1995). 
The authors hypothesized that these recessive mutations in SNAP29 gene are 
‘unmasked’ by the 3Mb hemizygous deletion at 22q11.2 and potentially contributed 
to express atypical phenotypes caused by autosomal recessive diseases (McDonald-
McGinn et al. 2013). 
Given the complex clinical symptoms of 22q11.2DS and the large number of genes 
spanned by the deletions, the mechanism of unmasking additional risk alleles by the 
deletion could feasibly play a role in the clinical heterogeneity. As the 
haploinsufficiency of 22q11.2 genes is relevant to most of 22q11.2DS patients, it is 
logical to hypothesize that the background genetic variants that exist on the non-
deleted 22q11.2 chromosome could have an important function in conferring 
additional risk to variable phenotypes such as neuropsychiatric disease. To date no 
study has investigated the presence of second rare functional variants in the remaining 
haploinsufficient chromosome in 22q11.2DS patients with psychiatric phenotypes. 
Alternatively, a wide range of studies have investigated the association of common 
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variants, minor allele frequency >0.1, with the expression of the neuropsychiatric 
symptoms in 22q11.2DS patients. These studies sought to test the hypothesis that 
22q11.2DS patients with psychiatric phenotypes would be expected to carry common 
risk variants for neuropsychiatric disease on the remaining chromosome.  
 
5.2.3. Investigating common variants in 22q11.2 region 
The high susceptibility to develop psychiatric diseases in patients carrying a 22q11.2 
deletion provides excellent opportunities for identifying candidate genes that might be 
implicated in cognitive, behavioural, and psychiatric phenotypes (Bassett & Chow 
2008; Meechan et al. 2011). A large number of the genes located within the commonly 
deleted region are expressed in brain (Maynard et al. 2003; Meechan et al. 2009), 
therefore a large number of studies have tested the association of common variants 
present in some of these genes with neuropsychiatric phenotypes in 22q11.2DS 
patients. As discussed in detail in chapter 1 section 1.3.2, the promising results 
identified in some of these studies are not replicated by other studies; either by finding 
evidence for association in the opposite direction, or failure to provide a supportive 
replication for association with psychiatric phenotypes in 22q11.2DS.  
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5.3. Aims of this chapter 
It has been suggested that, despite carrying a single, relatively homogeneous deletion, 
the reason why the 22q11.2 deletion confers an incomplete penetrance to develop 
psychiatric illnesses could be due to the presence of genetic variants that remain on 
the non-deleted chromosome. To date no study has systematically screened the entire 
non-deleted 22q11.2 chromosome and as such no genetic variant at 22q11.2 has been 
unambiguously shown to influence the increased risk of psychiatric disease. 
 
Work described in this chapter will investigate a well-characterised cohort of 22q11.2 
deletion carriers to identify genetic variants present on the remaining, non-deleted 
region of 22q11.2. The cohort will be investigated by two approaches: 
1) An association analysis of 22q11.2 deletion carriers with and without 
psychiatric disorders for common SNPs spanned by the 22q11.2 deletion. 
2) Secondary deletions spanned by the primary 22q11.2 deletion can be 
detected as regions carrying SNPs that have null genotypes in 22q11.2DS 
patients. Small duplications within the deleted region can be identified by 
CNV calling using PennCNV. The frequency of rare deletions and 
duplications identified by these approaches will be compared between 
22q11.2 deletion carriers with and without a psychiatric disorder. 
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5.4. Materials and methods 
5.4.1. Samples 
DNA samples of the well-characterized 76 22q11.2DS patients were used for the 
analysis conducted in this chapter. The characterization of the 76 patients were fully 
explained in chapter 3 sections 3.5.1 and 3.5.2.  
The patients were grouped into 3 psychiatric diagnosis groups based on the manifested 
phenotypes including: 22q11.2DS+ADHD, 22q11.2DS+ASD, and 
22q11.2DS+PSYCH (Table 5- 1). 
Specific details of the 22q11.2DS patients are described in chapter 2 sections 2.1. 
Protocols of DNA extraction from the collected biological samples from 22q11.2DS 
patients, DNA quantification and quality control are fully explained in chapter 2 
section 2.2.  
 
 
 
 
 
Table 5- 1: Number of 22q11.2 deletion carriers affected and unaffected by psychiatric 
disorders. 
 
Categories 
 
Description 
 
Number of 22q11.2DS 
individuals 
22q11.2DS+ADHD 22q11.2 deletion carriers with 
ADHD 
29 
22q11.2DS+ASD 22q11.2 deletion carriers with ASD 18 
22q11.2DS+PSYCH 
 
22q11.2 deletion carriers with 
ADHD and/or ASD 
37 
22q11.2DS-PSYCH 22q11.2 deletion carriers without 
ADHD or ASD 
35 
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5.4.2. Genotyping SNPs within the non-deleted 22q11.2 chromosome 
5.4.2.1. Common SNPs for association analysis 
The DNA for all 22q11.2DS patients was genotyped using an Illumina Infinium 
Human CoreExome-24 BeadChip array as described in chapter 2 section 2.3.1.  
Genotype data for samples passing the initial QC was subjected to stringent QC 
procedures which were aimed at excluding low quality genetic variants. All QC was 
performed using Plink (Purcell et al. 2007) . SNPs were removed if they had one of 
the following standard QC criteria: 
1) Had a minor allele frequency (MAF) < 0.05. 
2) Had a missing rate of > 0.01 over all samples. 
3) The genotype frequencies significantly (p-value <1.0x10-6) deviated from 
those expected under Hardy-Weinberg equilibrium (HWE). 
The SNPs that survived these QC procedures were then used as a backbone to impute 
the genotypes of the majority of SNPs that were not included on the array. All 
imputation protocols are fully explained in chapter 2 section 2.4. Following 
imputation, the SNPs at 22q11.2 were further filtered to select those with good 
imputation quality (SNPs with MAF ≥0.01 and INFO score ≥0.8).  
A summary of the genotypes quality control analyses is described in Figure 5- 2. 
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Figure 5- 2: Flowchart for common raw and imputed genotypes quality 
control. 
Yes 
 
 
Removed from the analysis 
Removed from the analysis 
Removed from the analysis 
 
Raw genotypes in Illumina 
microarrays 
Included in the association 
analyses 
Yes 
Yes 
No 
No 
No 
 
SNP with a 
MAF ≥0.05? 
SNP with a 
samples missing 
rate ≤0.01? 
 SNP with a HWE 
p-value ≥1.0x10-6? 
Yes 
Removed from the analysis 
 
 Removed from the analysis 
Yes 
No 
No 
SNP with an 
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>0.8? 
 SNP with a MAF 
≥0.01? 
Imputation 
(Imputed genotypes) 
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5.4.2.2. Association analysis of common SNPs 
Association analysis was performed for each SNP spanning 22q11.2 by comparing its 
allele frequency in the 22q11.2DS patients affected with ADHD 
(22q11.2DS+ADHD), ASD (22q11.2DS+ASD), and either ADHD or ASD 
(22q11.2DS+PSYCH) to its frequency in the deletion carriers with no psychiatric 
illness (22q11.2DS-PSYCH) (Table 5- 1). 
Association analysis of the SNPs within the shared ~1.5Mb deletion spanning LCR22s 
A-B was conducted using all 22q11.2 deletion carriers, while the SNPs spanning 
LCR22s B-D were tested for association using only carriers of the ~3Mb deletion. The 
association analysis was carried out by logistic regression using Plink (Purcell et al. 
2007). The resulting p-value of each marker was corrected for multiple testing using 
either Bonferroni correction (in which the significance threshold was calculated by 
dividing an alpha of 0.05 by number of tested SNPs) (Dunn 1961), or the less 
conservative FDR correction (FDR calculated for p-value for each marker using R 
using Benjamini–Hochberg approach) (Benajmini & Hochberg 1995). 
 
5.4.2.3. Association analysis of common SNPs spanned by dosage sensitive genes 
In chapter 4 section 4.5.3, the differential gene expression analysis results revealed 39 
genes spanning the 3Mb 22q11.2 region that are dosage sensitive in 22q11.2DS 
patients compared to non-deleted controls (Table 5- 2). A targeted association analysis 
was performed, which focussed only on the SNPs that spanned the 39 dosage sensitive 
genes. Again, association analysis of SNPs spanned by dosage sensitive genes within 
the shared ~1.5Mb deletion (LCR22s A-B) was performed on all 22q11.2 deletion 
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carriers, whereas the SNPs spanned by dosage sensitive genes within LCR22s B-D 
were tested for association in only the carriers of the ~3Mb deletion. 
 
 
 
 
5.4.3. Identification of secondary CNVs within the non-deleted 22q11.2 
chromosome 
5.4.3.1. Identifying secondary deletions 
A second deletion that spanned the primary 22q11.2 deletion would result in a null 
genotype for any SNP spanned by both deletions. To identify 22q11.2DS patients 
carrying SNPs at 22q11.2 that had null genotypes the analysis was restricted to the 
array-based genotypes only.  
 
Target gene 
 
CHR 
 
Region 
 
Target gene 
 
CHR 
 
Region 
DGCR6 22 1.5Mb DGCR6L 22 1.5Mb 
DGCR2 22 1.5Mb TMEM191B 22 1.5Mb 
DGCR14 22 1.5Mb PI4KAP1 22 1.5Mb 
HS.572896 22 1.5Mb ZNF74 22 3Mb 
SLC25A1 22 1.5Mb SCARF2 22 3Mb 
CLTCL1 22 1.5Mb KLHL22 22 3Mb 
MRPL40 22 1.5Mb MED15 22 3Mb 
C22orf39 22 1.5Mb DKFZp434N035 22 3Mb 
UFD1L 22 1.5Mb PI4KA 22 3Mb 
CLDN5 22 1.5Mb PIK4CA 22 3Mb 
SEPT5 22 1.5Mb SNAP29 22 3Mb 
GNB1L 22 1.5Mb CRKL 22 3Mb 
LOC728139 22 1.5Mb AIFM3 22 3Mb 
C22orf29 22 1.5Mb LZTR1 22 3Mb 
TXNRD2 22 1.5Mb THAP7 22 3Mb 
COMT 22 1.5Mb HIC2 22 3Mb 
C22orf25 22 1.5Mb TMEM191C 22 3Mb 
DGCR8 22 1.5Mb LOC220686 22 3Mb 
TRMT2A 22 1.5Mb    
RANBP1 22 1.5Mb    
ZDHHC8 22 1.5Mb    
 Table 5- 2: 22q11.2 dosage sensitive genes identified in 22q11.2DS patients by differential 
gene expression analysis.   
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Therefore, all 22q11.2 deletion carriers were screened for null genotypes at the SNPs 
spanning LCR22s A-B, while only the carriers of a ~3Mb 22q11.2 deletion were used 
to identify null genotypes at the SNPs spanning LCR22s B-D.  
In order to exclude low quality SNPs that were more prone to failure, an additional 71 
individuals who did not carry a deletion at 22q11.2 were also screened. SNPs that were 
also null in the non-deleted controls were unlikely to be pathogenic deletions, but more 
likely to indicate low quality genotyping. The genotype cluster plots of the remaining 
null SNPs were manually inspected for genotype calling quality. A flow diagram to 
illustrate the process of null genotypes SNPs screening in Figure 5- 3. 
 
5.4.3.2. Identifying secondary duplications 
Genome-wide CNVs were called by PennCNV using non-imputed genotype data as 
explained in chapter 2 section 2.5.1. All SNPs located in the 3Mb deleted region were 
used for PennCNV calling to identify secondary duplications that possibly occur in 
the non-deleted 22q11.2 chromosome. Duplication calling was set at a liberal criteria 
aimed at identifying CNVs that span a minimum 3 constitutive SNPs with a minimum 
size of 12bp.   
 
5.4.3.3. Association analysis of secondary 22q11.2 CNVs 
Association analysis was performed by comparing frequencies of null genotype SNPs 
at 22q11.2 between 22q11.2DS patients who were either affected or unaffected by 
psychiatric diseases, as defined in Table 5- 1 by Fisher’s exact test using R. 
Significance of association findings was assessed by Bonferroni multiple testing 
correction to account for the identified Null SNPs (Bonferroni threshold= 0.017). 
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Figure 5- 3: Flowchart for null genotypes SNPs screening. 
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5.5. Results 
5.5.1. SNPs quality control 
Following the stringent genotypic QC procedures, of the 790 3Mb 22q11.2 SNPs, 177 
high quality SNPs (MAF ≥0.05, sample missing rate ≤0.01 and HWE p-value ≥1.0x10-
6) remained and these were then used as a backbone to impute the genotypes of the 
majority of SNPs that were not included on the array. 
Imputation resulted in 6,595, however, only 5,027 common SNPs with a high 
imputation quality (MAF ≥0.01 and INFO score ≥0.8) that spanned the 3Mb deletion 
at 22q11.2 were selected. Of the 5,027 22q11.2 SNPs, 3,327 SNPs spanned LCR22s 
A-B and 1,700 SNPs spanned LCR22s B-D. 
 
5.5.2. Investigating whether SNPs within the non-deleted 22q11.2 chromosome 
are associated with psychiatric disease in 22q11.2DS patients 
These association analyses sought to establish whether genetic variants within the non-
deleted 22q11.2 chromosome could potentially have a role in the increased risk of 
22q11.2DS to develop psychiatric illnesses. 
 
5.5.2.1. ADHD in 22q11.2DS 
The results of association analysis of all 5,027 SNPs spanning the 3Mb deleted region 
between 22q11.2DS+ADHD and 22q11.2DS-PSYCH patients identified 89 SNPs that 
were nominally associated with ADHD, with the strongest evidence for association at 
rs759406 (p-value = 0.0024) spanned by PRODH gene. A Manhattan plot of all SNPs 
is presented in Figure 5- 4, A1. However, after interpreting the results to account for 
the analysis of 5,027 SNPs, no genetic variant met the stringent significance threshold 
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set by Bonferroni correction (Bonferroni p-value= 9.9x10-6). Given that Bonferroni 
assumes that all SNPs are segregating independently, the results were also corrected 
using the less stringent FDR, which allows for the correlation between SNPs. This 
again revealed that no SNP exceeded the 5% threshold of FDR (most significant SNP 
was rs759406; FDR= 0.998). A Manhattan plot of all SNPs is presented in Figure 5- 
4, A2.  
 
5.5.2.2. ASD in 22q11.2DS 
Association analysis that compared 22q11.2 common variants between patients in 
22q11.2DS+ASD and 22q11.2DS-PSYCH groups identified 76 SNPs that were 
nominally associated with ASD, with rs759406 having the strongest evidence for 
association (p-value = 0.0020) which is spanned by PRODH. All SNPs with nominal 
p-value are presented in a Manhattan plot in Figure 5- 4, B1. However, after multiple 
testing correction, no genetic variant survived the conservative Bonferroni 
significance threshold (Bonferroni p-value= 9.9x10-6) and also no variant survived the 
less conservative FDR significant threshold (most significant SNP was rs759406; 
FDR= 0.968). A Manhattan plot of all SNPs after FDR correction is presented in 
Figure 5- 4, B2.  
 
5.5.2.3. Psychiatric illnesses in 22q11.2DS 
Results of association analysis that compared the 22q11.2 SNPs in deletion carriers 
with either ADHD and/or ASD (22q11.2DS+PSYCH) to those unaffected carriers 
(22q11.2DS-PSYCH) identified 43 SNPs that were nominally associated with 
psychiatric illnesses, with the strongest evidence for association at rs759406 (p-value 
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= 0.0024) spanned by PRODH gene. All SNPs are presented in a Manhattan plot in 
Figure 5- 4, C1. However, after Bonferroni multiple testing correction, no genetic 
variant reached the stringent significance level (Bonferroni p-value= 9.9x10-6) and 
also no genetic variant met the less stringent FDR significance level (most significant 
SNP was rs759406; FDR= 0.999). A Manhattan plot of all SNPs is presented in Figure 
5- 4, C2.  
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A Results of association analysis of 22q11.2 SNPs 
between 22q11.2DS+ADHD and 22q11.2-PSYCH 
patients 
B Results of association analysis of 22q11.2 SNPs 
between 22q11.2DS+ASD and 22q11.2-PSYCH 
C Results of association analysis of 22q11.2 SNPs 
between 22q11.2DS+PSYCH and 22q11.2-PSYCH 
1) 
2) 
1) 
2) 
1) 
2) 
 
 
 
Figure 5- 4: Manhattan plots for association analyses results for 3Mb 22q11.2 SNPs. 
Association analysis of 3,327 SNPs within the shared ~1.5Mb deletion spanning LCR22s A-B was conducted using all 76 deletion carriers, while the 1,700 SNPs spanning LCR22s 
B-D were tested for association using only 73 carriers of the ~3Mb deletion. P-values for each marker is plotted and represented by a single circle. The Y-axis shows the -log10 for 
the p-value of each marker and p-value thresholds are highlighted by red lines. X-axis shows some of spanning genes and genomic location (hg19). Plots 1) Uncorrected p-value for 
each marker is plotted. The corrected Bonferroni significance threshold (Bonferroni p-value= 9.9x10-6) is highlighted by the red line. Plots 2) P-values for all SNPs are corrected by 
FDR multiple correction. The FDR threshold (FDR= 5.0x10-2) is highlighted by red. In the plots, SNPs with the strongest association indicated by a purple circle and a black bold 
SNP name. Correlated SNPs are coloured based on the correlation coefficient scale in the plots. The plots are generated by Locus Zoom tool (Pruim et al. 2010).  
A. Showing Manhattan plots for association analysis comparing individuals in 22q11.2DS+ADHD and 22q11.2DS-PSYCH groups. SNP with the strongest association to ADHD at 
(rs759406) with nominal p-value= 0.0024 and FDR= 0.998. 
B. Showing Manhattan plots for association analysis comparing individuals in 22q11.2DS+ASD and 22q11.2DS-PSYCH groups. SNP with the strongest association to ADHD at 
(rs759406) with nominal p-value= 0.0020 and FDR= 0.968. 
C. Showing Manhattan plots for association analysis comparing individuals in 22q11.2DS+PSYCH and 22q11.2DS-PSYCH groups. SNP with the strongest association to ADHD at 
(rs759406) with nominal p-value= 0.0024 and FDR= 0.999. 
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5.5.3. Investigating whether SNPs within the non-deleted 22q11.2 chromosome 
and spanned by the dosage sensitive genes are associated with psychiatric 
diseases in 22q11.2DS patients 
Of the 5,027 SNPs that passed the genotypic QC procedures, 2,103 SNPs spanned a 
dosage sensitive gene at 22q11.2. Association analyses comparing allele frequency of 
SNPs in the non-deleted chromosome and spanned by dosage sensitive genes between 
affected and unaffected 22q11.2 deletion carriers with psychiatric diseases sought to 
establish whether an additional risk allele occurs in the non-deleted haploinsufficient 
genes could potentially have additional role in the elevated risk of 22q11.2DS to 
develop psychiatric illnesses in addition to the low expression level of the spanning 
genes. 
 
5.5.3.1. ADHD in 22q11.2DS 
The results of association analysis that compared the allele frequency of the 2,103 
SNPs spanned by 22q11.2 dosage sensitive genes between 22q11.2DS+ADHD and 
22q11.2DS-PSYCH patients identified the 13 SNPs that were nominally associated 
with ADHD with the strongest evidence for association at rs2075269 (p-value = 0.024) 
spanned by THAP7 gene. A Manhattan plot of all SNPs with nominal p-values is 
presented in Figure 5- 5, A1. However, after accounting for the analysed 2,103 SNPs, 
no genetic variant met the stringent significance threshold set by Bonferroni correction 
(Bonferroni p-value= 2.4x10-5). We also corrected the results using the less stringent 
FDR which also revealed that no SNP exceeded the 5% threshold of FDR (most 
significant SNP was rs2075269; FDR= 0.996). A Manhattan plot of all SNPs with 
FDR corrected p-values is presented in Figure 5- 5, A2.  
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5.5.3.2. ASD in 22q11.2DS 
Thirty-one SNPs that were nominally associated with ASD with rs165659 (spanned 
by PI4KA) having the strongest evidence for association (p-value = 0.013) the allele 
frequency of the 2,103 SNPs was compared between the individuals of 
22q11.2DS+ASD and 22q11.2DS-PSYCH groups. A Manhattan plot of all SNPs is 
presented in Figure 5- 5, B1. However, after multiple testing correction by Bonferroni, 
no single SNP met the stringent Bonferroni significance threshold (Bonferroni p-
value= 2.4x10-5). Also, no SNP reached the less stringent FDR significance threshold 
(most significant SNP was rs165659; FDR= 0.999). A Manhattan plot of all SNPs is 
presented in Figure 5- 5, B2.  
 
5.5.3.3. Psychiatric illnesses in 22q11.2DS 
The results of an association analysis that compared the common variants spanned by 
dosage sensitive genes in 22q11.2 between 22q11.2DS+PSYCH and 22q11.2DS-
PSYCH patients identified only 3 SNPs nominally associated with psychiatric illness 
in 22q11.2DS. The strongest evidence for association identified at rs2075269 (p-value 
= 0.021) spanned by THAP7. A Manhattan plot of all SNPs is presented in Figure 5- 
5, C1.  However, following multiple testing correction, no genetic variant met the 
Bonferroni significance threshold (Bonferroni p-value= 2.4x10-5) and FDR 
significance threshold (FDR= 0.05) (most significant SNP was rs2075269; FDR= 
0.995). A Manhattan plot of all SNPs is presented in Figure 5- 5, C2.  
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Results of association analysis of 22q11.2 SNPs spanned 
by dosage sensitive genes between 22q11.2DS+ADHD 
and 22q11.2-PSYCH patients 
1) 
 
2) 
 
Results of association analysis of 22q11.2 SNPs spanned 
by dosage sensitive genes between 22q11.2DS+ASD and 
22q11.2-PSYCH patients 
1) 
2) 
 
Results of association analysis of 22q11.2 SNPs spanned 
by dosage sensitive genes between 22q11.2DS+PSYCH 
and 22q11.2-PSYCH patients 
A 
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C 
Figure 5- 5: Manhattan plots for association analyses results for 3Mb 22q11.2 SNPs spanned by dosages sensitive genes. 
Association analysis of 1,158 SNPs within the shared ~1.5Mb deletion spanning LCR22s A-B was conducted using all 76 deletion carriers, while the 945 SNPs spanning LCR22s 
B-D were tested for association using only 73 carriers of the ~3Mb deletion. P-values for each marker are plotted and represented by a circle. The Y-axis shows the -log10  p-value 
for each marker and p-value thresholds are highlighted by red lines. X-axis shows some spanning genes and genomic location (hg19). Plots 1) Uncorrected p-value for each marker 
is plotted. The corrected Bonferroni significance threshold (Bonferroni p-value= 2.4x10-5) is highlighted by the red line. Plots 2) P-values for all SNPs are corrected by FDR 
multiple correction. The FDR threshold (FDR= 5.0x10-2) is highlighted by red. In the plots, SNPs with the strongest association indicated by a purple circle and a black bold SNP 
name. Correlated SNPs are coloured based on the correlation coefficient scale in the plots. The plots are generated by Locus Zoom tool (Pruim et al. 2010).  
A. Showing Manhattan plots for association analysis comparing individuals in 22q11.2DS+ADHD and 22q11.2DS-PSYCH groups. SNP with the strongest association to ADHD 
at (rs2075269) with nominal p-value= 0.024 and FDR= 0.996. 
B. Showing Manhattan plots for association analysis comparing individuals in 22q11.2DS+ASD and 22q11.2DS-PSYCH groups. SNP with the strongest association to ADHD at 
(rs165659) with nominal p-value= 0.013 and FDR= 0.999. 
C. Showing Manhattan plots for association analysis comparing individuals in 22q11.2DS+PSYCH and 22q11.2DS-PSYCH groups. SNP with the strongest association to ADHD 
at (rs2075269) with nominal p-value= 0.021 and FDR= 0.995. 
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5.5.4. Investigating secondary CNVs within the 22q11.2 region 
5.5.4.1. Identification of null genotype SNPs within the 22q11.2 region 
Screening the 790 SNPs that spanned the ~3Mb deletion in the 76 patients with 
22q11.2DS and 71 non-deleted controls revealed a total of 127 SNPs with null 
genotypes. 77 of the 127 SNPs were also null in the non-deleted controls and were 
therefore excluded. 47 of the remaining 50 SNPs were subsequently excluded as 
manual inspection of their genotype cluster plots indicated that they were due to low 
quality genotype calls. This resulted in the identification of 3 SNPs (exm1586223, 
exm1588273, and rs9604911) that had null genotypes in the 22q11.2DS individuals. 
The genotype cluster plots of each of these 3 SNPs are presented in Figure 5- 6. 
 
The distance to the closest proximal and distal SNP that was successfully genotyped 
was used to estimate the maximum size of any potential deletion that each null 
genotype SNP could be indicating. As can be seen in Figure 5- 7 the 3 null genotype 
SNPs do not implicate a single gene. The SNP exm1588273 is located within exon 4 
of THAP7 gene at the distal part of the 3Mb deletion. The potential deletion implicated 
by its null genotype would have an estimated maximum size of ~640bp and would 
span chr22:18,918,666-18,936,993 (on hg19). This would potentially disrupt the gene 
THAP7 (Figure 5- 7, B). The SNP exm1586223 is located in exon 10 of the gene 
TANGO2, which is located within the 1.5Mb deleted region (Figure 5- 7, C). The 
estimated maximum size of this deletion could be ~1.6Kb, spanning 
chr22:20,050,940- 20,052,566 (on hg19). Finally, the null genotype at rs9604911 
could potentially implicate a deletion with an estimated maximum size of ~18.3Kb 
(chr22:21,354,936-21,355,576 on hg19). Although, the SNP is not itself located within 
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a gene, its implicated deletion would potentially disrupt the adjacent PRODH gene 
(Figure 5- 7, D). 
 
5.5.4.2. Identification secondary duplications within the 22q11.2 region 
Analysis of the 76 samples carrying 22q11.2 deletions using PennCNV did not 
identify any duplication that spanned at least 3 SNPs within the 3Mb region. Thus, no 
secondary duplications were included in the association analyses for potential 
secondary 22q11.2 CNVs in this study. 
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Figure 5- 6: GenomeStudio SNPs clustering plots for the three SNPs with true null genotypes. 
SNPs for the 147 individuals are plotted, including 22q11.2 deletion carriers and non-deleted controls. Each plot represents a SNP with the SNP identifier indicated above the plot. Each 
circle represents an individual. The X-axis represents the intensity value of allele A and the Y-axis is the intensity value of allele B. Blue dots are samples with homozygous allele B, red 
dots are samples with homozygous allele A, and purple dots are samples heterozygous allele A and B. Samples with true null genotypes SNPs are represented by black dots with allele A 
and B signal intensities equal to 0 and located in the bottom left corners of the plot and indicated by green arrows (GenomeSudio). 
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Figure 5- 7: Snapshots for the three Null SNPs on the UCSC genome browser. 
A. Showing the 3Mb 22q11.2 deletion region (chr22:18,658,219-21,865,185 on hg19).The three Null SNPs are 
highlighted by red circles with markers names (on 1Mb scale) and showed the location of these SNPs in the 3Mb 
region. B. Null exm1588273 SNP, indicated by red arrow, with the potential ~640bp deletion, indicated by green 
arrow, spanned by THAP7 gene (on 1Kb scale). C. Null exm1586223 SNP, indicated by red arrow, with the potential 
~1.6Kb deletion, indicated by green arrow, spanned by TANGO2 gene (on 1Kb scale). D. Null rs9604911 SNP, 
indicated by red arrow, with the potential ~18.3Kb deletion, indicated by green arrow, spanned by PRODH gene (on 
10Kb scale) (Genome.ucsc.edu, n.d.). 
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5.5.4.3. Association analysis of potential secondary deletions at the 22q11.2 region 
Comparing the rate of null genotype SNPs identified in 22q11.2DS patients with and 
without psychiatric disorders sought to establish whether additional secondary CNVs 
occurring within the non-deleted region of chromosome 22q11.2 could potentially 
play a role in the increased risk of psychiatric disorders. 
Association analysis identified no evidence for significantly increased rate of null 
genotype SNPs, Bonferroni threshold= 0.017, in either the 29 22q11.2DS patients with 
ADHD (uncorrected Fishers exact test p-value= 0.56), the 18 patients with ASD 
(uncorrected Fishers exact test p-value= 1.0), or the 37 patients with a childhood 
psychiatric disorder (uncorrected Fishers exact test p-value= 1.0) when compared to 
those with no psychiatric disease (n=35) (Table 5- 3). 
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A 
22q11.2DS+ADHD 
 
 
22q11.2DS-PSYCH 
 
 
Fisher 
exact two-
tailed p-
value 
Carrying a Null SNP Not carrying a Null SNP Total 
 
Carrying a Null SNP Not carrying a Null SNP Total 
Number of 
22q11.2DS patients 
Frequency Number of 
22q11.2DS patients 
Frequency - Number of 
22q11.2DS patients 
Frequency Number of 
22q11.2DS patients 
Frequency 
 
- 
 
2  
 
 
6.9% 
 
27  
 
93.1% 
 
29 
 
1 
 
2.6% 
 
34 
 
97.1% 
 
35 
 
0.59 
 
B 
22q11.2DS+ASD 
 
 
22q11.2DS-PSYCH 
 
 
Fisher 
exact two-
tailed p-
value 
Carrying a Null SNP Not carrying a Null SNP Total 
 
Carrying a Null SNP Not carrying a Null SNP Total 
Number of 
22q11.2DS patients 
Frequency Number of 
22q11.2DS patients 
Frequency - Number of 
22q11.2DS patients 
Frequency Number of 
22q11.2DS patients 
Frequency 
 
- 
 
0 
 
0.0% 
 
18 
 
100% 
 
18 
 
1 
 
 
2.6% 
 
34 
 
97.1% 
 
35 
 
1.0 
C 
22q11.2DS+PSYCH 
 
 
22q11.2DS-PSYCH 
 
 
Fisher 
exact two-
tailed p-
value 
Carrying a Null SNP Not carrying a Null SNP Total 
 
Carrying a Null SNP Not carrying a Null SNP Total 
Number of 
22q11.2DS patients 
Frequency Number of 
22q11.2DS patients 
Frequency - Number of 
22q11.2DS patients 
Frequency Number of 
22q11.2DS patients 
Frequency 
 
- 
 
2 
 
5.7% 
 
35 
 
94.6% 
 
37 
 
1 
 
 
2.6% 
 
34 
 
97.1% 
 
35 
 
1.0 
 
Table 5- 3: Results of association analyses of secondary 22q11.2 deletions between 22q11.2DS patients affected and unaffected by psychiatric diseases. 
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5.6. Discussion 
It is widely known that 22q11.2DS is associated with a wide spectrum of 
neuropsychiatric phenotypes. This chapter set out to identify whether additional 
genetic variants present on the non-deleted 22q11.2 chromosome influenced the 
increased risk to psychiatric disorders seen in 22q11.2DS patients. A number of 
studies have tested SNPs at 22q11.2 for association with psychiatric disease in 
22q11.2DS patients, but these have been selected because of their relevance to 
candidate genes and have generated inconclusive results.  
This study systematically tested 5,027 SNPs spanning the deletion at 22q11.2 for 
association with childhood psychiatric disorders in patients with 22q11.2DS. The 
results described in this chapter revealed no evidence for a significant association for 
common SNPs with neuropsychiatric symptoms in 22q11.2DS children (ADHD 
and/or ASD) (Bonferroni p-values >9.9x10-6, FDR >0.05).  
A reasonable explanation for the failure of this study to provide a positive finding is 
the small sample size involved in the analyses. Only 76 samples for well-characterized 
22q11.2DS patients with available psychiatric phenotypes information were analysed. 
While this is comparable to previous candidate based studies, due to the large number 
of SNPs (n= 5,027) analysed, the corrected significance threshold of this study was 
more stringent. A larger sample size would be required to achieve adequate statistical 
power (Klein 2007). It is however worth noting that while more samples were 
originally ascertained for this study, the rigorous quality control procedures resulted 
~19 recruited samples being excluded. 
The Genetic Power Calculator (Purcell, Cherny & Sham 2003) was used to calculate 
the power of this study. The sample size (37 22q11.2DS affected vs 35 22q11.2DS 
148 
 
unaffected) had an 80% power to detect an association at p-value= 0.05 for a risk allele 
with a genotype relative risk (GRR) of 2.03 and allele frequency of 0.06. It is however 
possible that as 22q11.2DS patients already carry a primary insult (i.e. the large 
deletion) then the effect size of an additional risk allele at chromosome 22q11.2 could 
be larger in these patients than is present in studies of other psychiatric disease cohorts. 
For example, it has been shown that all 22q11.2DS children have a lower IQ when 
compared to their non-deleted siblings (Niarchou et al. 2014). It is therefore plausible 
that this compromised cognition could result in risk alleles for psychiatric disease 
having a greater relative risk in children carrying the deletion. While unlikely, it is 
potentially possible that the samples used in this thesis had sufficient power to detect 
an additional risk allele whose disease penetrance was amplified in this way.  An 
estimate of the sample sizes required to obtain an 80% power to detect lower GRR are 
given in the Table 5- 4.  
 
 
GRR 
Sample size 
*P-value of 0.05 **P-value of 9.9x10-6 
Cases  Controls Cases Controls 
1.05 13,807 13,117 48,689 46,255 
1.1 3,483 3,309 12,284 11,670 
1.2 1,022 971 3,607 3,427 
1.3 461 438 1,626 1,545 
1.4 263 250 927 881 
1.5 170 162 601 571 
1.6 120 114 432 410 
1.7 89 85 315 300 
1.8 69 66 245 233 
1.9 55 52 196 186 
2.0 45 43 161 153 
2.01 44 42 158 150 
 
 
Table 5- 4: The required sample sizes to obtain an 80% power to detect a 
common risk variant (allele frequency = 0.05) with a range of GRR.  
 
* Uncorrected p-value threshold. 
** Bonferroni corrected p-value threshold in our study. 
 
 
Figure 6- 1* Uncorrected p-value threshold. 
** Bonferroni corrected p-value threshold in our study. 
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From Table 5-, it can be seen that a larger sample size is required to detect risk alleles 
with decreased effect size.  
 
While this study has focussed on testing risk alleles for association with psychiatric 
disease in patients with 22q11.2DS, any true risk allele present at 22q11.2 would also 
be identified (albeit with a reduced GRR) in association studies of non-deleted patients 
with psychiatric disease compared to controls. Several GWA studies of ASD have now 
suggested a number of common genetic variants associated with the risk of ASD. They 
yielded ~112 genome-wide significant loci spanned by 200 ASD candidate genes 
(Weiss et al. 2009; Wang et al. 2009; Anney et al. 2010; Salyakina et al. 2010). From 
all the reported findings for ASD and autism, none of these risk loci were found within 
the typical deleted region of 22q11.2 chromosome. Moreover, GWAS analysis was 
performed in a large case-control cohort for five psychiatric disorders; ASD, ADHD, 
bipolar disorder, major depressive disorder, and schizophrenia including 33,332 cases 
and 27,888 controls of European ancestry. The study identified SNPs at four 
significant risk loci at genome-wide significance threshold (p-value <5x10-8). These 
regions are on chromosomes 3p21 and 10q24, and SNPs mapped to two L-type 
voltage-gated calcium channel subunits, CACNA1C and CACNB2 (Cross-Disorder 
Group of the Psychiatric Genomics Consortium 2013). Again none of these reported 
psychiatric risk loci mapped to the 22q11.2 region. The results of the largest and very 
recent GWAS study conducted for schizophrenia identified 108 distinct genome-wide 
significant loci being associated with schizophrenia. Three loci of the 108 are found 
in chromosome 22 (chr22_39987017_D at 39,975,317-40,016,817; rs9607782 at 
41,408,556-41,675,156; and rs1023500 at 42,315,744-42,689,41 on hg19) (Ripke et 
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al. 2014), however none of the three loci was located in the common 22q11.2 deleted 
region. 
Taken as a whole, it is therefore possible that the findings of these GWA studies 
support those presented in this chapter, and that no psychiatric disease risk variants 
are present in the region of 22q11.2. 
 
The second part of this chapter attempted to identify evidence for small potential 
deletions within the remaining 22q11.2 chromosome of 22q11.2DS patients. These 
were identified by detecting SNPs that had null genotypes and this revealed 3 potential 
secondary deletions present in three 22q11.2DS patients. Association analysis 
indicated that these potential deletions were not significantly enriched in the 
22q11.2DS patients with psychiatric phenotypes (p-value >0.017). Nevertheless, it is 
of potential interest that the Null SNP (and a potential secondary deletion) carried by 
two 22q11.2DS patients with ADHD are located in the genes THAP7 and PRODH, as 
previous studies have identified nominally significant evidence for association to 
ADHD with common variants spanned by both genes (Neale et al. 2010; Stergiakouli 
et al. 2012; Hinney et al. 2011; Yang et al. 2013; Mick et al. 2010; Neale et al. 2008). 
In addition, transcripts for THAP7 were found to be significantly downregulated in 
22q11.2DS patients compared to non-deleted controls. 
This analysis of potential secondary deletions was intended as a preliminary 
investigation, however, the approach of identifying null SNPs was limited by the 
distribution of probes on the genotyping platform. In addition, a single marker with 
null genotypes is not a perfect representation of a small deletion, while this study did 
attempt to exclude them, null genotypes can also occur as a result of a failure in the 
151 
 
sample genotyping. A future study should utilise a next generation sequencing (NGS) 
in order to obtain a more detailed and precise understanding of the background variants 
in the non-deleted 22q11.2 chromosome in 22q11.2DS patients (McDonald-McGinn 
et al. 2013). This approach would allow a more systematic analysis and would not be 
dependant on the distribution of pre-selected SNPs that are present on the genotyping 
microarray. Future NGS based studies would also benefit from the increased power of 
studying larger numbers of individuals with 22q11.2DS in order to reduce both the 
false positive and negative rate of CNV detection. 
 
  
152 
 
Chapter 6: Investigating Additional Mutations Located 
Outside the 22q11.2 Region in 22q11.2DS Patients 
 
 
6.1. Summary 
A number of CNVs have now been implicated in different neurodevelopmental 
disorders and psychiatric diseases. It also has been shown that patients who carry more 
than one ‘pathogenic’ CNV are more likely to manifest a more severe or an atypical 
phenotype. This chapter will investigate the hypothesis that additional structural 
variants may contribute to the increased risk of neuropsychiatric illness in 22q11.2DS 
and that these ‘second hit’ CNVs may be enriched for CNVs previously associated 
with neurodevelopmental disorders and psychiatric diseases.  
To address this issue, a genome-wide analysis of CNVs was performed on 73 children 
with 22q11.2DS and the rate of large, rare CNVs was compared between those who 
are affected with a psychiatric disorder to those who are unaffected.  
The overall rate of CNVs ≥500Kb in 22q11.2DS patients with ADHD or ASD was 
0.18 and 0.11 which was 3-times and 1.8-times higher than the rate seen in unaffected 
22q11.2DS subjects (rate = 0.06). However, this increased rate of CNVs ≥500Kb was 
not significant in either the ADHD group  (p-value= 0.22) or the ASD (p-value=0.44). 
Similarly, a non-significant (p-value= 0.29) enrichment of CNVs ≥500Kb was 
revealed in 22q11.2DS affected by any childhood psychiatric illnesses (rate= 0.14) 
compared to those unaffected (rate= 0.06).  
As only a subset of CNVs are expected to be of ‘pathogenic’ relevance, the analyses 
focussed only on CNVs that overlapped with one of the 88 ‘pathogenic’ CNVs that 
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previously have been reported to increase risk to developmental delay and 
neuropsychiatric disease. This analysis again revealed no significant evidence for an 
enrichment of ‘pathogenic’ CNVs in the 22q11.2DS patients with either ADHD (rate= 
0.036; p-value= 0.85), ASD (rate= 0.056; p-value= 0.73), or any childhood psychiatric 
illnesses (rate= 0.028; p-value= 0.89). 
The main limitation of this study is the small sample size (n= 73) used in the analyses, 
which limited the power of the study. Larger sample size is required for more powerful 
results. 
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6.2. Introduction 
One of the molecular mechanisms that could explain the wide spectrum of 
neuropsychiatric phenotypes in 22q11.2DS is the presence of an additional pathogenic 
mutation. The additional mutation could occur in the form of a second risk allele 
within the non-deleted 22q11.2 chromosome. As illustrated in chapter 5, there was no 
evidence for a significant association of 22q11.2 SNPs occur in the 22q11.2 region 
with psychiatric phenotypes in 22q11.2DS. 
However, it has also been hypothesized that additional mutations could occur outside 
the 22q11.2 deleted region. Such genomic variations may be enriched for CNVs 
previously identified in neurodevelopmental delay and neuropsychiatric diseases and 
increase the risk to psychiatric diseases in 22q11.2DS independently from the primary 
deletion. Such pathogenic mutations are called “second hits” (Williams et al. 2013). 
 
6.2.1. Involvement of copy number variants in neuropsychiatric disorders 
Rapid developments in the microarray technologies have provided opportunities to 
examine the human genome for copy number variations (CNVs) (Cook & Scherer 
2008). These advances have resulted in a number of genomic rearrangements being 
associated with neurodevelopmental and neuropsychiatric disorders. For example, 
Kirov and colleagues studied CNVs in schizophrenia cases and found a 2.26-fold 
excess of large, rare CNVs in these cases compared to controls (p-value= 0.00027) 
(Kirov et al. 2009). The study also showed that structural variants identified in 
schizophrenia patients are enriched with CNVs previously implicated as susceptibility 
factors for neuropsychiatric diseases including 22q11.2 deletions, a susceptibility 
factor for schizophrenia; 14.0–15.4Mb 17p12 deletions, known to cause hereditary 
neuropathy with liability to pressure palsies; and 14.9–16.4Mb 16p13.1 duplications, 
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which has been previously implicated as a susceptibility factor for autism. Moreover, 
the study provided the first significant support for the association of 15q11.2 deletions 
and schizophrenia (p-value= 0.026) (Kirov et al. 2009). 
Several other independent studies have also investigated the role of CNVs in other 
neuropsychiatric disorders (McQuillin et al. 2011; Costain et al. 2014; Georgieva et 
al. 2014; Rucker et al. 2016; Fry et al. 2016). Recent studies strengthen the hypothesis 
that the same CNVs might contribute to the susceptibility of different neuropsychiatric 
disorders such as schizophrenia, ADHD, intellectual disability (ID), and 
developmental delay (DD) (Rees et al. 2014; Williams et al. 2012; Williams et al. 
2010; Elia et al. 2011; Jarick et al. 2014; Girirajan et al. 2010; Malhotra & Sebat 2012; 
Kaminsky et al. 2013). 
 
A list of 15 implicated CNVs, that have been previously either reported to be 
associated or showed a trend of enrichment with psychiatric diseases, were studied in 
a large schizophrenia case-control cohort (n= 13,198) (Rees et al. 2014). The results 
of the study showed that 13 of the 15 previously implicated CNVs occur in excess in 
schizophrenia cases. For six of these, the difference in the rate of CNVs detected in 
cases and controls was nominally significant (p-value <0.05). However, when this 
dataset was combined with previous large data (~20,732 cases and ~81,821 controls), 
11 CNVs showed a highly significant association with schizophrenia (p-values 
<4.1x10-4) (Table 6- 1) (Rees et al. 2014). 
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Regarding ADHD, eight association studies have investigated genome-wide CNVs in 
children with ADHD, and these have showed promising results (Elia et al. 2010; Elia 
et al. 2011; Jarick et al. 2014; Stergiakouli et al. 2012; Williams et al. 2012; Williams 
et al. 2010; Lionel et al. 2011; Lesch et al. 2011). All of the eight studies considered 
childhood ADHD patients; however, only three showed an increased CNV burden in 
the ADHD patients relative to controls (Williams et al. 2010; Stergiakouli et al. 2012; 
Williams et al. 2012). Williams and colleagues provided evidence supporting the 
enrichment of large, rare CNVs in ADHD children, mainly due to an increase rate of 
16p13.11, or 15q13.13 duplications (Williams et al. 2010; Williams et al. 2012). In 
addition, an increased burden of rare CNVs affecting genes belong to metabotropic 
glutamate receptor gene networks was identified in multiple ADHD cohorts (Elia et 
al. 2011). Furthermore, an excess of deletions and duplications at chromosome 
6q25.2-q27 at the PARK2 locus was reported in ADHD children (Jarick et al. 2014). 
These studies have also demonstrated an enrichment of ADHD-related CNVs at loci 
Table 6- 1: Results of meta-analysis of the 15 previously implicated CNVs on a large combined schizophrenia 
dataset (Rees et al. 2014). 
 
Locus 
Cases frequency 
(%) 
Controls frequency 
(%) 
OR (95% CI) P-values 
1q21.1 deletion 0.17 0.021 8.35 (4.65–14.99) 4.1x10-13 
1q21.1 duplication 0.13 0.037 3.45 (1.92–6.20) 9.9x10-5 
NRXN1 deletion 0.18 0.20 9.01 (4.44–18.29) 1.3x10-9 
3q29 deletion 0.082 0.0014 57.65 (7.58–438.44) 1.5x10-9 
WBS duplication 0.066 0.0058 11.35 (2.58–49.93) 6.9x10-5 
VIPR2 duplication 0.11 0.069 1.54 (0.77–3.09) 0.27 
15q11.2 deletion 0.59 0.028 2.15 (1.71–2.68) 2.5x10-10 
AS/PWS duplication 0.083 0.0063 13.20 (3.72–46.77) 5.6x10-6 
15q13.3 deletion 0.14 0.019 7.52 (3.98–14.19) 4.0x10-10 
16p13.11 duplication 0.31 0.13 2.30 (1.57–3.36) 5.7x10-5 
16p11.2 distal deletion 0.063 0.018 3.39 (1.21–9.52) 0.017 
16p11.2 duplication 0.35 0.030 11.52 (6.86–19.34) 2.9x10-24 
17p12 deletion 0.094 0.026 3.62 (1.73–7.57) 0.0012 
17q12 deletion 0.036 0.0054 6.64 (1.78–24.72) 0.0072 
22q11.2 deletion 0.29 0.00 NA (28.27–∞) 4.4x10-40 
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previously associated with different neurodevelopmental disorders, such as 
schizophrenia and/or autism was reported, and provided further supportive evidence 
of the hypothesis that genetic susceptibility factors might be shared by these disorders 
(Elia et al. 2010; Lionel et al. 2011; Williams et al. 2010). In total, these studies have 
resulted in a total of 15 CNVs being reported to be significantly implicated in 
childhood ADHD (Table 6- 2). 
 
 
 
 
A number of genome-wide association studies have investigated genomic structural 
variations in large case-control cohorts for association with intellectual disability, 
developmental delay (ID/DD), multiple congenital abnormalities, and ASD (Girirajan 
et al. 2012; Cooper et al. 2012; Malhotra & Sebat 2012; Kaminsky et al. 2013). Cooper 
and colleagues compared CNVs in 15,767 children with intellectual disability and 
various congenital defects to 8,329 adult controls. A significant excess of large CNVs 
was found among cases relative to controls. This enrichment was evident at 250Kb 
and becomes more obvious with larger CNV size. Fifty-nine pathogenic CNVs were 
 
Locus (hg19) 
 
CNV type 
 
OR (95% CI) 
 
P-value 
 
References 
 
Chr1:56053497-56064495 Deletion 22.85 (3–190) 1.54x10−3 (Elia et al. 2011) 
Chr1:72317292-72328395 Duplication Infinity 3.9x10−4 (Elia et al. 2011) 
Chr2:81419297-81446082 Duplication 5.07 (1–23) 3.83x10−2 (Elia et al. 2011) 
Chr3:1844168-1859889 Deletion 4.44 (1–13) 8.81x10−3 (Elia et al. 2011) 
Chr3:7183953-7197236 Deletion Infinity 8.14x10−5 (Elia et al. 2011) 
Chr4:113772340-113788584 Duplication 5.07 (1–23) 3.83x10−2 (Elia et al. 2011) 
Chr5:65027976-65046520 Deletion 22.85 (3–190) 4.68x10−4 (Elia et al. 2011) 
Chr6:146657076-146694047 Duplication 15.24 (3–72) 5.6x10-6 (Elia et al. 2011) 
Chr6:162659756-162767019 Duplication NA 2.8x10-4 (Jarick et al. 2014) 
Chr7:126525124-126536202 Deletion Infinity 8.14x10−5 (Elia et al. 2011) 
Chr7:153495598-153564827 Duplication 15.24 (3–72) 4.08x10−4 (Elia et al. 2011) 
Chr11:88269449-88351661 Deletion 38.12 (5–298) 1.36x10−6 (Elia et al. 2011) 
Chr15:29811982-30232981 Duplication 2.22 (1.5-3.6) 0.000178 (Williams et al. 2012) 
Chr16:15156431-18174650 Duplication 13.88 (2.3–82.2) 0·0008 (Williams et al. 2010) 
Chr19:38427720-38444834 Deletion 5.33 (2–17) 4.95x10−3 (Elia et al. 2011) 
Table 6- 2: CNV loci previously reported to be significantly associated with ADHD. 
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identified including 14 novel or previously weakly supported candidates (Cooper et 
al. 2012). Kaminsky and colleagues studied cases with various indications, including 
unexplained DD, ID, dysmorphic features, multiple congenital anomalies (MCA), 
ASD, or clinical features suggestive of a chromosomal syndrome (n= 15,749). 
Comparing CNVs in cases to those in 10,118 published controls, identified 14 
deletions, and 7 duplications that were significantly enriched in cases (Kaminsky et 
al. 2013). Girirajan and colleagues on the other hand, studied children who had 
developmental delay with or without congenital malformations. The main finding 
reported a recurrent, 520Kbb 16p12.1 microdeletion associated with childhood 
developmental delay (Girirajan et al. 2010). Malhorta and colleagues reviewed 
findings of other studies that reported significant evidences for a number of large 
CNVs that are strongly associated with neuropsychiatric and neurodevelopmental 
disorders (Malhotra & Sebat 2012). 
A total number of 72 large, rare CNVs were identified in these studies and showed 
overrepresentation in cases with neurodevelopmental phenotypes, or genomic 
disorders relative to controls (Girirajan et al. 2012; Cooper et al. 2012; Malhotra & 
Sebat 2012; Kaminsky et al. 2013). Most of these CNVs showed a significant 
association with multiple diagnostic categories, with the most significant CNVs 
spanning 22q11.2; 3q29; 15q11.2; 15q11.2-13.1; 16p12.1; and 16p11.2 regions. All 
72 CNVs were implicated as being potentially pathogenic CNVs as they occurred in 
higher frequency in cases compared to controls. Lists are given in this chapter section 
6.4.2.2. 
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6.2.2. The second hit hypothesis 
Girirajan and colleagues have established testing the second hit hypothesis in large 
case-control cohorts of ID/DD children. Initially they found an enrichment for a 
520.8Kb 16p12.1 deletion (chr16: 21,942,499-22,432,499 on hg18) in ID/DD children 
relative to controls (p-value= 0.000086, OR= 3.78) (Table 6- 3) (Girirajan et al. 2010). 
 
 ID/DD Cases Controls Significance 
16p12.1 
del 
Total 16p12.1 
del 
Total P-value OR 
Discovery set 20 11,873 2 8,540 0.0009 7.2 
Replication set 22 9,254 6 6,299 0.028 2.5 
Combined 42 21,127 8 15,199 0.000086 3.78 
 
Following this finding, the group studied the relevance of additional CNVs on the 
phenotype of ID/DD patients carrying a 16p12.1 deletion. Interestingly, they found a 
higher frequency of additional CNVs in ID/DD patients with 16p12.1 microdeletion 
relative to population controls (Table 6- 4) (Girirajan et al. 2010). ID/DD patients with 
16p12.1 microdeletion and a second large CNV were observed to manifest more 
severe or distinct phenotypes than the typical phenotypes of the syndrome (Girirajan 
et al. 2010). 
Table 6- 3: Frequency of 16p12.1 microdeletion in ID/DD cases and controls (Girirajan et 
al. 2010). 
Table 6- 4: Enrichment for ‘Second hit’ CNVs among 16p12.1 microdeletion carriers (Girirajan et al. 2010). 
 ID/DD cases 
with 16p12.1 deletion 
 
Controls 
 
Significance 
 Two 
large 
CNVs 
Total Percentage Two 
large 
CNVs 
Total Percentage P-value OR 
Discovery set 6 20 30% 9 217 4.1% 0.0005 9.7 
Replication 
set 
4 22 18.2% 12 254 4.7% 0.029 4.48 
Combined  10 42 23.8% 21 471 4.4% 0.000057 6.65 
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This study was then extended in order to investigate a cohort of 2,312 children who 
carry one of the 72 CNVs that have been previously implicated to be associated with 
neurodevelopmental phenotypes or genomic disorders including ID/DD, autism, 
cardiac abnormalities, speech deficits, craniofacial features, and other previously 
defined congenital malformations (Girirajan et al. 2012; Cooper et al. 2012; Malhotra 
& Sebat 2012; Kaminsky et al. 2013). It was found that 8.7% of the 2,312 affected 
children to have at least one additional large CNV, of which 0.5% of those carrying a 
second CNV carried a third variant. The presence of a second CNV was found to be 
significantly enriched in children with a phenotypically variable genomic disorder 
(10.3%) in comparison to those children with a syndromic genomic disorder (5.1%) 
(p-value= 4.49×10-6, OR= 2.13) (Girirajan et al. 2012). This possibly indicates that 
children with disorders associated with variable phenotypes are more likely to harbour 
a second hit than those with syndromes with typical phenotypes.  
In order to understand the clinical outcomes of additional CNVs, a further 
investigation was performed by focusing on three CNVs (16p11.2 deletion and 
duplication, 1q21.1 deletion, and 16p12.1 deletion). A phenotypic scoring system 
including a checklist of clinical phenotypic features described for sub-telomeric and 
balanced de novo chromosomal imbalances was used to study the clinical outcomes in 
the individuals carrying one of the three CNVs. The scales of this approach ranged 
from 1 to 14 with lower scores indicate few features, whereas higher scores mean 
multiple features. The results showed that children with multiple large CNVs have 
higher phenotypic scores compared to those with a single large CNV, indicating that 
more heterogeneous phenotypes can be seen in the patients with a second large CNV. 
The presence of multiple large CNVs was significantly associated with more variable 
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phenotypes in patients carrying a primary 16p11.2 deletion (p-value= 0.008) and 
1q21.1 deletion (p-value= 0.006) (Figure 6- 1) (Girirajan et al. 2012). 
In addition, children with autism in this cohort were studied to assess the impact of the 
additional CNVs on their IQ. A strong association of median IQ with the number of 
genes spanned by rare CNVs was observed in autistic children. Lower median IQ 
(below the intellectual disability threshold IQ <70) was found in children with more 
affected genes by CNVs (≥18 genes) compared to children with less affected genes 
(<18 genes) (p-value= 0.002) (Figure 6- 2) (Girirajan et al. 2012). 
These studies provided strong evidence for the second hit hypothesis in patients with 
neurodevelopmental delay. Those who carry an additional large CNV with a primary 
pathogenic CNV have been proved to have an increased risk to develop more severe 
phenotypes and/or additional clinical features than those with only a single large CNV. 
Based on that, it is possible that the increased risk of neuropsychiatric disorders in 
22q11.2DS is contributed to by the presence of an additional CNV elsewhere in the 
genome. 
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Figure 6- 2: Association between median IQ and the number of genes 
spanning CNVs in children with autism. 
The plot shows that lower IQ level was observed in autistic children with 
larger number of disrupted genes by CNVs. Children with ≥18 affected genes 
have decreased median IQ (below the threshold for intellectual disability= 70 
points). A significant association of IQ level with number of affected genes 
was observed when children with ≥18 affected genes were compared to those 
with <18 affected genes (p-value= 0.002 by the Wilcoxon rank-sum test) 
(Girirajan et al. 2012). 
Figure 6- 1: Phenotypic scores for children with one of the four CNVs that 
are associated with the most homogenous disorders. 
Children with one of these CNVs were grouped into either a group with a single 
additional CNV (1 hit) or a group with multiple additional CNVs (2 hits). 
Phenotypic scores ranged from 1-14 in which higher scores indicate more 
variable phenotypes. The median values of phenotypic scores for cases with 2 
hits were equally higher than those cases with 1 hit among all four CNVs. 
Significant evidence was found in 1q21.1 deletion and 16p11.2 deletion and a 
trend was observed in both 16p11.2 duplication and 16p12.1 deletion (Girirajan 
et al. 2012). 
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6.2.3. The second hit hypothesis in 22q11.2DS 
There are a few other studies that have investigated the second hit hypothesis in 
22q11.2DS (Bassett et al. 2008; Li et al. 2012; Williams et al. 2013; Girirajan et al. 
2010). However, none of these studies reported significant evidence for the second hit 
hypothesis in 22q11.2DS and psychiatric phenotypes. 
Li and colleagues studied only 15 samples with either 22q11.2 deletion or duplication, 
and identified two cases with additional CNVs. Both cases were for new-borns that 
manifested severe congenital heart defects. The additional CNVs identified in the two 
cases are: 1.56Mb Xp22.31 deletion (involving STS gene) carried by a 22q11.2 
deletion carrier, 605Kb 15q13.3 duplication (involving CHRNA7 gene), and 209Kb 
16p13.2 deletion (involving RBFOX1 gene) carried by a 22q11.2 duplication carrier. 
Only one CNV (15q13.3 duplication) of the three CNVs identified in this study have 
been previously implicated in neurodevelopmental delay and neuropsychiatric 
diseases (Girirajan et al. 2012; Cooper et al. 2012; Malhotra & Sebat 2012; Kaminsky 
et al. 2013). The other two CNVs are not shown in the list of the previously identified 
pathogenic CNVs (Li et al. 2012). 
In the study of developmental delay conducted by Girirajan and colleagues, that was 
discussed earlier, a subset of 22q11.2DS individuals (n= 113) was included (Girirajan 
et al. 2010). Testing specifically these individuals for the presence of a second hit 
CNV revealed a non-significant trend for additional CNV enrichment in 22q11.2DS 
individuals. 8% (9/113) of the 22q11.2DS patients had an additional large (>500Kb) 
CNV, in addition to 22q11.2, compared to only 4% (21/471) in controls (Girirajan et 
al. 2010). 
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Bassett and colleagues assessed the CNV content in 100 22q11.2DS adults, 44 of 
which experienced psychosis (Bassett et al. 2008). The study identified no excess of 
inherited CNVs or evidence of de novo CNVs in 22q11.2DS patients with 
schizophrenia (p-values =0.6). Also, the authors did not look particularly at pathogenic 
CNVs that may be second-hit loci (Bassett et al. 2008).  
Williams and colleagues investigated the second hit hypothesis in 22q11.2DS adults 
with (n= 23) and without psychosis symptoms (n= 25). This study showed no 
significant evidence for increasing rate of second CNV hits in 22q11.2DS adults with 
psychosis when compared to the rate in non-psychotic adults (Fisher’s p-value= 0.37) 
(Williams et al. 2013). The most interesting finding in this study is that a significant 
elevated CNVs average size (354Kb) was found in the psychotic 22q11.2DS group in 
comparison to average size (227Kb) in the non-psychotic 22q11.2DS group (p-value= 
0.02). The authors identified four of the additional CNVs spanning genes that had been 
reported to be associated with neuropsychiatric disorders including 2q13, 3p26.3-
p26.2, 7q31.1, and 10q21.1. None of these four CNVs overlapping one of the 
previously implicated CNVs that were enriched in neuropsychiatric diseases 
(Williams et al. 2013).  
None of these studies have investigated whether the presence of additional large, rare 
CNVs is related to childhood neuropsychiatric illnesses, ADHD and ASD, in 
22q11.2DS. Therefore, this chapter set out to investigate whether the second hit 
hypothesis is related to the childhood psychiatric diseases associated with 22q11.2DS 
in a well-characterized cohort of 22q11.2DS children. 
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6.3. Aims of this chapter 
It is now established that large, rare copy number variants are associated with 
neurodevelopmental delay and neuropsychiatric disorders. It has also been reported 
that patients who carry additional CNVs with a primary pathogenic lesion can express 
more severe and/or additional symptoms than the typical syndromic phenotypes. The 
work described in this chapter will investigate whether the presence of additional 
large, rare CNVs are related to the increased risk to psychiatric disease seen in children 
with 22q11.2DS. 
The second hit hypothesis in 22q11.2DS will be assessed in a well-characterised 
cohort of 22q11.2 deletion carriers by conducting a genome-wide analysis of 
additional large, rare CNVs between the 22q11.2DS patients with and without a 
psychiatric phenotype (ADHD and/or ASD). The sample will then be assessed for 
evidence of an increased rate of second hit CNVs in the 22q11.2DS patients with a 
psychiatric phenotype. As most CNVs are either benign or of unknown consequence, 
this analyses will also be conducted for the subset of ‘pathogenic’ CNVs, that intersect 
one of 88 CNVs that have been previously implicated to increase risk to developmental 
delay and neuropsychiatric disease. 
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6.4. Materials and methods 
6.4.1. Samples 
The full specific details of the samples analysed in this chapter are found in chapter 2 
(DNA extraction protocol in section 2.2, and genotyping microarray in section 2.3).  
CNV calling was conducted on the genotype data of the 76 well-characterised 
22q11.2DS samples that passed the genotype-based QC used in chapter 3 section 
3.5.1. However, as it is standard for CNV analysis (The International Schizophrenia 
Consortium 2008), the quality of the 76 samples were further assessed based on 
PennCNV QC statistics. Samples were therefore excluded on the basis of either a high 
SD in their genome-wide log R ratio (>0.36) and B allele frequency (>0.025), a 
genome-wide waviness factor out of -0.03 to 0.03 range, or because they carried more 
than 60 apparent CNVs larger than 100Kb. A summary of this additional quality 
control is described in Figure 6- 3. 
 
 
 
 
 
 
 
 
 
167 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.4.2. CNV calls for burden analyses 
6.4.2.1. CNV calling and quality control 
CNV analysis was limited to 523,228 autosomal non-imputed SNPs genotyped by the 
HumanCoreExome chip. CNVs spanning a minimum of 10 consecutive informative 
SNPs were defined by PennCNV (2009Aug27version) (K. Wang et al. 2007) using 
Figure 6- 3: Flowchart for sample quality control based on PennCNV QC 
statistics. 
 
Yes 
 
 Removed from the analysis 
Removed from the analysis 
Removed from the analysis 
76 22q11.2DS samples 
Included in the CNV burden analyses 
Yes 
Yes 
No 
No 
No 
Sample had a 
LRR_SD ≤ 
0.36? 
 
Sample had a 
number of large 
CNVs (≥100Kb) 
≤60? 
Sample had a 
waviness factor 
between 
-0.03-0.03? 
Sample had a 
BAF_SD ≤0.025? 
No 
Yes 
Removed from the analysis 
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the protocol described in chapter 2 section 2.5.1; with those copy number calls lower 
than two being classed as deletions, and greater than two as duplications. Rigorous 
quality control procedures were applied to all CNV calls in order to maximise the 
chances that our subsequent analysis included only true CNVs. Detailed CNVs quality 
control criteria were fully explained in chapter 2 section 2.5.2.  
In addition, CNVs were excluded if more than 50% of their length spanned a known 
segmental duplications present in the February, 2009 human reference sequence at the 
National Centre for Biotechnology Information reference build 37, hg19 
(Genome.ucsc.edu, n.d.). CNVs were excluded if they overlapped by >50% with one 
of the CNVs in a list of common CNVs (>1% in a large population control cohort of 
11,255) that had been independently identified and provided by Dr Elliott Rees. It has 
been previously reported that there is a significant excess of large CNVs in ID and 
MCA cases relative to controls. This enrichment was evident at 250Kb and becomes 
more obvious with larger CNV size (Cooper et al. 2012). This study therefore focused 
on large CNVs ≥200Kb. Finally, as this study aimed to investigate additional CNVs, 
only CNVs occur outside the 3Mb region deleted in 22q11.2DS were selected. 
Summary of CNV QC is illustrated in Figure 6- 4. 
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Figure 6- 4: Flowchart for CNV quality control. 
Removed from the analysis 
Yes 
 
 Removed from the analysis 
Removed from the analysis 
Removed from the analysis 
 
Called CNVs by 
PennCNV 
Included in the genome-wide 
CNV analysis 
Yes 
Yes 
No 
No 
No 
CNV 
spanned ≥10 
SNPs? 
CNV size 
≥100Kb? 
 
 
CNV with a 
SNP density 
≥20,000? 
Yes 
Removed from the analysis 
 
 
 Removed from the analysis 
Removed from the analysis 
Yes 
Yes 
No 
No 
No 
CNV occurs 
outside known 
LCR regions? 
Rare CNV (occurs 
in <1% of normal 
population)? 
 
True deletions 
& duplications in 
LRR and BAF 
traces? 
Merging two adjacent CNVs occur in an 
individual with interval space <50% of 
the newly merged CNV. 
 CNV occurs 
outside 22q11.2 
region? 
No 
Yes 
 CNV size 
≥200Kb? 
No 
Yes 
Removed from the analysis 
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6.4.2.2. ‘Pathogenic’ CNV loci 
‘Pathogenic’ CNVs used in the analyses in this chapter were taken from published 
genome-wide CNV association studies using large case-control cohorts of 
neuropsychiatric diseases. These CNVs were identified to be significantly enriched in 
a large cohort of cases relative to a large cohort of population controls. These CNVs 
included: 
1) 15 schizophrenia-associated CNVs studied by (Rees et al. 2014) (Table 6- 5). 
2) 15 ADHD-associated CNVs reported by (Jarick et al. 2014; Williams et al. 
2012; Elia et al. 2011; Williams et al. 2010) (Table 6- 6). 
3) 72 potentially pathogenic CNVs implicated in neurodevelopmental diseases 
and genomic disorders reported by (Girirajan et al. 2012; Cooper et al. 2012; 
Malhotra & Sebat 2012; Kaminsky et al. 2013) (Table 6- 7, Table 6- 8). 
As 14 CNVs were reported repetitively in the above three lists, therefore 
collectively we had 88 ‘pathogenic’ CNV loci used to identify candidate 
pathogenic CNVs in our cohort.
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CHR Start 
(hg19) 
End 
(hg19) 
CNV type CHR Start 
(hg19) 
End 
(hg19) 
CNV type 
1 146,570,001 147,390,000 1q21.1 deletion 
 
1 146,570,001 147,390,000 1q21.1 duplication 
2 50,150,000 51,260,000 NRXN1 deletion 
 
7 72,740,000 74,140,000 WBS duplication 
3 195,730,000 197,340,000 3q29 deletion 
 
7 158,820,000 158,940,000 VIPR2 duplication 
15 22,800,000 230,90,000 15q11.2 deletion 
 
15 24,820,000 28,430,000 AS/PWS duplication 
15 31,130,000 32,480,000 15q13.3 deletion 
 
16 15,510,000 16,300,000 16p13.11 duplication 
16 28,820,000 29,050,000 16p11.2 distal deletion 
 
16 29,640,000 30,200,000 16p11.2 duplication 
17 14,160,000 15,430,000 17p12 deletion     
17 34,810,000 36,200,000 17q12 deletion 
 
    
22 19,020,000 20,260,000 22q11.2 deletion 
 
    
 
 
 
 
Table 6- 5: Previously implicated copy number variation loci in schizophrenia (Rees et al. 2014). 
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CHR Start 
(hg19) 
End (hg19) CNV type CHR Start 
(hg19) 
End 
(hg19) 
CNV type 
1 56,280,909 56,291,907 Deletion 1 72,544,704 72,555,807 Duplication 
 
3 1,869,168 1,884,889 Deletion 2 81,565,786 81,592,571 Duplication 
 
3 7,208,953 7,222,236 Deletion 4 113,552,891 113,569,135 Duplication 
 
5 64,992,220 65,010,764 Deletion 6 146,615,383 146,652,354 Duplication 
 
7 126,737,888 126,748,966 Deletion 6 162,739,766 162,847,029 Duplication 
 
11 88,629,801 88,712,013 Deletion 7 153,864,665 153,933,894 Duplication 
 
19 33,735,880 33,752,994 Deletion 15 32,024,690 32,445,689 Duplication 
 
    16 15,248,930 18,267,149 Duplication 
 
Table 6- 6: Previously implicated copy number variation loci in ADHD (Jarick et al. 2014; Williams et 
al. 2012; Elia et al. 2011; Williams et al. 2010). 
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Table 6- 7: Previously implicated copy number variation loci in gnomic disorders, intellectual disability and developmental delay cases (Girirajan et al. 2012; Cooper et al. 2012; 
Malhotra & Sebat 2012; Kaminsky et al. 2013).   
 
CHR 
Start  
(hg19) 
End 
(hg19) 
 
CNV type 
 
CHR 
Start  
(hg19) 
End 
(hg19) 
 
CNV type 
 
CHR 
Start  
(hg19) 
End 
(hg19) 
 
CNV type 
1 10001 10,077,413 1p36 deletion syndrome 16 21,942,499 22,432,499 16p12.1 deletion 2 239,705,243 242,471,327 2q37 deletion 
1 146,573,376 147,393,376 1q21.1 deletion 16 28,822,499 29,052,499 16p11.2 (SH2B1) deletion 22 19,020,000 20,290,000 DiGeorge/VCFS deletion 
10 81,960,020 88,800,020 10q23 deletion 16 29,652,499 30,202,499 16p11.2 deletion 22 21,910,000 23,670,000 22q11.2 distal deletion 
15 22,798,636 23,088,559 15q11.2 deletion 17 1,053,250 2,633,250 17p13.3 deletion 22 43,000,056 51,163,134 Phelan-McDermid syndrome 
15 24,818,907 28,426,405 Prader-Willi/Angelman 
deletion 
17 1,203,250 1,323,250 17p13.3(YWHAE) deletion 3 195,745,603 197,355,603 3q29 deletion 
15 31,132,708 32,482,708 15q13.3 deletion 17 2,423,250 2,593,250 17p13.3(PAFAH1B1) 
deletion 
4 1,529,198 2,030,202 Wolf-Hirschhorn 
15 32,012,708 32,452,708 15q13.3 deletion 
(chr15:32Mb-32.4Mb) 
17 16,789,275 18,299,275 Smith Magenis syndrome 5 175,717,394 177,057,394 Soto syndrome 
15 72,952,946 74,362,947 15q24 deletion 17 29,095,874 30,275,887 NF1 deletion syndrome 6 155,000 605,5001 6p25 deletion 
15 75,972,945 78,202,945 15q24.2q24.3 deletion 17 34,815,887 36,225,887 17q12 deletion 6 100,813,279 100,943,279 6q16 deletion 
15 83,182,945 84,738,996 15q25 deletion 17 43,704,217 44,164,182 17q21.31 deletion 7 72,742,064 74,142,064 William syndrome 
16 3,749,999 3,949,999 Rubinstein-Taybi deletion 17 58,285,218 60,305,218 17q23 deletion 8 8,092,590 11,892,591 8p23.1 deletion 
16 15,502,499 16,292,499 16p13.11 deletion 19 13,079,000 16,699,000 19p13.12 deletion 9 137,810,179 141,080,179 9q34 deletion 
16 21,532,499 29,102,499 16p11.2p12.1 deletion 2 148,723,530 149,293,530 2q23.1 deletion X 102,413,344 113,413,741 PLP1 deletion 
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Table 6- 8: (Continue) Previously implicated copy number variation loci in gnomic disorders, intellectual disability and developmental delay cases (Girirajan et al. 2012; Cooper 
et al. 2012; Malhotra & Sebat 2012; Kaminsky et al. 2013). 
 
CHR 
Start  
(hg19) 
End 
(hg19) 
 
CNV type 
 
CHR 
Start  
(hg19) 
End 
(hg19) 
 
CNV type 
 
CHR 
Start  
(hg19) 
End 
(hg19) 
 
CNV type 
1 146,573,376 147,393,376 1q21.1 duplication 16 28,822,499 29,052,499 16p11.2(SH2B1) 
duplication 
22 21,910,000 23,670,000 22q11.2 distal duplication 
10 81,960,020 88,800,020 10q23 duplication 16 29,652,499 30,202,499 16p11.2 duplication 22 43,000,056 51,163,134 22q13 duplication 
15 24,818,907 28,426,405 Prader-Willi/Angelman 
duplication 
17 1,203,250 1,323,250 17p13.3(YWHAE) 
duplication 
3 195,745,603 197,355,603 3q29 duplication 
15 31,132,708 32,482,708 15q13.3 duplication 17 2,423,250 2,593,250 17p13.3(PAFAH1B1) 
duplication 
4 1,529,198 2,030,202 WHS duplication 
15 32,012,708 32,452,708 15q13.3 duplication 
(chr15:32Mb-32.4Mb) 
17 16,789,275 18,299,275 Potocki Lupski syndrome 5 175,717,394 177,057,394 5q35 duplication 
15 72,952,946 74,362,947 15q24 duplication 17 29,095,874 30,275,887 NF1 duplication 6 155,000 6,055,001 6p25 duplication 
15 75,972,945 78,202,945 15q24.2q24.3 duplication 17 34,815,887 36,225,887 17q12 duplication 6 100,813,279 100,943,279 6q16 duplication 
15 83,182,945 84,738,996 15q25 duplication 17 43,704,217 44,164,182 17q21.31 duplication 7 72,742,064 74,142,064 WBS duplication 
16 15,502,499 16,292,499 16p13.11 deletion 17 58,285,218 60,305,218 17q23 duplication 8 8,092,590 11,892,591 8p23.1 duplication 
16 21,532,499 29,102,499 16p11.2p12.1 duplication 2 239,705,243 242,471,327 2q37 duplication 9 137,810,179 141,080,179 9q34 duplication 
16 21,942,499 22,432,499 16p12.1 duplication 22 19,020,000 20,290,000 22q11.2 duplication X 102,413,344 113,413,741 PLP1 duplication 
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6.4.3. CNV burden analyses 
6.4.3.1. Genome-wide CNV burden analysis 
CNV calls were stratified according to their sizes into two categories (≥200Kb CNVs 
and ≥500Kb). To conduct the global burden analysis, the rate of additional CNVs was 
determined in each of the 3 categories of psychiatric diseases (22q11.2DS+ADHD, 
22q11.2DS+ASD, and 22q11.2DS+PSYCH) and compared to the rate seen in the 
22q11.2DS patients who had no psychiatric disease (22q11.2DS-PSYCH).  This one-
sided test of CNV burden analysis performed using Plink (Purcell et al. 2007) with 
significance being empirically assessed by 10,000 permutations.  
 
6.4.3.2. ‘Pathogenic’ CNV burden analysis 
The genomic coordinates were determined for each of the CNVs identified in the 
22q11.2DS patients and also for the 88 CNVs that had been previously implicated in 
neurodevelopmental delay and neuropsychiatric disease (described in this chapter 
section 6.4.2.2). CNVs from the 22q11.2DS cohort were selected if they overlapped 
with any of the 88 ‘pathogenic’ CNV by >50%. A burden analysis was then performed 
on this subset of CNVs in the same way that was described for all CNVs. 
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6.5. Results 
6.5.1. Sample quality control 
Three of the initial 76 samples did not pass our stringent quality control procedures. 
They were identified to carry more than 60 large CNVs (≥100Kb); also, the three 
samples were identified to have a WF value > 0.03. Therefore, they were removed 
from the analysis. The remaining 73 samples with 22q11.2DS were used for all CNV 
analyses described in this chapter and based on the presence or absence of psychiatric 
phenotypes were categorized into 3 groups: 22q11.2DS+ADHD, 22q11.2DS+ASD, 
and 22q11.2DS+PSYCH. Numbers of patients in each group are given in (Table 6- 9). 
 
 
 
 
 
 
 
 
 
Categories 
 
Description 
 
Number of individuals 
22q11.2DS+ADHD 22q11.2 deletion carriers with ADHD 
phenotypes 
28 
22q11.2DS+ASD 22q11.2 deletion carriers with ASD 
phenotypes 
18 
22q11.2DS+PSYCH 
 
22q11.2 deletion carriers with ADHD 
and/or ASD phenotypes 
36 
22q11.2DS-PSYCH 22q11.2 deletion carriers with no 
ADHD and ASD phenotypes 
33 
Table 6-9: Number of 22q11.2 deletion carriers affected and unaffected by psychiatric disorders. 
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6.5.2. CNV detection 
PennCNV analysis of the 73 individuals with 22q11.2DS identified a total of 18 large 
(≥200kb), rare (<1% population frequency) CNVs that survived the stringent QC 
criteria. Of the 18 CNVs, 5 were deletions (27.8%) and 13 were duplications (86.7%) 
mapped to 18 distinct genomic regions. Which means that none of the 18 CNVs were 
detected in more than one sample. 
Of the 18 CNVs ≥200Kb, 7 CNVs are larger than 500Kb (1 deletion and 6 
duplications) (Table 6- 10). 
The 18 CNVs are carried by 14 22q11.2DS patients, 3 patients were found to carry 
multiple additional CNVs, while the remaining 11 patients carry a single additional 
CNV: 
1) 1 patient has 3 second CNVs. 
2) 2 patients have 2 second CNVs each. 
3) 11 patients have a single second CNV each.  
Of the 18 CNVs, 11 were found in the 22q11.2DS-PSYCH patients (n= 8). Two 
patients carried multiple CNVs in addition to 22q11.2 deletion (one patient has 3 
CNVs and the other has 2 CNVs). While each of the remaining 6 patients has a single 
CNV (Table 6- 11). 
Seven CNVs were found in the 22q11.2DS+PSYCH group where only 1 patient had 
2 CNVs and 5 had a single additional CNV. None of the 7 CNVs were found in 
multiple samples (Table 6- 11). 
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Six CNVs were carried by five 22q11.2DS+ADHD patients, with only 1 patient 
having 2 CNVs and 4 patients having 1 additional CNV each. No single CNV was 
identified in more than one ADHD patient (Table 6- 11). 
Four CNVs were identified in 4 individuals who had 22q11.2DS+ASD. Each patient 
carried a single additional CNV. Also there is no single additional CNV was detected 
in multiple ASD patients (Table 6- 11). 
Investigating the intersection of these 18 CNVs with 88 ‘pathogenic’ CNVs, that had 
been previously implicated to neuropsychiatric disease, identified 3 that overlapped 
with a ‘pathogenic’ CNV. The 3 CNVs were carried by 3 22q11.2DS patients, one of 
which showed symptoms of both ADHD and ASD, while the other 2 had no 
psychiatric phenotype (Table 6- 12).
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CHR Start 
(hg19) 
End 
(hg19) 
CNV type Size 
(Kb) 
Genomic 
loci 
Sample ID ADHD ASD PSYCH 
1 248,072,026 248,688,317 Duplication 616.3 1 E_006_1_1   - 
2 136,648,077 137,093,578 Duplication 445.5 3 E_015_1_1   - 
2 138,600,801 138,865,871 Duplication 265.1 2 E_015_1_1   - 
3 234,877 1,238,287 Deletion 1003.4 5 E_089_1_1   - 
3 6,728,385 7,035,024 Duplication 306.6 4 E_116_1_1   - 
3 141,845,000 142,085,310 Duplication 240.3 6 E_033_1_1   - 
4 86,089 437,081 Deletion 351.0 7 E_116_1_1   - 
9 11,578,233 11,890,045 Deletion 311.8 8 E_072_1_1  + + 
9 87,414,794 88,373,138 Duplication 958.3 9 E_064_1_1 +  + 
9 116,958,266 117,360,729 Duplication 402.5 10 E_001_1_1 + + + 
10 76,071,203 76,295,789 Deletion 224.6 11 E_077_1_1   - 
12 37,927,114 38,891,067 Duplication 964.0 12 E_084_1_1 +  + 
15 32,067,075 32,514,341 Duplication 447.3 13 E_034_1_1   - 
16 7,048,405 7,356,303 Deletion 307.9 14 E_054_1_1   - 
16 29,644,174 30,199,713 Duplication 555.5 15 E_070_1_1 + + + 
20 52,288,724 53,267,627 Duplication 978.9 16 E_012_1_1 + + + 
22 22,312,879 22,560,977 Duplication 248.1 17 E_015_1_1   - 
22 23,700,907 25,010,874 Duplication 1310.0 18 E_064_1_1 +  + 
Table 6- 10: Additional large, rare CNVs identified in 22q11.2DS cohort. 
CNVs highlighted by blue were carried by a single 22q11.2DS patient (E_015_1_1). 
CNVs highlighted by grey were carried by a single 22q11.2DS patient (E_116_1_1). 
CNVs highlighted by yellow were carried by a single 22q11.2DS patient (E_064_1_1). 
(+) Affected with psychiatric disorder. 
(-) Unaffected with psychiatric disorder. 
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Table 6- 11: Number of patients carry second CNVs in psychiatric disease categories. 
Table 6- 12: Second CNVs intersected one of the 88 previously reported implicated CNVs in neurodevelopmental and neuropsychiatric disorders. 
22q11.2DS 22q11.2DS+ADHD 22q11.2DS+ASD 22q11.2DS+PSYCH 22q11.2DS-PSYCH 
*Number 
of CNVs 
Number of patients 
carry second CNVs 
Number 
of CNVs 
Number of patients 
carry second CNVs 
Number 
of CNVs 
Number of patients 
carry second CNVs 
Number 
of CNVs 
Number of patients 
carry second CNVs 
Number 
of CNVs 
Number of patients 
carry second CNVs 
 
18 
14  
6 
5  
4 
4  
7 
6  
11 
8 
1 second 
CNV 
 ≥2 second 
CNVs 
1 second 
CNV 
≥2 second 
CNVs 
1 second 
CNV 
≥2 second 
CNVs 
1 second 
CNV 
 ≥2 second 
CNVs 
1 second 
CNV 
≥2 second 
CNVs 
11 3 4 1 4 0 5 1 6 2 
 
Called CNVs 
 
 
Previously implicated CNVs 
 
22q11.2DS carriers 
CHR Start 
(hg19) 
End 
(hg19) 
CNV type Size 
(Kb) 
CHR Start 
(hg19) 
End 
(hg19) 
CNV type Samples ID Psychiatric 
phenotype 
16 29,644,174 30,199,713 Dup 555.54 16 29,652,499 30,202,499 16p11.2 duplication E_034_1_1 22q11.2DS+PSYCH 
(ADHD and ASD) 
15 32,067,075 32,514,341 Dup 447.27 15 32,012,708 32,452,708 15q13.3 duplication 
(chr15:32Mb-32.4Mb) 
E_070_1_1 
 
22q11.2DS-PSYCH 
22 22,312,879 22,560,977 Dup 248.10 22 21,910,000 23,670,000 22q11.2 distal 
duplication 
E_015_1_1 
 
22q11.2DS-PSYCH 
* Total number of second CNVs detected in patients in the psychiatric category. 
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6.5.3. Investigating whether 22q11.2DS patients with ADHD or ASD are enriched 
for second hit CNVs 
This analysis sought to assess whether additional large, rare CNVs could potentially 
have an impact on the increased risk of childhood psychiatric disease in 22q11.2DS 
children.  
 
6.5.3.1. ADHD in 22q11.2DS 
The 6 distinct CNVs detected in the 22q11.2DS+ADHD patients were used for burden 
analyses. Results of global CNV burden analysis revealed a 3-fold enrichment of 
CNVs ≥500Kb in the 22q11.2DS+ADHD patients (rate =0.18) compared to 
22q11.2DS-PSYCH patients (rate =0.06) (Table 6- 13), however, this enrichment was 
not statistically significant (p-value= 0.20). A less pronounced difference in the rate 
of ≥200Kb CNVs between the two groups was observed (enrichment rate= 0.63; p-
value= 0.83) (Table 6- 13). 
The analysis was then restricted to the CNVs that overlapped with one of the 88 
previously implicated CNVs with developmental delay or psychiatric diseases. Of the 
6 additional CNVs identified in ADHD patients, only a single CNV was ‘pathogenic’ 
and included in the burden analysis. This revealed a 0.6-fold enrichment for 
‘pathogenic’ CNVs in 22q11.2DS+ADHD patients (rate = 0.036) relative to those with 
no psychiatric symptoms (rate = 0.060), however, this finding was not statistically 
significant (p-value= 0.85) (Table 6- 13). 
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Table 6- 13: Results of CNV burden analyses comparing 22q11.2DS+ADHD individuals (n= 28) and 22q11.2DS-PSYCH 
individuals (n= 33). 
 
Global CNVs 
 
 CNVs ≥ 200Kb CNVs ≥ 500Kb 
22q11.2DS 
+ADHD 
22q11.2DS  
-PSYCH 
*Ratio **EMP 
p-value 
22q11.2DS 
+ADHD 
22q11.2DS  
-PSYCH 
Ratio EMP 
p-value 
Number of CNVs 6 11 - - 5 2 - - 
Total number of 
samples 
28 33 - - 28 33 - - 
***Rate 0.21      0.33 0.63 0.83 0.18 0.06 3 0.20 
****Proportion 0.18     0.24 0.75 0.82 0.14 0.06 2.3 0.26 
Total CNVs 17 7 
 
Pathogenic CNVs 
 
  22q11.2DS 
+ ADHD 
22q11.2DS 
- PSYCH 
Ratio EMP 
P-value 
Number of CNVs 1 2 - - 
 
 
Pathogenic loci 
 
16p11.2 
duplication 
 
15q13.3 duplication 
(chr15:32Mb-32.4Mb) 
 
22q11.2 distal 
duplication 
 
 
- 
 
 
 
 
- 
 
 
Total number of 
samples 
28 33 - - 
Rate 0.036 0.060 0.6 0.85 
Proportion 0.036 0.060 0.6 0.85 
Total CNVs 3 
*Ratio: 22q11.2DS affected patients/22q11.2DS unaffected patients. 
**EMP p-value: Empirical p-value, corrected for all tests. 
***Rate: Number of CNVs (Number of CNVs/ Total number of samples). 
****Proportion: Proportion of sample with one or more CNVs (Number of samples carry ≥1 CNVs/Total number of samples). 
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6.5.3.2. ASD in 22q11.2DS 
The 4 distinct additional CNVs detected in the 22q11.2DS+ASD patients were tested 
for burden. Genome-wide CNV burden analysis revealed a 1.8-fold enrichment of 
CNVs ≥500Kb in the 22q11.2DS+ASD patients (rate =0.11) compared to 22q11.2DS-
PSYCH patients (rate =0.06) (Table 6- 14), however, this enrichment was not 
statistically significant (p-value= 0.44). Similarly, the rate of ≥200Kb CNVs was not 
increased in the 22q11.2DS+ASD patients (rate =0.22) relative to the 22q11.2DS-
PSYCH patients (rate =0.33), which again was not significant (p-value= 0.79) (Table 
6- 14). 
Restricting the analysis to the CNVs that overlapped with one of the 88 previously 
implicated CNVs with developmental delay or psychiatric disease identified only a 
single CNV of the 4 additional CNVs that was potentially ‘pathogenic’. The rate of 
‘pathogenic’ CNVs in 22q11.2DS+ASD patients was 0.056 compared to 0.060 in 
those with no psychiatric symptoms and this was not statistically significant (p-value= 
0.73) (Table 6- 14).
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Table 6- 14: Results of CNV burden analyses comparing 22q11.2DS+ ASD individuals (n= 18) and 22q11.2DS-PSYCH 
individuals (n= 33). 
 
Global CNVs 
 
 CNVs ≥ 200Kb CNVs ≥ 500Kb 
22q11.2DS 
+ASD 
22q11.2DS  
-PSYCH 
*Ratio **EMP 
p-value 
22q11.2DS 
+ASD 
22q11.2DS  
-PSYCH 
Ratio EMP 
p-value 
Number of CNVs 4 11 - - 2 2 - - 
Number of samples 18 33 - - 18 33 - - 
***Rate 0.22    0.33 0.67 0.79 0.11 0.06 1.8 0.44 
****Proportion 0.22 0.24 0.92 0.68 0.11 0.06 1.8 0.44 
Total CNVs 15 4 
 
Pathogenic CNVs 
 
  22q11.2DS 
+ ASD 
22q11.2DS 
- PSYCH 
Ratio EMP 
P-value 
Number of CNVs 1 2 - - 
 
 
Pathogenic loci 
16p11.2 
duplication 
 
15q13.3 duplication 
(chr15:32Mb-32.4Mb) 
 
22q11.2 distal 
duplication 
 
 
- 
 
 
 
 
- 
 
 
Number of samples 18 33 - - 
Rate 0.056 0.060 0.93 0.73 
Proportion 0.056 0.060 0.93 0.73 
Total CNVs 3 
*Ratio: 22q11.2DS affected patients/22q11.2DS unaffected patients. 
**EMP p-value: Empirical p-value, corrected for all tests. 
***Rate: Number of CNVs (Number of CNVs/ Number of samples). 
****Proportion: Proportion of sample with one or more CNVs (Number of samples carry ≥1 CNVs/Total number of samples). 
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6.5.4. Investigating whether 22q11.2DS patients with psychiatric phenotypes are 
enriched for second hit CNVs 
In an attempt to increase the power of the study a final analysis was conducted which 
collectively looked at the rate of additional large, rare CNVs carried by 22q11.2 
deletion carriers who had ADHD, ASD, or both.  
The 7 distinct additional CNVs identified in the 22q11.2DS+PSYCH patients were 
included in the burden analyses. Results of global CNV burden analysis revealed a 
2.29-fold enrichment of CNVs ≥500Kb in the 22q11.2DS+PSYCH samples (rate = 
0.14) relative to those with no psychiatric symptoms (rate = 0.06) (Table 6- 15), 
however, this excess was not statistically significant (p-value= 0.29). The difference 
in the frequency of CNVs ≥200Kb between the two groups was less pronounced with 
the observed rate in the 22q11.2DS+PSYCH samples being 0.19 and 0.33 in those 
with no psychiatric symptoms (p-value= 0.88) (Table 6- 15). 
The analysis was then limited to the CNVs that overlapped with one of the 88 CNVs 
previously reported to be associated with developmental delay or psychiatric diseases. 
A single CNV intersected one of the reported ‘pathogenic’ CNVs which was not 
significantly enriched in the 22q11.2DS+PSYCH patients (rate = 0.028) compared to 
those with no psychiatric symptoms (rate=0.060; p-value= 0.89) (Table 6- 15).
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Table 6- 15: Results of CNV burden analyses comparing 22q11.2DS+PSYCH individuals (n= 36) and 22q11.2DS-PSYCH 
individuals (n= 33). 
  
Global CNVs 
 
 CNVs ≥ 200Kb CNVs ≥ 500Kb 
22q11.2DS 
+PSYCH 
22q11.2DS  
- PSYCH 
*Ratio **EMP 
p-value 
22q11.2DS   
+PSYCH 
22q11.2DS  
- PSYCH 
Ratio EMP 
p-value 
Number of CNVs 7 11 - - 5 2 - - 
Number of samples 36 33 - - 36 33 - - 
***Rate 0.19 0.33 0.58 0.88 0.14 0.06 2.29 0.29 
****Proportion 0.17 0.24 0.69 0.86 0.11 0.06 1.83 0.37 
Total CNVs 18 4 
 
Pathogenic CNVs 
 
  22q11.2DS 
+PSYCH 
22q11.2DS 
-PSYCH 
Ratio EMP 
P-value 
Number of CNVs 1 2 - - 
 
 
Pathogenic loci 
 
16p11.2 
duplication 
 
15q13.3 duplication 
(chr15:32Mb-32.4Mb) 
 
22q11.2 distal 
duplication 
 
 
- 
 
 
 
 
- 
 
 
Number of samples 36 33 - - 
Rate 0.028 0.060 0.47 0.89 
Proportion 0.028 0.060 0.47 0.89 
Total CNVs 3 
*Ratio: 22q11.2DS affected patients/22q11.2DS unaffected patients. 
**EMP p-value: Empirical p-value, corrected for all tests. 
***Rate: Number of CNVs (Number of CNVs/ Number of samples). 
****Proportion: Proportion of sample with one or more CNVs (Number of samples carry ≥1 CNVs/Total number of samples). 
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6.6. Discussion 
Recent studies have shown that a secondary CNV in patients carrying a primary 
pathogenic CNV can modify the phenotype in neurodevelopmental delay and other 
multiple syndromic disorders (Girirajan et al. 2010; Girirajan et al. 2012). The main 
aim of this chapter was to investigate whether the increased risk of psychiatric 
phenotypes in 22q11.2DS is conferred by additional genomic structural variants that 
manifest independently to the primary microdeletion.  
Thus, CNV burden analyses were performed to test if there is additional CNVs being 
enriched in 22q11.2DS patients affected by neuropsychiatric diseases. Results of 
global CNVs burden analyses revealed a potential trend for enrichment of CNVs 
≥500Kb in 22q11.2DS individuals with ADHD (by 3-fold), ASD (by 1.8-fold) and 
psychiatric illnesses (by 2.29-fold). However, none of these observations were 
statistically significant (p-values >0.05). By restricting the burden analysis on the 
previously reported ‘pathogenic’ CNVs, the study also failed to provide an evidence 
for a significant enrichment for ‘pathogenic’ CNVs in 22q11.2DS patients who 
showed neuropsychiatric diseases symptoms (p-values >0.05). 
This potential enrichment observed in 22q11.2DS patients with psychiatric diseases is 
mainly due to five affected patients harbouring a single CNV ≥500Kb each, compared 
to only two unaffected individuals carrying one CNVs ≥500Kb each. Only one of the 
five affected patients carry a second CNV that overlap with one of the 88 reported 
pathogenic CNV. This individual has a ~555Kb duplication at 16p11.2 (chr16: 
29,652,499-30,202,499 on hg19) and showed symptoms of ADHD and ASD.  
Recurrent structural variations at 16p11.2 region (chr16: 29,652,499-30,202,499 on 
hg19) have been reported in a large genome-wide association study including 751 
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families and 512 children with autism (Weiss et al. 2008). An excess of 593Kb 
duplications spanning this region found in three autistic families, inherited in two 
families (6 cases and 1 control) and occur as de novo events in the third family (1 case 
and 1 control). The study provided significant evidence for an enrichment of 16p11.2 
duplications in autistic subjects in the families compared to control subjects (p-value= 
1.1x10−4 for both 16p11.2 deletions and duplications) (Weiss et al. 2008). In addition, 
presence of 16p11.2 duplications was also observed in four independent samples from 
512 autistic children compared to none in 434 control children, an observation that 
was statistically significantly (p-value= 0.007 for both 16p11.2 deletions and 
duplications) (Weiss et al. 2008). Subsequent studies, reviewed by Malhotra and Sebat 
(Malhotra & Sebat 2012), have also reported significant evidence for involvement of 
duplications at 16p11.2 in ID/DD/Congenital malformations (p-value= 2.2x10-8; OR= 
3.4) with a frequency of ~0.2%, in ASD (p-value= 6.2x10-11; OR= 11.8) with a 
frequency of ~1% in ASD, in schizophrenia (p-value= 3.2x10-14; OR= 9.4) with a 
frequency of ~0.3%, and in bipolar disease/recurrent depression (p-value= 0.0008; 
OR= 3.9). Additionally, in a large case-control cohort of unexplained ID, DD, 
dysmorphic features, multiple congenital anomalies, ASD, or clinical features 
suggestive of a chromosomal syndrome; a significant burden of 16p11.2 duplication 
was identified (1 in 404 in patients) relative to normal controls (p-value= 2.5x10-5; 
OR= 6.28) (Kaminsky et al. 2013). This duplication has been reported to be highly 
significantly associated with ID and MCA (p-value= 0.0004 and 1.0x10-6) (Cooper et 
al. 2012; Girirajan et al. 2012), in addition to the other significant evidence of this 
duplication being associated with to other multiple psychiatric diseases (Malhotra & 
Sebat 2012). Moreover, in a very recent genome-wide chromosomal microarray study 
conducted in 202 adults with idiopathic ID, an increased frequency of 16p11.2 
189 
 
duplication was observed which suggested a potential enrichment of this recurrent 
CNV in the adult population of ID and comorbid psychiatric disorder (Wolfe et al. 
2017). 
It is however of potential interest that when looking at the secondary CNVs ≥100Kb, 
a 22q11.2DS patient carries a ~124Kb deletion that spans the 16p11.2p12.1 
pathogenic region (chr16: 21,532,499-29,102,499 on hg19) and has symptoms of only 
ADHD. Recurrent de novo deletions at 16p11.2p12.1 region (chr16: 21,532,499-
29,102,499 on hg19) have been reported in five cases with developmental disabilities, 
distinct facial features, and multiple congenital abnormalities (Hernando et al. 2002; 
Ballif et al. 2007). Four of the five cases were identified among 8,789 patients with 
developmental disabilities who were screened for analysis with a targeted microarray. 
The precise breakpoints for the deletions in these individuals were determined. The 
proximal breakpoint is shared in the four subjects, while distal breakpoints were 
~28.5Mb (subject 2), ~29.3 Mb (subjects 3 and 4), and ~30.1 Mb (subject 1) from the 
16p telomere, resulting in overall deletion size ranges from ~7.1Mb, ~7.9Mb, and 
~8.7Mb (Ballif et al. 2007) (Figure 6- 5). Although the size of the deletion identified in 
this study is smaller (~124Kb) compared to the deletion identified in the four reported 
individuals (~7.1Mb- ~8.7Mb), it does overlap with the proximal region of the 
reported deletions and shares the same proximal breakpoint (Figure 6- 5). Deletions at 
16p11.2-12.1 have been nominally associated with ID/DD in one study (p-value= 
0.011) (Girirajan et al. 2012), but this was not supported in another study (p-value= 
0.43) (Cooper et al. 2012). The CNV spans 4 genes; METT9, IGSF9, U6, and OTOA 
(Figure 6-5). CNVs spanning OTOA genes have been reported to be the most common 
CNVs detected in 686 patients with non-syndromic hearing loss (13% of CNVs 
identified) (Shearer et al. 2014).  
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Comparing our findings to the previous studies, only one CNV (15q13.3 duplication) 
identified by Li and colleagues was also detected in one of our 22q11.2 deletion 
carriers, who has no symptoms of psychiatric phenotypes (Li et al. 2012), while none 
of the potentially pathogenic CNVs identified by Williams and colleagues overlapped 
with our detected CNVs (Williams et al. 2013). 
Williams and colleagues found a significant increased CNVs average size (354Kb) in  
psychotic 22q11.2DS patients in comparison to average size (227Kb) in non-psychotic 
22q11.2DS patients (p-value= 0.02) (Williams et al. 2013). This observation is 
consistent with the finding in our study that a trend of higher rate of larger CNVs 
(≥500Kb) was found in 22q11.2DS with additional psychiatric phenotypes risk 
compared to those without psychiatric phenotypes by 2.29-fold (p-value= 0.29), while 
rate of smaller CNVs (≥200Kb) has less pronounced difference (0.58-fold) between 
22q11.2DS with and without psychiatric phenotype (p-value= 0.88). This possibly 
indicates larger CNVs are more likely to be seen in 22q11.2DS individuals with 
Figure 6- 5: Schematic of the 16p11.2-p12.2 region (hg19) with a summary of the deletions identified in our case 
and the four reported subjects in (Ballif et al. 2007). 
Red bars indicate deleted regions for each reported subject of the four. Blue bar indicates deleted region for our subject. 
Orange bars indicate regions of copy number variation based on the Database of Genomic Variants. The locations of 
select genes from 4100 known genes in the region are shown. Figure obtained from (Ballif et al. 2007) with 
modification. 
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psychiatric diseases. This is also in line with the finding of other large studies which 
reported that enrichment for additional CNVs  in patients with ID and MCA was more 
evident in larger CNVs (≥250Kb) than smaller CNVs (Cooper et al. 2012). 
Due to the small sample size used in this study and because no pathogenic loci were 
hit multiple times, statistical analyses failed to show a significant evidence for CNVs 
enrichment in 22q11.2DS affected with psychiatric diseases. Identification of 
recurrent CNVs in further datasets including larger sample size is required for proof 
of disease causality. 
 
The Genetic Power Calculator (Purcell, Cherny & Sham 2003) was used to calculate 
the power of this study. Our sample size of 36 22q11.2DS patients affected with 
psychiatric disease and 33 unaffected patients has an 80% power to detect a variant 
with an allele frequency of 0.06 and an effect size of 2.08 at a p-value of 0.05. This 
indicates that our sample size is able to detect a single locus with large effect size. 
The pwr package version 1.2-0 (Champely 2016), Power analysis functions in R, and 
G*Power v3.0.10 were used to calculate the power of CNV burden study (Rucker et 
al. 2016; Tansey et al. 2014), that compares proportions of large, rare CNVs between 
22q11.2DS patients with (n= 36) and without (n= 33) psychiatric phenotypes. The 
study had an 80% power to detect a significant finding with an effect size of 0.68 at 
the alpha level of 0.05. That means by using this sample size, our study can detect an 
enrichment for CNVs that are common with an effect size of 0.68 and larger sample 
size is required to detect significant CNV burden for rare CNVs. 
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Also, in this study we could not assess the inheritance of most of our rare CNVs, this 
is due to no available samples from the parents of the patients included in the study. 
In addition, although we focused on CNVs that large enough to be detected at high 
sensitivity and specificity irrespective of SNP array, however, our results should be 
considered preliminary as CNVs were only determined using statistical algorithms and 
no validation via more precise methods, such as quantitative real time PCR, was 
performed. 
 
In conclusion, the study in this chapter investigated whether the high risk of 
neuropsychiatric phenotypes in 22q11.2DS is conferred by presence of additional 
pathogenic CNVs. Despite 2.29-fold enrichment for additional large CNVs was 
observed in 22q11.2DS patients with a psychiatric phenotype compared to those with 
no psychiatric phenotype, the results in this chapter failed to provide significant 
evidence to support a role of additional second CNVs influencing the psychiatric 
phenotype of 22q11.2DS. 
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Chapter 7: Investigating 22q11.2 Deletions in Parkinson’s 
Disease Patients 
 
 
7.1. Summary 
It is widely known that 22q11.2 deletions are associated with a diverse spectrum of 
multi systemic phenotypes. Recently idiopathic Parkinson’s disease cases have been 
reported within 22q11.2 deletion cohorts (Krahn et al. 1998; Booij et al. 2010; Zaleski 
et al. 2009; Butcher et al. 2013). This finding suggests that 22q11.2 microdeletions 
increase the risk of PD. The study in this chapter aims to investigate the association of 
22q11.2 deletions with PD by analysing deletions spanning chromosome 22q11.2 in 
an idiopathic PD cohort (n= 6,462) and healthy controls (n= 6,202) and comparing the 
rate of 22q11.2 deletions between the two groups. 
Five independent PD cases (0.08%) were identified that carried a 3Mb deletion at 
22q11.2, while none of the control cohort (0.0%) carried a deletion. Association 
analysis revealed that this enrichment was short of nominal significance (p-value = 
0.069). Analysis of the 5,599 PD cases that had data available for Parkinson’s disease 
age at onset revealed a significant enrichment for 22q11.2 deletions in the 660 EOPD 
cases (0.61%) compared to 4,939 LOPD cases (0.02%) (p-value= 9.0x10-4). 
Comparing the rate of 22q11.2 deletions between EOPD cases (0.61%) and unaffected 
controls (0%) showed highly significant evidence for an increased rate of 22q11.2 
deletion in EOPD cases (p-value= 9.0x10-7). These findings suggest that patients with 
a 22q11.2 deletion have an increased risk to develop PD, particularly the early age at 
onset form of the disease. The analysis has been included in a meta-analysis of 
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multiple large PD cohorts that fully supported the findings of this chapter, which was 
conducted by the International Parkinson’s Disease Genetics consortium (Mok et al. 
2016).  
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7.2. Introduction 
7.2.1. Parkinson’s disease 
Parkinson’s disease (PD) is a neurodegenerative disorder of the central nervous system 
that specifically causes a defect in the motor system (Jankovic 2008). Abnormality in 
the motor system in PD patients is due to extensive degradation of dopaminergic 
neurons in the substantia nigra within the midbrain area in the brain (Gaig & Tolosa 
2009). The substantia nigra has a central role in brain functions mainly in motor 
planning, eye movement, learning, and addiction (Gaig & Tolosa 2009). The reason 
for the death of dopamine-generating cells in the substantia nigra in PD patients is not 
fully understood (de Lau & Breteler 2006). 
 
7.2.1.1. Prevalence of PD 
PD is the second most common neurodegenerative disease after Alzheimer’s disease. 
Prevalence of PD varies among people based on their age, sex, and ethnic background 
(de Lau & Breteler 2006) . The population prevalence is estimated at 0.3%, but 
increases with age up to 1–2% in people older than 60 years, and 3–4% in those older 
than 80 years (Nussbaum & Ellis 2003). The median age of PD onset is around 60 
years (Lees et al. 2009). However, 5-10% of PD cases have an early age of onset PD 
which occurs between ages of 20-50 years old. Moreover, while rare, juvenile-onset 
forms of the disease show the symptoms before the age of 20 years (Samii et al. 2004). 
Regarding to ethnic background, PD appears to be more prevalent in Caucasians 
(Figure 7- 1) (de Lau & Breteler 2006), however, the rate among different ethnic 
backgrounds have been shown to be inconsistent. This is attributed to differences in 
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response rates, survival, and case-ascertainment in each epidemiological study (de Lau 
& Breteler 2006).  
 
 
 
 
 
 
 
 
 
 
 
 
7.2.1.2. Symptoms of PD 
PD is characterized by the presence of motor and non-motor phenotypic features. The 
most prominent and one of the earliest phenotypes in PD patients is movement 
abnormalities that include shaking, rigidity, slow movement, and walking difficulty 
(Jankovic 2008). Clinical features are considered as the crucial signs for PD diagnosis 
(Litvan et al. 2003). There are four phenotypic features used to distinguish PD; tremor 
at rest, rigidity, akinesia (or bradykinesia), and postural instability. These features are 
collectively grouped under the acronym TRAP and they represent the motor symptoms 
seen in PD (Jankovic 2008). Non-motor symptoms of PD are usually developed in the 
Figure 7- 1: Population and age-based prevalence 
studies of PD. 
PD prevalence increases as age increases in all ethnical 
background. The figure indicated that Caucasian 
showed the highest PD rate compared to other ethnical 
groups (de Lau and Breteler 2006). 
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late course of the disease. These symptoms include neuropsychiatric phenotypes such 
as disorders of speech, cognition, mood, behaviour, and thought (Jankovic 2008). 
Executive dysfunction is the most common cognitive deficit in PD patients. It is 
represented by defects in the processes of planning, cognitive flexibility, abstract 
thinking, rule acquisition, initiating appropriate actions and inhibiting inappropriate 
actions, and selecting relevant sensory information (Jankovic 2008). Non-motor 
features also include sleep behaviour disorder and sensory abnormalities such as 
olfactory dysfunction, pain, paresthesia, akathisia, oral pain, and genital pain. These 
symptoms occur frequently in PD patients, however, they are not used as diagnostic 
signs of the disease (Jankovic 2008). 
  
7.2.2. Pathogenesis of PD 
The main cause of the motor symptoms seen in PD patients is the loss of dopamine-
generating cells in the substantia nigra. Due to the excessive neurons loss, the main 
pathological hallmark in PD appears in the brain of PD individuals as Lewy bodies, 
which are intracellular aggregations of α-synuclein protein (Dickson et al. 2009). 
However, the causes for the degradation of dopaminergic neurones, formation of 
Lewy bodies, and accumulations of α-synuclein are still unknown (Dickson et al. 
2009). 
The first genetic mutation to be associated with PD was discovered in the α-synuclein 
(SNCA) gene, where the p.A53T mutation was segregating in an Italian kindred and in 
three unrelated Greek families with autosomal dominant inheritance of PD 
(Polymeropoulos et al. 1997). This finding gave insights about the possibility of 
genetic mutations involvement in PD development. Several mutations have since been 
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identified in monogenic forms of PD. For example, mutations in SNCA were found to 
cause the early onset autosomal dominant inherited form of PD (Lesage & Brice 
2009). Mutations in the LRRK2 gene were identified in patients developing the late 
onset autosomal dominant inherited form of PD (Cookson 2010). In contrast, loss-of-
function mutations in PARK2, P1NK1, and DJ-1 genes were found to cause rare forms 
of autosomal recessive PD with early onset (Bonifati et al. 2003; Kitada et al. 1998; 
Valente et al. 2004). In addition, mutations in ATP13A2, PLA2G6, and FBXO7 genes 
have been identified to cause atypical PD with juvenile onset (Paisan-Ruiz et al. 2009; 
Shojaee et al. 2008; Ramirez et al. 2006). 
The idiopathic form of PD is thought to develop by a complex interplay of several 
genetic variants that interact with many other non-genetic, environmental risk factors 
(Polito et al. 2016). Several genome-wide association studies have now been 
performed and these have confirmed that the causative genes SNCA, LRKK2, and 
MAPT are also risk factors for sporadic PD (Simón-sánchez et al. 2009; Satake et al. 
2009). In a large PD case-control cohort, 11 loci that met the threshold for genome-
wide significance (p-value <5×10-8) were identified which were also reported in a 
larger replication cohort. Six were previously reported loci (MAPT, SNCA, HLA-
DRB5, BST1, GAK, and LRRK2) and five were newly identified loci (ACMSD, STK39, 
MCCC1/LAMP3, SYT11, and CCDC62/HIP1R) (IPDGC 2011). 
 
7.2.3. PD in 22q11.2DS cases 
It is now widely known that 22q11.2 deletions are associated with a diverse spectrum 
of multi systemic phenotypes. Recently, unrelated idiopathic PD cases have been 
reported within 22q11.2 deletion cohorts. Krahn and colleagues first reported the case 
of a 30 years old man with a 22q11.2 deletion who also developed childhood onset of 
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schizophrenia with Parkinson’s disease-like phenotype. The standard chromosomal 
analysis identified a normal 46,XY karyotype, however, FISH with DNA probe 
D22S75 revealed a microdeletion. Thus, the patient's karyotype was 46,XY.ish del 
(22)(q11.2q11.2)(D22S75) (Krahn et al. 1998). Later in 2009, Zaleski and colleagues 
reported 2 additional unrelated patients both with 22q11.2DS and early onset (age <45 
years) PD (Zaleski et al. 2009). Booij and colleagues identified a case with 22q11.2DS 
whose diagnosis with early-onset PD had been confirmed using dopamine transporter 
(DAT) imaging. DAT is a protein that expressed exclusively in the membrane of 
presynaptic terminals of dopamine-generating cells (Booij et al. 2010). The largest 
single study was reported by Butcher and colleagues who identified that 5.9% of 
22q11.2DS patients aged 35-64 years (4 out of a single cohort of 68 patients) 
developed PD (Butcher et al. 2013). The patients had no reported family history of 
Parkinson’s disease. In addition, the genetic screening did not detect any known 
pathogenic mutations related to Parkinson’s disease. A post- mortem analysis was 
performed on three of the four patients and revealed typical loss of midbrain 
dopaminergic neurons, with two patients showing α-synuclein-positive Lewy bodies. 
The authors estimated that 22q11.2 deletions increased the incidence of early-onset 
PD in their cohort by 0.4%, compared to that of 0.03% seen in the general population. 
Butcher and colleagues also compared the neuropathology between 22q11.2+PD cases 
(n= 3) to non-22q11.2DS+PD cases (n= 1), and 22q11.2–PD cases (n= 3) to non-
deleted controls (n= 10). This revealed that similar pathological features, characterized 
by presence of Lewy bodies and dopaminergic degradation in brain tissues, were found 
in 22q11.2+PD cases and non-22q11.2+PD cases. In contrast, similar normal 
pathological results were seen in 22q11.2–PD cases and non-deleted controls (Butcher 
et al. 2013).  
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Taken together, these reports suggest that microdeletions at 22q11.2 might have a key 
role in increasing the risk of Parkinson’s disease. However, these previous studies 
have focused on the identification of PD in 22q11.2DS patients, no previous study has 
investigated the rate of 22q11.2 deletions in a large cohort of PD patients. 
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7.3. Aims of the study 
Based on the initial findings of 22q11.2DS patients developing PD, studies have 
focused on identifying PD patients among 22q11.2 deletion carriers. However, no 
previous studies have investigated deletions spanning the 22q11.2 locus in idiopathic 
PD patients. This study set out to estimate the frequency of 22q11.2 deletions in 
idiopathic PD in a large PD case-control cohort. The study will investigate association 
with PD by performing the following lines of investigations: 
1) Detecting CNVs spanning the typical 3Mb deleted region in 22q11.2DS 
(chr22:18,658,219-21,865,185 on hg19) in PD patients and controls. 
2) Investigating the association of 22q11.2 deletions with PD by comparing the 
proportion of 22q11.2 deletions in PD patients and controls. 
3) Investigating the relationship of 22q11.2 deletions and PD age at onset  by 
comparing their  rate in patients with early PD onset age to those with late PD 
onset age. 
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7.4. Materials and methods 
7.4.1. Participants 
The work in this chapter used the genotype data from a large case-control PD dataset 
which is typically referred to as the IPDGC NeuroX dataset (Nalls et al. 2014). It was 
composed of 6,462 PD cases and 6,202 controls from the UK (804 cases, 684 
controls), USA (2,069 cases, 2,652 controls), France (564 cases, 479 controls), 
Germany (1,298 cases, 883 controls), Greece (736 cases, 891 controls), Netherlands 
(316 cases, 447 controls), and the Parkinson's Progression Markers Initiative (PPMI) 
cohort (675 cases, 166 controls). All cases were recruited from neurological clinic 
visits and were diagnosed according to the standard UK Brain Bank criteria with a 
modification to allow the inclusion of cases that had a family history of PD. Cases had 
a ratio of males:females of 1.78:1 and had a mean age at onset of 60.2 years (SD 
=12.5). Controls were recruited from clinic visits, had a mean age of 63.2 (SD =15.6) 
and had a ratio of males:females of 1.21:1.  
 
7.4.2. 22q11.2 CNV calls 
All samples had been previously genotyped using a semi-custom genotyping array 
called NeuroX (Nalls et al. 2014). This meant that the genotypes of 267,607 SNPs 
were available for genome-wide CNV analysis. CNV calling was performed using 
PennCNV (K. Wang et al. 2007) using the same calling protocol that was explained 
in chapter 2 section 2.5.1.  
As this study was specifically aiming to identify CNVs at 22q11.2DS then the CNV 
calling was restricted to only those that spanned either the 3Mb deleted region at 
22q11.2 (chr22:18,658,219-21,865,185 on hg19) that is flanked by LCR22sA–D, or 
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the 1.5Mb deleted region (chr22:18,658,219-20,519,134 on hg19). Both deletions and 
duplications within these regions were identified. 
 
7.4.3. Samples quality control 
Derivatives of LRR and BAF, generated by PennCNV, were identified by using 
(LRR_SD and BAF_SD). Samples were excluded if they had a LRR_SD greater than 
0.30; a BAF_SD greater than 0.15; or a number of CNVs 3 SDs above the mean CNV 
number of the case (27.7 CNVs) or control groups (24.1 CNVs). A summary of 
samples quality control is explained in Figure 7- 2. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7- 2: Flowchart for samples quality control based on PennCNV 
Statistics. 
Yes 
 
 Removed from the analysis 
Removed from the analysis 
Removed from the analysis 
PD and control 
samples 
Included in the CNV analysis 
Yes 
Yes 
No 
No 
No 
Sample with 
a LRR_SD 
≤0.30? 
Sample with a 
BAF_SD ≤0.15? 
 
Sample 
had a CNVs number 
 ≤ 3SDs of the mean 
CNVs number? 
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7.4.4. CNV quality control 
The CNV calls were subjected to the same quality control procedure that was 
described in chapter 2 section 2.5.2. 
 
7.4.5. 22q11.2 deletions association analyses 
For association analysis, the number of chromosome 22q11.2 deletions was compared 
between PD cases and controls using the Fisher’s exact test (two-sided). Similarly, the 
number of 22q11.2 deletions found in PD patients with early and late PD onset was 
compared by Fisher’s exact test (two-sided).  
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7.5. Results 
7.5.1. Samples quality control 
All samples of PD case and control met the quality control criteria. Therefore, all 6,462 
patients with PD and 6,202 controls were included for the subsequent analyses. 
 
7.5.2. Identifying 22q11.2 deletions in PD patients 
Genome-wide analysis identified a total of 233,783 CNVs in this cohort, however, 
only 176 CNVs were located on chromosome 22.  Following quality control filtering, 
5 individuals were identified as carrying large deletions that spanned 
chr22:18,658,219-21,865,185 on hg19 (Table 7-1). 
 
 
 
 
The five deletion carriers were unrelated patients with PD and all carried the most 
common 3Mb deletion in 22q11.2DS spanning LCRs A-D (Figure 7- 3). 
 
 
Quality control filers 
 
 
*Threshold 
 
**Initial 
total 
 
***Removed 
 
****Final 
total 
 
Number of constitutive 
SNPs spanned by a CNV 
 
 
10 SNPs 
 
176 
 
0 
 
176 
Large CNV calls 
 
100Kb 176 124 52 
Genotypes dense CNVs 
 
SNP density of 20,000 52 3 49 
 
Merging adjacent large 
CNVs 
2 adjacent large CNVs in an 
individual with the gap length 
<50% of the entire length of 
the newly merged CNV 
 
49 
 
1 
 
48 
 
Typical 22q11.2 deletion 
Outside the common 3Mb 
22q11.2 region or the rare 
1.5Mb 22q11.2 region 
 
48 
 
43 
 
5 
Table 7- 1: CNV quality control filtering.  
* Filtering threshold or criteria. 
** Initial total: Initial total number of samples. 
*** Removed: Number of removed samples due to failure in matching filtering threshold criteria. 
**** Final total: Final total number of samples.  
 
 
* Filtering threshold or criteria. 
** Initial total: Initial total number of samples. 
*** Removed: Number of removed samples due to failure in matching filtering threshold criteria. 
**** Final total: Final total number of samples.  
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7.5.3. Investigating the association of 22q11.2 deletions in PD patients 
The number of 22q11.2 deletions in PD patients (n= 6,462) was compared to that in 
control cohort (n= 6,202). The results of this association analysis revealed a pattern of 
enrichment for 22q11.2 deletions in patients with Parkinson’s disease, where cases 
had increased rate of 22q11.2 deletions (0.08%) compared to controls (0.0%) which 
fell just short of nominal significance (p-value= 0.063) (Table 7- 2). 
 
 
 
 
 
 
 
7.5.4. Investigating the association of PD age of onset and 22q11.2 deletions 
As the previous reports had indicated that patients with 22q11.2DS developed PD 
before 50 years of age, the data was further analysed to investigate whether the 
presence of 22q11.2 deletion is associated with PD age of onset. 5,599 of PD cases, 
which included all 5 PD patients that carried a 22q11.2 deletion, had available data for 
 Total 22q11.2 deletion 
carriers 
Frequency  
PD patients 6,462 5 0.08% 
Controls 6,202 0 0.0% 
Two-sided Fisher’s 
exact test p-value 
0.063 
Table 7- 2: Results of association analyses of deletions in chromosome 22q11.2 in 
PD cases and controls.  
 
Window position 
chromosome 22 
 
Low copy repeats 
Figure 7- 3: Genomic location of the 22q11.2 deletions found in the five patients with PD and location of the low 
copy repeat regions. 
207 
 
PD age at onset. The average age of onset of PD in the 5 carriers of a 22q11.2 deletion 
was 43.9 years (SE= 4.37), while it was 60.3 years (SE= 0.14) in PD patients without 
a 22q11.2 deletion. This finding indicates PD cases with 22q11.2 deletion develop PD 
earlier than those without 22q11.2 deletion by ~16.4 years (SE= 4.0). 
To formally test the relationship between deletions at 22q11.2 and PD age at onset the 
PD cases were considered as early onset PD (EOPD) if they presented with PD 
symptoms by <45 years, and late onset PD (LOPD) if they expressed PD phenotypes 
by >45 years of age (Wickremaratchi et al. 2009). In the NeuroX dataset, 660 PD 
patients had EOPD, whereas 4,939 PD patients had LOPD (Table 7- 3). 
 
 
 
 
 
 
Association analysis revealed a significant enrichment for 22q11.2 deletions in EOPD 
cases (n=4; frequency=0.61%) compared to that seen in LOPD cases (n=1; 
frequency=0.02%) (p-value= 9.0x10-4). Furthermore, when compared to the control 
cohort, the increased rate of 22q11.2 deletions detected in the EOPD patients was 
highly significant (p-value = 9.0x10-7). On the other hand, no evidence of a significant 
enrichment of 22q11.2 deletions was identified in LOPD cases when they were 
compared to controls (p-value= 0.443) (Table 7- 4). 
 
Table 7-  3: Patients with Parkinson’s disease entered into the age at onset 
analysis. 
 22q11.2 deletion 
carriers 
Non-22q11.2 
deletion carriers 
Total number 
EOPD patients 
(AAO <45 years) 
4 656 660 
LOPD patients 
(AAO >45 years) 
1 4,938 4,939 
Controls 0 6,202 6,202 
AAO= Age at onset. 
EOPD= Early onset of PD. 
LOPD= Late onset of PD. 
 
 
AAO= Age at onset. 
EOPD= Early onset of PD. 
LOPD= Late onset of PD. 
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 Number of 
22q11.2 deletion 
carriers 
Total number Frequency of 22q11.2 
deletion carriers 
Association tests 
p-values 
EPDO patients vs LOPD patients 
EOPD patients 
(AAO <45 years) 
4 660 0.61% 
 
 
9.0x10-4 
LOPD patients 
(AAO >45 years) 
1 4,939 0.02% 
 
EPDO patients vs controls 
EOPD patients 
(AAO <45 years) 
4 660 0.61% 
 
 
9.0x10-7 
Controls 0 6,202 0% 
LPDO patients vs controls 
 
LOPD patients 
(AAO >45 years) 
1 4,939 0.02% 
 
 
0.443 
Controls 0 6,202 0% 
 
 
 
 
  
Table 7- 4: Results of association analyses of deletions spanning 3Mb 22q11.2 region according to PD age 
at onset. 
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7.6. Discussion 
In the study presented in this chapter, the rate of 22q11.2 deletions was compared in a 
large idiopathic PD case-control cohort. Five unrelated PD patients were found to 
carry a ~3Mb deletion spanning LCR22s A-D at 22q11.2, while none of the controls 
carried any deletion at 22q11.2. Association analysis revealed that while the 
proportion 22q11.2 deletions was increased in PD patients (rate=0.08%) compared to 
controls (rate=0.0%), the difference fell just short of nominal significance (p-value= 
0.063). PD cases with known PD loci mutations were excluded from this analysis. 
Also the selected cases had no reported psychiatric symptoms and other age-related 
disease, such as Alzheimer’s disease, were excluded. The five PD 22q11.2 carriers 
fulfilled the UK Brain Bank for Parkinson’s disease. A single patient had a valvular 
heart lesion with no additional information about the cardiac anomaly, while another 
was found with mitral valve prolapse identified after PD was diagnosed. Regarding to 
psychiatric illness, only a single patient had depression before PD diagnosis, while 
none of the 5 patients had schizophrenia before onset of PD. Two cases had a cleft 
palate or oropharyngeal malformation before the onset of PD, with one expressing 
bifid uvula during investigations for dysphagia after diagnosis of PD. One patient was 
identified to have hypocalaemia. These identified phenotypes are relevant to the 
clinical features seen in 22q11.2DS which confirm the influence of 22q11.2 deletions 
in the symptoms in these PD patients. 
The results from this association analysis have been included in a larger meta-analysis 
that combined four large PD case-control cohorts (Total PD cases= 9,387, Total 
controls= 13,863) (Mok et al. 2016). In addition to the 5 PD patients carrying deletions 
at 22q11.2 that were identified in this chapter, 3 unrelated patients with PD were 
identified to carry the most common 3Mb deletion in 22q11.2DS from three 
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independent PD cohorts; UK-WTCCC2, Dutch Parkinson’s Disease Genetics 
Consortium, and USA-NIA. Two PD patients were found to carry 22q11.2 deletions 
in the UK-WTCCC2 PD cohort (1,592 cases and 4,939 controls). Only a single PD 
patient was a 22q11.2 deletion carrier from the Dutch PD cohort (740 cases and 1,996 
controls) (Figure 7- 4). No deletion carriers were identified in the smallest cohort from 
the USA-NIA (593 cases and 726 controls). The results of the meta-analysis conducted 
by Mok and colleagues (Mok et al. 2016) revealed that PD patients have higher rate 
of 22q11.2 deletions (0.09%) compared to controls (0%), supporting the findings in 
the NeuroX sample that were presented in this chapter. This finding was statistically 
highly significant (p-value= 5.6x10-4) (Table 7- 5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Studies  
 
22q11.2 deletion 
carriers 
Total Frequency 
 
Combined the 
four PD 
cohorts 
PD patients 8 9,387 0.09% 
Controls 0 13,863 0.0% 
*Meta-analysis 
p-value 
0.00056 
Table 7-  5: Results of meta-analysis of 22q11.2 deletions in PD cases and controls 
for the combined four independent PD case-control including NeuroX cohort. 
Window position 
chromosome 22 
Figure 7- 4: Genomic location of the 22q11.2 deletions found in the eight patients with PD from the four combined 
independent PD cohorts and location of the low copy repeat regions (Mok et al. 2016). 
* Meta-analysis by Mantel-Haenszel test (Two-sided). 
 
 
* Meta-analysis by Mantel-Haenszel test (Two-sided). 
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The initial clinical reports of PD occurring in subjects with 22q11.2DS typically 
reported the patients to have an early age at onset. As the age at onset was known for 
5,599 of the PD patients analysed in this study, the data was further investigated to 
compare the rate of deletions in 22q11.2 region between PD cases with LOPD and 
those with EOPD. This revealed highly significant evidence (p-value= 9.0x10-4) that 
the EOPD cases (0.61%) carried more 22q11.2 deletions than the LOPD cases 
(0.02%). Comparing the frequency of 22q11.2 deletions in EOPD (0.61%) comparing 
to controls (0.0%) further demonstrated the significant over-representation of 
deletions in the EOPD patients (p-value= 9.0x10-7).  
 
In the meta-analysis, conducted by Mok and colleagues (Mok et al. 2016), the age at 
onset of PD data was available for a total of 8,451 patients. Analysis of these samples 
allowed them to further investigate the role of 22q11.2 deletions and PD age of onset. 
The results showed a higher rate of 22q11.2 deletions in the EOPD patients (0.5%) 
compared to that in the LOPD patients (0.04%) and unaffected controls (0%). The 
results of Mantel-Haenszel exact test (two-sided) revealed a significant enrichment for 
22q11.2 deletion in EOPD relative to LOPD (p-value= 7.0x10-4). Interestingly, highly 
significant evidence was found when rate of 22q11.2 deletions was compared between 
EOPD patients and unaffected controls (p-value= 1.47x10-11), while a nominally 
significant evidence was found when LOPD patients were compared to controls (p-
value= 0.023) (Table 7- 6) (Mok et al. 2016). These support the association between 
EOPD and 22q11.2DS that were identified reported in this chapter and are in line with 
the previous 22q11.2DS cases that had been reported to show symptoms of PD-like 
motor abnormalities (Krahn et al. 1998; Zaleski et al. 2009; Booij et al. 2010; Butcher 
et al. 2013). 
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It has been reported that EOPD have been associated with rare mutations. 4-6% of 
EOPD cases have known genetic mutations in genes including LRRK2, PARK2, 
SNCA, PARK7, and PINK1 (Houlden & Singleton 2012). EOPD patients with 22q11.2 
deletions identified in this study share the same proximal deleted region (1.5Mb). This 
is also consistent with those 22q11.2DS cases with EOPD identified by Butcher and 
colleagues. This region involves approximately 30 genes, however, none of which 
overlap any known PD loci.   
There are however, a number of candidate genes that might be implicated in PD-
related pathways that are located in this region. These include microRNA miR-185, 
which is predicted to target LRRK2 (Dweep et al. 2011; Heman-Ackah et al. 2013), 
and DGCR8 that are key regulator genes in the biogenesis of brain microRNA (Stark 
et al. 2008). Altered gene expression in 22q11.2DS by disrupted microRNA-mediated 
posttranscriptional regulation could possibly directly or indirectly impact on the 
expression of PD risk genes elsewhere in the genome (Brzustowicz & Bassett 2012). 
Other possible 22q11.2 candidate genes are SEPT5, encoding a protein that 
functionally interacts with the product of PARK2 (Zhang et al. 2000), COMT 
(Levodopa inhibition), and 6 mitochondrial genes (Maynard et al. 2008). All of these 
genes have been shown to be brain expressed in 22q11.2DS mice models (Meechan et 
 Frequency of 22q11 deletions 
(No. CNVs/No. samples)  
Association Tests* 
(p-value) 
Studies EOPD subjects 
(AAO<45 years) 
LOPD subjects 
(AAO<45 years) 
Controls EOPD vs LOPD EOPD vs Controls LOPD vs Controls 
Combined 
cohort 
0.5% 
(5/1,014) 
0.04% 
(3/7,437) 
0% 
(0/13,863) 
7.0x10-4 1.47x10-11 0.023 
Table 7- 6: Results of meta-analysis of 22q11.2 regions and PD age at onset in the combined large PD cohort including 
NeuroX cohort. 
*Meta-analysis by Mantel-Haenszel test (Two-sided). 
 
 
*Meta-analysis by Mantel-Haenszel test (Two-sided). 
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al. 2009; Maynard et al. 2003), as well as DGCR8, SEPT5, and COMT have been 
identified as dosage sensitive in our study in chapter 4. 
In conclusion, in this chapter deletions at 22q11.2 were analysed in a large cohort of 
idiopathic PD and controls. A potential trend for an increasing 22q11.2 deletion rate 
in PD cases was revealed (p-value= 0.069), which was supported by a significant meta-
analysis that including this PD case-control cohort and three independent PD cohort 
(p-value= 5.6x10-4). In addition, this study provided significant evidence for 
association of 22q11.2 deletions with early onset PD compared to late onset (p-value= 
9.0x10-4), which was also supported in the meta-analysis of Mok and colleagues (Mok 
et al. 2016). This evidence can be used to make clinicians aware of the possibility that 
22q11.2DS patients could develop PD symptoms at an early age. Also, screening for 
deletions in the 22q11.2 region is advised in patients with EOPD and psychiatric 
features. The biological mechanism behind the association of 22q11.2 deletions and 
EOPD should be investigated in future studies. 
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Chapter 8: General Discussion and Future Direction 
 
 
8.1. Introduction 
The 22q11.2 deletion is one of the most common pathogenic CNVs with an estimated 
incidence of 1 in 4000 births (Scambler 2000). It is widely known to be a strong risk 
factor for psychotic disorder and schizophrenia with about 25% of adult deletion 
carriers developing schizophrenia (Murphy et al. 1999). Children carrying the 22q11.2 
deletion have an increasing risk to develop behavioural and psychiatric disorders such 
as ADHD (41%) and ASD (26%) (Niarchou et al. 2014). However, the syndrome is 
associated with incomplete penetrance of neuropsychiatric diseases as some patients 
express psychiatric phenotypes while others do not (Niarchou et al. 2014). 22q11.2 
hemizygous microdeletions occur as a de novo mutation in 95% of 22q11.2DS patients 
and are inherited in the remaining 5% (Scambler 2000). The vast majority of the 
patients (85%) share a ~3Mb deletion and the remaining patients carry a smaller 
~1.5Mb deletion (Scambler 2000). 
The molecular mechanisms that underlie the increasing risk of psychiatric phenotypes 
from a single homogenous microdeletion on chromosome 22q11.2 are yet not clearly 
understood. This PhD thesis attempted to contribute to our understanding of how 
deletions at 22q11.2 are involved in the pathogenesis of neuropsychiatric disorders. 
This chapter discusses the general considerations drawn from the results and outlines 
the future studies that may be undertaken.  
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8.2. Implication of this PhD results to the 22q11.2DS knowledge 
8.2.1. Investigating the molecular mechanisms underlie the psychiatric 
phenotype variability in 22q11.2DS 
As a central working hypothesis, the increased risk of neuropsychiatric phenotypes in 
22q11.2DS was hypothesized to be due to dosage sensitive genes within the 
haploinsufficient region on chromosome 22q11.2.  
 
To conduct the work in this thesis it was first necessary to characterise a cohort of 76 
children with 22q11.2DS who had high quality genotypic data and were ethnically 
homogenous. Gene dosage sensitivity in 22q11.2DS was then investigated by 
differential gene expression analysis for genome-wide genes to highlight differentially 
expressed genes in 22q11.2 deletion carriers relative to non-deleted controls. Thirty-
nine genes within the 22q11.2 deleted region were found to be dosage sensitive in 
22q11.2DS, 29 of which had been previously shown to be expressed in the brain. Most 
of these genes had been also supported to be differentially expressed in other 
expression studies in 22q11.2DS patients. 7 of the 39 dosage sensitive genes were also 
reported in a smaller 22q11.2DS cohort (n= 7) (van Beveren et al. 2012), while 29 of 
them were also identified in a larger 22q11.2DS cohort (n= 46) (Jalbrzikowski et al. 
2015). Moreover, 7 of the 39 dosage sensitive genes were also found to be 
differentially expressed in brain tissues of the 22q11.2DS mice models compared to 
the wild-type mice (Sivagnanasundaram et al. 2007). Mouse models of heterozygous 
knockouts for some of these genes have been reported to express impaired cognitive 
functions that are processed in the prefrontal cortex and hippocampus, which are 
considered as endophenotypes of schizophrenia and psychiatric symptoms in 
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22q11.2DS patients (Gogos et al. 2009; Gogos et al. 1998; Hsu et al. 2007; Mukai et 
al. 2004; Paylor et al. 2006; Suzuki et al. 2009). It has been suggested that the deletion 
might regulate the expression of other nearby genes, causing positional effects. 
Differential expression analysis of genes flanking the deletion on 22q11.2 indicated 
that no significant evidence of there being a positional effect on the expression of 
genes located nearby the deletion.  
The results of pathway analysis of differentially expressed genes located outside the 
deleted region highlighted significant (FDR <0.05) functional biological groups that 
could be involved in the pathogenesis of some phenotypes related to 22q11.2DS. 
These included functional groups related to immune system and protein synthesis, 
particularly functions in leukocyte activation and post translational modifications. 
However, it is difficult to associate the identified functional categories to the 
psychiatric phenotypes seen in 22q11.2DS as they are enriched for differentially 
expressed genes in the peripheral whole blood. Specific brain tissue are ideally 
required to accurately investigate psychiatric phenotypes in 22q11.2DS. 
 
However, it has been shown that due to tight haemostatic regulation that can 
compensate for a gene dosage imbalance, not all genes spanned by deletions are 
dosage sensitive. This thesis therefore next investigated the hypothesis that risk 
variants remaining on the intact 22q11.2 chromosome can potentially be exposed by 
the primary deletion and act as modifying factors for neuropsychiatric illnesses seen 
in 22q11.2DS. To investigate this, the variants present on the remaining 22q11.2 
chromosome were screened in 22q11.2 patients. After identifying common variants 
by genotyping then by imputing genotype data, association analyses were conducted 
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to test whether the identified common variants were associated with the psychiatric 
phenotypes in 22q11.2DS. The results of these analyses failed to provide significant 
evidence for either common SNPs (p-values <9.9x10-6) or for putative CNVs (p-values 
<0.017) being associated with neuropsychiatric diseases in 22q11.2DS.  
Despite this, a non-significant trend of secondary small 22q11.2 deletions was 
observed in 22q11.2DS patients with psychiatric phenotypes (rate= 5.7%) relative to 
patients with no psychiatric phenotypes (rate= 2.6%). This implicated 2 secondary 
small 22q11.2 deletions that were found in 2 patients with psychiatric disease, which 
are potentially disrupting the genes PRODH and THAP7.  
Although there are a large number of studies that have analysed common variants in 
22q11.2DS affected with psychiatric phenotypes (Gothelf et al. 2005; Bearden et al. 
2004; Kates et al. 2006; Shashi et al. 2006; Shashi et al. 2010; Bassett et al. 2007; 
Baker et al. 2005; Glaser, Debbane, et al. 2006; van Amelsvoort et al. 2008; Vorstman, 
Turetsky, et al. 2009; Jungerius et al. 2008; Ikeda et al. 2010; Raux et al. 2007), they 
have typically focused on candidate genes spanned by the deletion. The findings of 
these studied were inconsistent and generally failed to replicate. To our knowledge, 
this is the first study that has systematically looked at the variants spanning the non-
deleted 22q11.2 allele and studied their association to the psychiatric phenotypes. A 
few studies have investigated the risk of phenotypes associated with 22q11.2DS other 
than the psychiatric ones, such as Bernard-Soulier Syndrome and other atypical 
features (Budarf et al. 1995; Ludlow et al. 1996; McDonald-McGinn et al. 2013). 
These studies have identified additional mutations in genes that are relevant to the 
additional phenotypes. These promising results were achieved by applying more 
precise approaches to detect these mutations such as whole and targeted exome 
sequencing methods, which are recommended for future investigations. 
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Based on the evidence that a second CNV hit hypothesis was relevant in 
neurodevelopmental and psychiatric disorders, this thesis investigated whether CNVs 
that are additional to the primary 22q11.2 deletions could be relevant in psychiatric 
disease. The presence of a second CNV in addition to the main pathogenic 22q11.2 
deletion was investigated by calling genome-wide CNVs using PennCNV. Then, the 
frequency of additional CNVs was compared in 22q11.2DS affected with childhood 
psychiatric disease to those unaffected. Again the results failed to provide significant 
evidence for additional large, rare CNVs in 22q11.2DS patients with psychiatric 
phenotypes. However, a non-significant potential trend for enrichment for large, rare 
CNVs was observed in patients with ADHD, ASD, and psychiatric illnesses 
(enrichment rates = 3, 1.8, and 2.29; p-values= 0.20, 0.44, and 0.29 respectively). 
Focusing on CNVs that span one of those previously implicated in a psychiatric 
phenotype, also failed to show an evidence for enrichment of pathogenic CNVs in 
22q11.2DS patients affected with psychiatric disease. Despite not identifying a 
significant result, this study is the first to analyse the second CNV hits in 22q11.2DS 
with childhood psychiatric symptoms, ADHD and ASD. Three previous studies also 
attempted to investigate the presence of additional CNV phenotypic modifiers, 
however, in cohorts of 22q11.2DS adults (Bassett et al. 2008; Williams et al. 2013), 
and in a combined cohort of 22q11.2 deletion and duplication carriers (Li et al. 2012). 
These studies showed no significant evidence for either an increased burden of large, 
rare CNVs or enrichment for previously identified CNVs in 22q11.2DS with 
psychiatric disease. 
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8.2.2. Investigating 22q11.2 deletions in Parkinson’s disease patients 
This PhD thesis provided the opportunity to investigate the presence of deletions 
spanning the common 22q11.2 deleted region in the largest case-control cohort of 
idiopathic PD. This analysis was based on the previously reported cases of 22q11.2DS 
who manifested early onset of PD (Krahn et al. 1998; Zaleski et al. 2009; Booij et al. 
2010; Butcher et al. 2013). However, no previous study had analysed 22q11.2 
deletions in PD patients. Deletions within the commonly 22q11.2 deleted region were 
called using PennCNV and association analyses revealed a trend of an increased 
burden of 22q11.2 deletions in PD patients compared to controls (p-value =0.063). 
However, comparing the rate of deletions according to disease age at onset revealed 
significant evidence for a higher rate of 22q11.2 deletions in PD cases with an early 
onset compared to those with late onset, and healthy controls (p-values = 9.0x10-4, and 
9.0x10-7 respectively). The data from this study was subsequently combined with other 
PD cohorts and included in a meta-analysis which identified highly significant 
evidence for an increased rate of 22q11.2 deletions in PD cases compared to controls 
(p-value =0.00056). Additionally, the meta-analysis also confirmed the highly 
significant increase of 22q11.2 deletions in EOPD relative to LOPD and controls (p-
values = 7.0x10-4, and 1.47x10-11 respectively). These significant findings provide 
strong support that 22q11.2DS patients could develop PD symptoms in early age.  
The possible molecular mechanisms, that have been studied in the rest of PhD thesis 
should be tested by future studies in a cohort of adult 22q11.2DS with and without PD 
to investigate whether they are relevant to the increased risk of EOPD in 22q11.2DS 
patients. 
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8.3. Limitations of this PhD study 
8.3.1. Small sample size underpowered the study  
The main limitation of this study was that it was conducted in a small sample size of 
22q11.2DS patients (n= 76). Nevertheless, it is worth noting that at the time of starting 
these PhD studies, this was the largest available study 22q11.2DS for investigating the 
psychiatric phenotypes by gene expression analysis. Although more samples were 
collected by the ongoing ECHO study, I had to stop processing more samples at some 
point to start analysing the collected data from the microarrays experiments. Despite 
a number of genotyped samples that had been excluded (n= 19), however, the selected 
76 samples were well-characterized and passed a rigorous protocol of QC that selected 
only true 22q11.2 deletion carriers that came from homogenous Caucasian 
populations. In addition, the identity of these samples were confirmed with the 
reported data by sex chromosome and IBD analyses to avoid related, duplicated, and 
potentially contaminated samples.  
In association studies, particularly GWAS studies, an increased sample size is required 
as they typically assay more than half a million polymorphisms. Analysing this 
number of variants means only a p-value< 5x10-8 (genome-wide significance level) 
can be confidently reported as an association signal (Pe’er et al. 2008). However, in 
order to achieve this level of significance a large number of samples are required 
(Pe’er et al. 2008). Accordingly, many research centres have collaborated to recruit 
more samples for GWAS analysis and to share control cohorts. This approach is 
necessary for 22q11.2DS and will yield better powered studies.  
 
221 
 
8.3.2. Limited efficiency in the ascertainment of 22q11.2DS patients with ASD 
The method used to diagnose ASD phenotype in 22q11.2DS children is a potential 
limitation in this study. Unlike the diagnosis of ADHD in 22q11.2DS children, the 
ASD was diagnosed based on the SCQ score, which is not a categorical diagnosis that 
could certainly identify healthy 22q11.2DS children without ASD. However, this 
method is based on splitting the patients based on the SCQ score cut off of 15. Patients 
with an SCQ above 15 have ASD, while those with an SCQ below 15 have no ASD. 
This could artificially classify the patients into two groups as the SCQ scores are 
normally distributed among 22q11.2DS patients.  Therefore, this might limit the power 
of the test by dichotomizing the continues variable (SCQ score) that have a normal 
distribution among our 22q11.2DS cohort. 
However, the SCQ questionnaire is a conventional method that have been used to 
diagnose ASD by using the threshold of 15 that suggests ASD (Berument et al. 1999). 
In addition, the SCQ questionnaire is an understandable form of the ADI-R for the 
parents and can be completed as a written questionnaire rather than a semi-structured 
interview. It consists of questions that are derived from the ADI-R and focus on 
behaviours that can be identified by non-professionals (Charman & Baird 2002). 
Furthermore, the SCQ diagnosis method takes less time to be completed as it is a 
written questionnaire rather than an interview (Charman & Baird 2002). The SCQ cut-
off of 15 for ASD diagnosis has a high sensitivity (0.96) and specificity (0.8) in 
identifying children with the disease (Charman & Baird 2002). Therefore, this method 
was selected over the ADI-R in the research protocols (Charman & Baird 2002).  
An alternative method for ASD diagnosis is ADI-R (Rutter, Bailey & Lord 2003), 
which is a semi-structured interview conducted with the primary caregiver to assess 
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autism. The interview covers the same four phenotypic domains in the SCQ 
questionnaire mentioned in chapter 2 section 2.1.2.1. 
However, SCQ score is highly correlated with ADI-R score (r2= 0.71) and it is 
effective as the ADI-R in distinguishing children with autism from typically 
developing children; however, the ADI-R is better in identifying children with autism 
from those with ID (Intellectual disability) (Berument et al. 1999). Therefore, although 
the ADI-R interview is long, it is a better method for assessing ASD in 22q11.2DS 
children as the ID is also associated with the syndrome. Additionally, the SCQ is 
considered by the researchers who developed both the SCQ and ADI-R as a good 
screening method but inappropriate for determining a diagnosis in the level of the 
individual (Berument et al. 1999). 
 
8.3.3. Limited efficiency in detecting secondary small 22q11.2 CNVs 
The association study presented in this thesis aimed to detect common variants in the 
22q11.2 region. Additional analysis is required to investigate rare variants. 
Nevertheless, we attempted to identify rare small CNVs that potentially occurred on 
the non-deleted chromosome at 22q11.2 by using the array-based genotypes only. The 
identification of rare second deletions was based on screening null genotypes SNPs, 
while identification of rare second duplications was performed by PennCNV calling. 
Both approaches are not very precise in detecting small CNVs as they rely only on the 
genotyped markers present on the array and it is possible that some regions do not 
have enough coverage. Even for the most up to date genome-wide microarrays, it is 
virtually impossible to include probes against every single nucleotide position (Hurd 
& Nelson 2009). In addition, genotyping microarrays utilize hybridization probes to 
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analyse the prevalence of known DNA sequences (Kahvejian et al. 2008) and as such 
cannot be used to identify unknown genetic changes (Kahvejian et al. 2008). 
Other methods such as targeted exome or whole exome sequencing are more efficient. 
Contrary to microarrays, the high-throughput sequencing technologies that target 
exome sequencing directly provide nucleotide sequences at the thousands of exonic 
loci tested (Biesecker 2010). This means, that it could provide greater details of 
common and rare genetic variants in the coding genes, either within the non-deleted 
chromosome 22 by using target exome sequencing, or both 22q11.2 locus and other 
genomic loci by whole exome sequencing. However, one main limitation is that exome 
sequencing is more expensive than hybridization-microarray technologies on the basis 
of  per-sample (Biesecker 2010). In addition, exome sequencing for many individuals 
generates a large quantity of data and sequence information, that requires a large 
amount of data analysis (Kahvejian et al. 2008). The statistical analysis of such 
volumes of sequencing data for multiple individuals is challenging (Kahvejian et al. 
2008).  
 
8.3.4. Transcriptome profiling of peripheral blood in 22q11.2DS 
A major limitation of the expression analysis is the fact the cells originally came from 
blood. This is because it is the most accessible tissue for studies including children as 
it is neither feasible nor ethical to extract brain samples from living 22q11.DS patients. 
Sullivan and colleagues investigated the correlation of the expression profile in whole 
blood to different CNS regions in controls and, depending on CNS region, found 
correlations ranging from 0.44 to 0.58 (Sullivan et al. 2006). The authors also 
concluded “that gene expression in whole blood is neither perfectly correlated and 
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useful nor perfectly uncorrelated and useless with gene expression in multiple tissues” 
(Sullivan et al. 2006). Encouragingly, this thesis found that there was an overlap 
between genes differentially expressed in hippocampal tissue from Df1+/- murine 
models of 22q11.2DS (Sivagnanasundaram et al. 2007) and genes differentially 
expressed in PMBCs from 22q11.2DS patients. This was supported by the previous 
finding of van Beveren and colleagues, who also identified an overlap in dosage 
sensitive genes in 22q11.2DS patients and 22q11.2DS mice models (van Beveren et 
al. 2012).  
Another consideration is that gene expression will change over time and the expression 
profiles relevant to psychiatric disorders might occur only during a specific critical 
development period. Amati and colleagues observed there are dynamic changes in 
expression profiles of the 22q11.2 genes and orthologous genes during mouse 
development (Amati et al. 2007). However, as previously indicated, phenotypes of 
ADHD and ASD mainly occur during childhood (Schneider et al. 2014). Therefore, 
the cohort analysed in this thesis were selected children with 22q11.2DS who had an 
average age 11.9 years. 
 
Overall, this study was relatively small in scale, and a larger sample would provide 
more robust analysis. In addition, using more efficient and precise method to diagnose 
ASD in 22q11.2DS children than the SCQ score is highly recommended. Moreover, 
the study only utilised array-based genotypes for the detection of potential secondary 
CNVs at 22q11.2. Applying more robust approach, such as sequencing, will increase 
the efficiency to detect them. Furthermore, RNA was extracted from peripheral blood 
samples for differential gene expression analysis. 
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8.4. Conclusion and future direction 
This study provided strong evidence for the involvement of 22q11.2 deletions in the 
early onset form of PD. Although the present study failed to provide significant 
evidence for some of the potential molecular mechanisms that underlie 
neuropsychiatric phenotypes, particularly the presence of additional risk genetic 
variants within the non-deleted 22q11.2 chromosome, it did identify a number of 
dosage sensitive genes in 22q11.2DS. At this point it is not possible to make definitive 
conclusions, but one can speculate that the dosage sensitive genes in 22q11.2DS could 
possibly play key roles in modifying the psychiatric phenotypes.  
These preliminary findings although promising, need further investigation mainly due 
to the studies being underpowered. A collaboration between research groups is 
therefore required to obtain sufficient sample sizes to maximize the power of such 
studies.  
Based on the evidence of the 22q11.2 deletion being a risk factor for early onset of 
PD, future studies should investigate an adult 22q11.2 deletion cohort with available 
PD data. This could investigate the biological mechanisms that underlie the increasing 
risk of PD in the deletion carriers. That can be achieved by using similar approaches 
to those used in this thesis to test the potential molecular mechanisms in 22q11.2DS 
children with ADHD and ASD phenotypes. Large cohorts of 22q11.2DS adults will 
also enable to investigations of other 22q11.2DS adulthood-related psychiatric 
phenotypes such as schizophrenia (Schneider et al. 2014).  
The dosage sensitive genes identified in the present study are strong candidates for 
further investigations into the behavioural phenotype associated with 22q11.2DS. 
Among these genes, DGCR8 was found to be dosage sensitive in 22q11.2DS, and is a 
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component of the “microprocessor” complex that is essential for microRNA 
production (Tomari & Zamore 2005). Mouse models with haploinsufficiency of 
Dgcr8 gene have showed reduced Dgcr8 expression and also a downregulation of a 
specific set of mature miRNA and an upregulation of a number of genes. This means 
that reduced Dgcr8 expression can lead to reduced miRNA expression, which in turn 
resulted in the upregulated expression of other genes (Stark et al. 2008). It would 
therefore be interesting to look at DGCR8-target genes in 22q11.2DS patients and 
analyse their expression patterns to investigate the impact of haploinsufficiency of 
DGCR8 on miRNA and other genome-wide genes. Thus, further investigations are 
necessary to study the interaction between the genes and the possibility of 22q11.2 
dosage sensitive genes being regulator genes for adjacent genes. As this gene 
expression study has used RNA samples extracted from peripheral blood, future 
studies will be required to establish how they reflect gene expression in the human 
brain by using pluripotent stem cell (iPS cell) derived neuronal cells in 22q11.2DS. 
This work is needed to validate current findings and to investigate expression 
differences in genes not expressed in blood.  
An additional molecular mechanism that can potentially influence the increased risk 
of psychiatric disease is the presence of differentially methylated genes. This 
hypothesis was raised on the basis of DGCR8 being shown to have a reduced 
expression in 22q11.2 deletion carriers. miR-185 is also another gene spanned by the 
22q11.2 deletion which encodes miRNA-185 that is regulated by DGCR8 (Y. Wang 
et al. 2007). A recent study has shown that the expression of miR-185 is reduced to 
~25% in Df(16)A+/- mice compared to the wild-type mice (Xu et al. 2013). As 
miRNA-185 regulates the expression of DNA methyl-transferase1 and somatic 
mutations at miR-185 have been previously shown to result in genome-wide changes 
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in DNA methylation in tumour cells (Zhang et al. 2011), it could potentially lead to a 
disruption in DNA methylation in 22q11.2DS. This can be analysed by conducting 
studies that aim to quantify genome-wide patterns of DNA methylation in 22q11.2DS 
patients. Hannon and colleagues performed an example of such studies in 
schizophrenia and provided promising findings using epigenetic approach to 
understand the nature of complex psychiatric traits and diseases (Hannon et al. 2016).   
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Appendices 
 
 
9.1. Gene expression analysis 
9.1.1. Samples quality control 
9.1.1.1. Confirming sample gender molecularly 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9- 1: Gender-specific probes (RPS4Y1 and XIST genes) in our expression data. 
Vawter and colleagues reported that the expression of RPS4Y1 is high in males while the 
expression of XIST gene is low in males and the vice versa in females (Vawter et al. 
2004). Expression values of both probes were plotted for each 22q11.2DS and control 
samples. Males are expected to be on the right side of the plot as they have high 
expression of RPS4Y1 gene and low expression of XIST gene. On the other hand, females 
are expected to be on the left side of the plot as they have a high expression of XIST gene 
and low expression of RPS4Y1 gene. All females in our cohort are aligned in Y-axis with 
high expression of XIST gene and low expression of RPS4Y1 gene. On the other hand, 
males are aligned in X-axis with high expression RPS4Y1 gene and low expression of 
XIST gene. Gender of a single control sample was not confirmed molecularly. 
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Gender-specific probes Fold change 
(Females vs males) 
P-value 
RPS4Y1 -5.264277509 2.73x10-33 
XIST 2.914531949 1.01x10-19 
 
 
 
 
 
 
 
.
Table 9- 1: Differential gene expression analysis on gender-specific probes. 
Gender-specific probes are significantly differentially expressed when females 
compared to males. RPS4YI probe is downregulate, while XIST probe is 
upregulated in females compared to males. 
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9.1.1.2. Confirming the 22q11.2 deletion status by signal intensity of the 3Mb 22q11.2 probes 
 
Figure 9- 2: Heat map for the 3Mb 22q11.2 probes.  
In the heat map each column represents a sample and each raw represents a probe and the numbers are signal intensity values 
(expression values) for each probe in each sample. Expression of 22q11.2 probes is coloured based on the intensity values, probes 
with high expression are coloured by green shadows, while probes with low expression are coloured by red shadows. The map shows 
that the non-deleted controls have more green probes indicating more 22q11.2 probes have high expression which means no 22q11.2 
deletion was found in these individuals. While the 22q11.2 deletion carriers have more red probes indicating more 22q11.2 probes 
have low expression due to the hemizygous 22q11.2 deletions in these individuals. 
* The sample has a 1.5Mb 22q11.2 deletion which can be observed by more red probes within the proximal 1.5Mb region of 22q11.2 
(top rows) and more green probes within the distal region of 22q11.2 (bottom rows).  
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9.1.2. Gene expression data pre-processing (Normalization and Transformation) 
Data normalization and transformation are required to eliminate non-biological 
variance among samples and to make the data more appropriate for gene expression 
comparisons. In order to determine the most appropriate approaches of normalization 
and transformation for our data, different combinations of normalization and 
transformation methods were applied (Figure 9- 3). For each combined method, pre-
processed expression data was plotted and data inter-array correlation (IAC) value was 
calculated. Intensity box plots and IAC scores were compared between all pre-
processing approaches with different normalization and transformation methods. 
Then, the most suitable normalization and transformation methods for our data were 
selected, which show equal intensity box levels for all samples and a high IAC score 
for the normalized and transformed data. 
The resulted plots showed quantile normalization is the most appropriate 
normalization method either combined with variance stabilizing transformation or 
Log2 transformation. However, Log2 transformed data has higher IAC score (IAC= 
0.967) than VS transformed data (IAC= 0.965). Although there are other 
transformation methods have equal IAC value that is resulted by Log2 transformation, 
however, unlike the transformed data by log2, the boxplots showed that the data are 
variable and not suitable for ideal comparison after transforming the data with these 
methods. 
Accordingly, our gene expression data was pre-processed by quantile normalization 
and Log2 transformation based on this evidence. The data after pre-processing by the 
selected methods showed an improved intensity distribution and appeared more 
comparable. 
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VS transformation and quantile normalization                                         VS transformation and RS normalization 
 
VS transformation and quantile normalization                                         VS transformation and RS normalization 
VS transformation and SS normalization                                           VS transformation and RI normalization 
 
Transformation 
Variance stabilization 
transformation 
Log2 
transformation 
Cubic root 
transformation 
Simple scaling 
normalization 
Robust spline 
normalization 
Rank invariant 
normalization 
Quantile 
normalization 
Normalization 
 
 
 
Figure 9- 3: Schismatic flowchart for combined normalization and transformation methods applied on gene 
expression data to determine the best approaches to our data. 
Each transformation approach was applied with different normalization methods. 
Figure 9- 4: Intensity boxplots for regular probes after Variance Stabilizing Transformation (VST) combined with 
different methods of normalization. 
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Log2 transformation and quantile normalization                                         Log2 transformation and RS normalization 
Log2 transformation and SS normalization                                           Log2 transformation and RI normalization 
  Cubic root transformation and quantile normalization                        Cubic root transformation and RS normalization 
 
Cubic root transformation and SS normalization                               Cubic root transformation and RI normalization 
 
Figure 9- 5: Intensity boxplots for regular probes after Log2 transformation combined with different methods of 
normalization. 
Figure 9- 6: Intensity boxplots for regular probes after cubic root transformation combined with different methods of 
normalization. 
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 Normalization 
 
 
Transformation 
 Quantile SSN RSN RI 
VS 0.965 0.964 0.964 0.965 
Log2 0.967 0.965 0.967 0.965 
Cubic Root 0.95 0.939 0.942 0.967 
 
 
Table 9- 2: Mean IAC values for gene expression data following normalization and 
transformation. 
Figure 9- 7: Plots for probes intensity before and after background correction, quantile 
normalization, and log2 transformation. 
A. Intensity plots before background correction, quantile normalization, and log2 transformation. 
B. Intensity plots after background correction, quantile normalization, log2 transformation. 
1) Intensity boxplots for regular probes. Each box represents intensity signals range and average for each 
sample. Normalized and transformed data showed more comparable intensity levels among samples than 
unprocessed data. 
2) Density curves illustrating the distribution of signal intensities in different samples. Each coloured line 
represents a sample. The density curves for all samples become identical after normalization and 
transformation. 
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9.1.3. Batch effects 
9.1.3.1. Batch effects identification 
Batch effects were identified by using dendrogram visualization approach on pre-
processed data. Dendrogram cluster categorized the samples based on highly variable 
probes among all samples (Dunning et al., 2016). 
The number of samples in the largest two clusters was determined based on their 
gender, phenotype status, origin, wave and batch. Thus, variances that play a 
significant role in sample clustering can be identified by applying categorical 
statistical analysis, such as a Fisher’s exact test.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cluster 1 Cluster 2 
Figure 9- 8: Dendrogram after background correction, normalization, and 
transformation. 
Dendrogram clusters were categorized based on highly variable probes among samples by 
calculating IQR for each probe among all samples. Probes then were ordered based on IQR 
values to identify the 500 most variable probes. These probes then were used to categorize the 
samples into clusters. Dendrogram identifies two main clusters. 
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Sample phenotype Case Control Total 
Cluster 1 15 19 34 
Cluster 2 18 16 34 
Total 33 35 68 
P-value 0.314 
Table 9- 3: Results of Fisher’s exact test based on number of cases and 
controls in the dendrogram two clusters. 
Figure 9- 9: Dendrogram after background correction, normalization, and 
transformation. 
Samples are shown based on their phenotype status in both clusters. 
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Sample gender Male Female Total 
Cluster 1 21 13 34 
Cluster 2 14 20 34 
Total 35 33 68 
Fisher’s exact test 
P-value 
0.0725 
Table 9- 4: Results of Fisher’s exact test based on number of males and 
females in the dendrogram two clusters. 
 
 
 
Figure 9- 10: Dendrogram after background correction, normalization, and 
transformation. 
Samples are shown based on their gender in both clusters. M= male, F= female. 
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Sample wave Wave A Wave B Total 
Cluster 1 11 23 34 
Cluster 2 1 33 34 
Total 12 56 68 
Fisher’s exact test 
P-value 
0.0041 
Table 9- 5: Results of Fisher’s exact test based on number of samples form 
wave A and wave B in the dendrogram two clusters. 
 
 
 
Figure 9- 11: Dendrogram after background correction, normalization, and 
transformation. 
Samples are shown based on their wave in both clusters. A= wave A, B= wave B. 
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Sample origin London BBAG  Cardiff ECHO Total 
Cluster 1 5 29 34 
Cluster 2 17 17 34 
Total 22 46 68 
Fisher’s exact test 
P-value 
0.0019 
 
The results revealed that there are two covariates are significant, sample wave (p-
value= 0.0041) and sample origin (p-value = 0.0019). This finding is logic as the two 
waves were processed in two different seasons, samples of wave A were hybridized 
in April 2014 while those of wave B were processed in February 2015. Difference in 
the time may have an influence on sample hybridization and/or gene expression 
pattern potentially due to atmosphere temperature. Moreover, although samples from 
Cardiff research group and London research group were collected using the same 
Table 9- 6: Results of Fisher’s exact test based on number of samples form 
Cardiff ECHO study and London BBAG study in the dendrogram two 
clusters. 
 
 
 
Figure 9- 12: Dendrogram after background correction, normalization, and 
transformation. 
Samples are shown based on their origin in both clusters. ECHO= Cardiff ECHO study, 
London= London BBAG study. 
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PAXgene approach, samples collecting, transferring, and storing procedures might 
differ in both groups and cause a specific effect. 
 
9.1.3.2. Batch effects correction 
Sample wave and origin were considered as batch effects. Adjusting batch effects was 
performed by using ComBat package on R (Johnson et al. 2007). 
Then, expression data corrected for wave and origin was re-analysed by using the 
approach of dendrogram clustering and Fisher’s exact test to confirm that all batch 
effects were corrected. The results showed there is no significant batch effect, which 
means both samples wave and origin were successfully adjusted. Therefore, the gene 
expression data is ready for differential gene expression analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cluster 1 Cluster 2 
 
 
 
Figure 9- 13: Dendrogram after background correction, normalization, transformation, and 
batch effect correction.  
Dendrogram identifies two clusters. 
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Table 9- 7: Results of Fisher’s exact test based on number of cases and 
controls in the dendrogram two clusters. 
Sample phenotype Case Control Total 
Cluster 1 4 4 8 
Cluster 2 29 31 60 
Total 33 35 68 
Fisher’s exact test 
P-value 
0.6112 
 
 
 
Figure 9- 14: Dendrogram after background correction, normalization, transformation, 
and batch effect correction. 
Samples are shown based on their phenotype status in both clusters.  
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Sample gender Male Female Total 
Cluster 1 4 4 8 
Cluster 2 23 37 60 
Total 27 41 68 
Fisher’s exact test 
P-value 
0.395 
 
 
 
         
 
 
 
 
 
 
 
Table 9- 8: Results of Fisher’s exact test based on number of males and 
females in the dendrogram two clusters. 
 
 
 
Figure 9- 15:  Dendrogram after background correction, normalization, 
transformation, and batch effect correction. 
Samples are shown based on their gender in both clusters. M= male and F= female. 
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Sample wave Wave A Wave B Total 
Cluster 1 1 7 8 
Cluster 2 11 49 60 
Total 12 56 68 
Fisher’s exact test 
P-value 
0.569 
 
 
 
 
 
 
 
Table 9- 9: Results of Fisher’s exact test based on number of samples from wave 
A and wave B in the dendrogram two clusters.  
 
 
 
Figure 9- 16: Dendrogram after background correction, normalization, transformation, and 
batch effect correction. 
Samples are shown based on their wave in both clusters. A= from wave A and B= from wave B. 
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Sample origin London BBAG Cardiff ECHO Total 
Cluster 1 4 4 8 
Cluster 2 18 42 60 
Total 22 46 68 
Fisher’s exact test 
P-value 
0.2271 
 
 
 
  
Table 9- 10: Results of Fisher’s exact test based on number of samples from 
London BBAG study and Cardiff ECHO study in the dendrogram two 
clusters.  
 
 
 
Figure 9- 17:  Dendrogram after background correction, normalization, transformation, 
and batch effect correction. 
Samples are shown based on their origin in both clusters. ECHO= from Cardiff ECHO study 
and London= from London BBAG study. 
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